OPDIVO QVANTIG

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling. • Severe and Fatal Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1) ] • Complications of Allogeneic HSCT [see Warnings and Precautions (5.2) ] • Most common adverse reactions (≥10%) with OPDIVO QVANTIG as monotherapy in patients with Renal Cell Carcinoma were: musculoskeletal pain, fatigue, pruritus, rash, hypothyroidism, diarrhea, cough, and abdominal pain. (6.1) • Safety of OPDIVO QVANTIG for the following indications is based on safety of intravenous nivolumab in these populations. The most common adverse reactions with intravenous nivolumab for these indications are presented below. • As monotherapy for the treatment of advanced renal cell carcinoma; adjuvant treatment of completely resected Stage IIB, IIC, III, or IV melanoma; unresectable or metastatic melanoma; adjuvant treatment of NSCLC, metastatic NSCLC; squamous cell carcinoma of the head and neck; urothelial carcinoma; MSI-H or dMMR mCRC; hepatocellular carcinoma; esophageal cancer: fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, pyrexia, headache, abdominal pain, vomiting, and urinary tract infection. (6.1) • In combination with cabozantinib for the first-line treatment of advanced renal cell carcinoma: diarrhea, fatigue, hepatotoxicity, palmar-plantar erythrodysesthesia syndrome, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection. (6.1) • In combination with platinum-doublet chemotherapy for the neoadjuvant treatment of NSCLC: nausea, constipation, fatigue, decreased appetite, and rash. (6.1) • In combination with cisplatin and gemcitabine for the treatment of urothelial cancer: nausea, fatigue, musculoskeletal pain, constipation, decreased appetite, rash, vomiting, and peripheral neuropathy. (6.1) • In combination with fluoropyrimidine- and platinum- containing chemotherapy for the treatment of esophageal cancer and gastric cancer: nausea, peripheral neuropathy, decreased appetite, fatigue, constipation, stomatitis, diarrhea, vomiting, abdominal pain, and musculoskeletal pain. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data in WARNINGS AND PRECAUTIONS reflect exposure to OPDIVO QVANTIG as a single agent in 247 patients enrolled in CHECKMATE-67T, with additional data from intravenous nivolumab single-agent (1994 patients), and from intravenous nivolumab in combination with cabozantinib (320 patients) for select adverse reactions. Advanced Renal Cell Carcinoma CHECKMATE-67T was a multicenter, randomized, open-label study in adult patients with advanced or metastatic RCC. Patients received OPDIVO QVANTIG dose of 1,200 mg of nivolumab and 20,000 units of hyaluronidase subcutaneously every 4 weeks (n=247) or 3 mg/kg of nivolumab intravenously every 2 weeks (n=245). Among patients who received OPDIVO QVANTIG, 52% were exposed for 6 months or longer and 20% were exposed for greater than 1 year. Serious adverse reactions occurred in 28% of patients who received OPDIVO QVANTIG. Serious adverse reactions in >1% of patients included pleural effusion (1.6%), pneumonitis (1.6%), hyperglycemia (1.2%), hyperkalemia (1.2%), hemorrhage (1.2%) and diarrhea (1.2%). Fatal adverse reactions occurred in 3 patients (1.2%) who received OPDIVO QVANTIG and included myocarditis, myositis, and colitis complications. Permanent discontinuation of OPDIVO QVANTIG due to an adverse reaction occurred in 10% of patients. The most common adverse reaction which resulted in permanent discontinuation was pneumonitis (2%). Dosage interruptions of OPDIVO QVANTIG due to an adverse reaction occurred in 34% of patients. Adverse reactions which required dosage interruption in >2% of patients included COVID-19 (4.5%), increased blood creatinine (2.8%), anemia, diarrhea, and fatigue (2.4% each). The most common adverse reactions (≥10%) were musculoskeletal pain, fatigue, pruritus, rash, hypothyroidism, diarrhea, cough, and abdominal pain. Tables 5 and 6 summarize adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-67T. Table 5: Adverse Reactions* in ≥5% of Adult Patients with RCC Receiving OPDIVO QVANTIG in CHECKMATE-67T * Toxicity was graded per NCI CTCAE v5. a Includes multiple related terms Adverse Reaction OPDIVO QVANTIG (n=247) Intravenous Nivolumab (n=245) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) General Fatigue a 20 2.4 25 3.3 Injection site reaction a 8 0 0 0 Edema 5 0.4 11 0.8 Musculoskeletal and Connective Tissue Musculoskeletal pain a 31 1.6 39 3.3 Skin and Subcutaneous Tissue Pruritus 16 0.4 21 0 Rash a 15 1.2 13 1.2 Gastrointestinal Diarrhea a 11 0.4 14 0.4 Abdominal pain a 10 0 10 0.4 Nausea 8 0 9 0 Constipation 8 0 6 0 Vomiting 6 0.4 4.9 0 Respiratory, Thoracic, and Mediastinal Cough 11 0 11 0 Endocrine Hypothyroidism a 12 0 17 0 Metabolism and Nutrition Hyperglycemia 9 2.4 13 2.0 Decreased appetite 9 0 11 0.8 Clinically important adverse reactions in <5% of patients who received OPDIVO QVANTIG include: Cardiac: myocarditis Respiratory, thoracic, and mediastinal: pneumonitis, dyspnea Endocrine: adrenal insufficiency, hyperthyroidism, thyroiditis Gastrointestinal: colitis, pancreatitis Hepatobiliary: hepatitis Nervous system: peripheral neuropathy Skin and subcutaneous tissue: psoriasis, erythema Musculoskeletal and connective tissue: arthritis Blood and lymphatic system: eosinophilia Eye disorders: uveitis Immune system: hypersensitivity Table 6: Laboratory Values Worsening from Baseline a (≥20%) in Patients with RCC Receiving OPDIVO QVANTIG in CHECKMATE-67T a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: OPDIVO QVANTIG group (range: 232 to 235 patients) and intravenous nivolumab group (range: 240 to 244 patients). Laboratory Abnormality OPDIVO QVANTIG Intravenous Nivolumab All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Hematology Hemoglobin decreased 46 7 48 9 Lymphocytes decreased 36 6 45 9 Chemistry Creatinine increased 38 1.3 43 0.4 Sodium decreased 34 2.6 40 2.5 Potassium increased 34 3.0 45 2.9 Alkaline phosphatase increased 32 2.1 33 2.0 Calcium increased 29 2.1 31 4.1 Albumin decreased 25 1.7 35 0.4 ALT increased 21 1.3 26 4.1 Adverse Reactions in Patients Treated with Intravenous Nivolumab The safety of OPDIVO QVANTIG for its approved indications [see Indications and Usage (1) ] has been established in adequate and well-controlled clinical studies of intravenous nivolumab. Below is a description of adverse reactions in these adequate and well-controlled clinical studies. First-line Renal Cell Carcinoma CHECKMATE-214 The safety of intravenous nivolumab with ipilimumab was evaluated in CHECKMATE-214, a randomized open-label trial in 1082 patients with previously untreated advanced RCC; patients received intravenous nivolumab 3 mg/kg over 60 minutes with ipilimumab 1 mg/kg intravenously every 3 weeks for 4 doses followed by intravenous nivolumab as a single agent at a dose of 3 mg/kg by intravenous infusion every 2 weeks (n=547) or sunitinib 50 mg orally daily for the first 4 weeks of a 6-week cycle (n=535) [see Clinical Studies (14.1) ] . The median duration of treatment was 7.9 months (range: 1 day to 21.4+ months) in intravenous nivolumab and ipilimumab-treated patients and 7.8 months (range: 1 day to 20.2+ months) in sunitinib-treated patients. In this trial, 57% of patients in the intravenous nivolumab and ipilimumab arm were exposed to treatment for >6 months and 38% of patients were exposed to treatment for >1 year. Serious adverse reactions occurred in 59% of patients receiving intravenous nivolumab and ipilimumab. Study therapy was discontinued for adverse reactions in 31% of intravenous nivolumab and ipilimumab patients. Fifty-four percent (54%) of patients receiving intravenous nivolumab and ipilimumab had a dose interruption for an adverse reaction. The most frequent serious adverse reactions reported in ≥2% of patients treated with intravenous nivolumab and ipilimumab were diarrhea, pyrexia, pneumonia, pneumonitis, hypophysitis, acute kidney injury, dyspnea, adrenal insufficiency, and colitis; in patients treated with sunitinib, they were pneumonia, pleural effusion, and dyspnea. The most common adverse reactions (reported in ≥20% of patients) were fatigue, rash, diarrhea, musculoskeletal pain, pruritus, nausea, cough, pyrexia, arthralgia, and decreased appetite. The most common laboratory abnormalities which have worsened compared to baseline in ≥30% of intravenous nivolumab and ipilimumab-treated patients include increased lipase, anemia, increased creatinine, increased ALT, increased AST, hyponatremia, increased amylase, and lymphopenia. Tables 7 and 8 summarize adverse reactions and laboratory abnormalities, respectively, that occurred in >15% of intravenous nivolumab and ipilimumab‑treated patients in CHECKMATE-214. Table 7: Adverse Reactions in >15% of Patients Receiving Intravenous Nivolumab and Ipilimumab - CHECKMATE-214 Toxicity was graded per NCI CTCAE v4. a Includes asthenia. b Includes peripheral edema, peripheral swelling. c Includes dermatitis described as acneiform, bullous, and exfoliative, drug eruption, rash described as exfoliative, erythematous, follicular, generalized, macular, maculopapular, papular, pruritic, and pustular, fixed-drug eruption. d Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity, spinal pain. Adverse Reaction Intravenous Nivolumab and Ipilimumab (n=547) Sunitinib (n=535) Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Adverse Reaction 99 65 99 76 General Fatigue a 58 8 69 13 Pyrexia 25 0.7 17 0.6 Edema b 16 0.5 17 0.6 Skin and Subcutaneous Tissue Rash c 39 3.7 25 1.1 Pruritus/generalized pruritus 33 0.5 11 0 Gastrointestinal Diarrhea 38 4.6 58 6 Nausea 30 2 43 1.5 Vomiting 20 0.9 28 2.1 Abdominal pain 19 1.6 24 1.9 Constipation 17 0.4 18 0 Musculoskeletal and Connective Tissue Musculoskeletal pain d 37 4 40 2.6 Arthralgia 23 1.3 16 0 Respiratory, Thoracic and Mediastinal Cough/productive cough 28 0.2 25 0.4 Dyspnea/exertional dyspnea 20 2.4 21 2.1 Metabolism and Nutrition Decreased appetite 21 1.8 29 0.9 Nervous System Headache 19 0.9 23 0.9 Endocrine Hypothyroidism 18 0.4 27 0.2 Table 8: Laboratory Values Worsening from Baseline a Occurring in >15% of Patients on Intravenous Nivolumab and Ipilimumab - CHECKMATE-214 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab and ipilimumab group (range: 490 to 538 patients) and sunitinib group (range: 485 to 523 patients). Laboratory Abnormality Intravenous Nivolumab and Ipilimumab Sunitinib Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Chemistry Increased lipase 48 20 51 20 Increased creatinine 42 2.1 46 1.7 Increased ALT 41 7 44 2.7 Increased AST 40 4.8 60 2.1 Increased amylase 39 12 33 7 Hyponatremia 39 10 36 7 Increased alkaline phosphatase 29 2 32 1 Hyperkalemia 29 2.4 28 2.9 Hypocalcemia 21 0.4 35 0.6 Hypomagnesemia 16 0.4 26 1.6 Hematology Anemia 43 3 64 9 Lymphopenia 36 5 63 14 In addition, among patients with TSH ≤ ULN at baseline, a lower proportion of patients experienced a treatment-emergent elevation of TSH > ULN in the intravenous nivolumab and ipilimumab group compared to the sunitinib group (31% and 61%, respectively). CHECKMATE-9ER The safety of intravenous nivolumab with cabozantinib was evaluated in CHECKMATE-9ER, a randomized, open-label study in patients with previously untreated advanced RCC. Patients received intravenous nivolumab 240 mg over 30 minutes every 2 weeks with cabozantinib 40 mg orally once daily (n=320) or sunitinib 50 mg daily, administered orally for 4 weeks on treatment followed by 2 weeks off (n=320) [see Clinical Studies (14.1) ] . Cabozantinib could be interrupted or reduced to 20 mg daily or 20 mg every other day. The median duration of treatment was 14 months (range: 0.2 to 27 months) in intravenous nivolumab and cabozantinib-treated patients. In this trial, 82% of patients in the intravenous nivolumab and cabozantinib arm were exposed to treatment for >6 months and 60% of patients were exposed to treatment for >1 year. Serious adverse reactions occurred in 48% of patients receiving intravenous nivolumab and cabozantinib. The most frequent (≥2%) serious adverse reactions were diarrhea, pneumonia, pneumonitis, pulmonary embolism, urinary tract infection, and hyponatremia. Fatal intestinal perforations occurred in 3 (0.9%) patients. Adverse reactions leading to discontinuation of either intravenous nivolumab or cabozantinib occurred in 20% of patients: 7% intravenous nivolumab only, 8% cabozantinib only, and 6% both drugs due to same adverse reaction at the same time. Adverse reaction leading to dose interruption or reduction of either intravenous nivolumab or cabozantinib occurred in 83% of patients: 3% intravenous nivolumab only, 46% cabozantinib only, and 21% both drugs due to same adverse reaction at the same time, and 6% both drugs sequentially. The most common adverse reactions reported in ≥20% of patients treated with intravenous nivolumab and cabozantinib were diarrhea, fatigue, hepatotoxicity, palmar-plantar erythrodysesthesia syndrome, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection. Tables 9 and 10 summarize adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-9ER. Table 9: Adverse Reactions in >15% of Patients Receiving Intravenous Nivolumab and Cabozantinib - CHECKMATE-9ER Toxicity was graded per NCI CTCAE v4. a Includes abdominal discomfort, abdominal pain lower, abdominal pain upper. b Includes gastroesophageal reflux disease. c Includes asthenia. d Includes hepatotoxicity, ALT increased, AST increased, blood alkaline phosphatase increased, gamma-glutamyl transferase increased, autoimmune hepatitis, blood bilirubin increased, drug induced liver injury, hepatic enzyme increased, hepatitis, hyperbilirubinemia, liver function test increased, liver function test abnormal, transaminases increased, hepatic failure. e Includes mucosal inflammation, aphthous ulcer, mouth ulceration. f Includes dermatitis, dermatitis acneiform, dermatitis bullous, exfoliative rash, rash erythematous, rash follicular, rash macular, rash maculo-papular, rash papular, rash pruritic. g Includes blood pressure increased, blood pressure systolic increased. h Includes primary hypothyroidism. i Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity, spinal pain. j Includes productive cough. k Includes nasopharyngitis, pharyngitis, rhinitis. Adverse Reaction Intravenous Nivolumab and Cabozantinib (n=320) Sunitinib (n=320) Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Gastrointestinal Diarrhea 64 7 47 4.4 Nausea 27 0.6 31 0.3 Abdominal pain a 22 1.9 15 0.3 Vomiting 17 1.9 21 0.3 Dyspepsia b 15 0 22 0.3 General Fatigue c 51 8 50 8 Hepatobiliary Hepatotoxicity d 44 11 26 5 Skin and Subcutaneous Tissue Palmar-plantar erythrodysesthesia syndrome 40 8 41 8 Stomatitis e 37 3.4 46 4.4 Rash f 36 3.1 14 0 Pruritus 19 0.3 4.4 0 Vascular Hypertension g 36 13 39 14 Endocrine Hypothyroidism h 34 0.3 30 0.3 Musculoskeletal and Connective Tissue Musculoskeletal pain i 33 3.8 29 3.1 Arthralgia 18 0.3 9 0.3 Metabolism and Nutrition Decreased appetite 28 1.9 20 1.3 Nervous System Dysgeusia 24 0 22 0 Headache 16 0 12 0.6 Respiratory, Thoracic and Mediastinal Cough j 20 0.3 17 0 Dysphonia 17 0.3 3.4 0 Infections and Infestations Upper respiratory tract infection k 20 0.3 8 0.3 Table 10: Laboratory Values Worsening from Baseline a Occurring in >20% of Patients on Intravenous Nivolumab and Cabozantinib - CHECKMATE-9ER a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab and cabozantinib group (range: 170 to 317 patients) and sunitinib group (range: 173 to 311 patients). Laboratory Abnormality Intravenous Nivolumab and Cabozantinib Sunitinib Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Chemistry Increased ALT 79 9.8 39 3.5 Increased AST 77 7.9 57 2.6 Hypophosphatemia 69 28 48 10 Hypocalcemia 54 1.9 24 0.6 Hypomagnesemia 47 1.3 25 0.3 Hyperglycemia 44 3.5 44 1.7 Hyponatremia 43 11 36 12 Increased lipase 41 14 38 13 Increased amylase 41 10 28 6 Increased alkaline phosphatase 41 2.8 37 1.6 Increased creatinine 39 1.3 42 0.6 Hyperkalemia 35 4.7 27 1 Hypoglycemia 26 0.8 14 0.4 Hematology Lymphopenia 42 6.6 45 10 Thrombocytopenia 41 0.3 70 9.7 Anemia 37 2.5 61 4.8 Leukopenia 37 0.3 66 5.1 Neutropenia 35 3.2 67 12 Previously Treated Renal Cell Carcinoma CHECKMATE-025 The safety of intravenous nivolumab was evaluated in CHECKMATE-025, a randomized open-label trial in 803 patients with advanced RCC who had experienced disease progression during or after at least one anti-angiogenic treatment regimen received intravenous nivolumab 3 mg/kg over 60 minutes by intravenous infusion every 2 weeks (n=406) or everolimus 10 mg daily (n=397) [see Clinical Studies (14.1) ] . The median duration of treatment was 5.5 months (range: 1 day to 29.6+ months) in intravenous nivolumab-treated patients and 3.7 months (range: 6 days to 25.7+ months) in everolimus-treated patients. Rate of death on treatment or within 30 days of the last dose was 4.7% on the intravenous nivolumab arm. Serious adverse reactions occurred in 47% of patients receiving intravenous nivolumab. Study therapy was discontinued for adverse reactions in 16% of intravenous nivolumab patients. Forty-four percent (44%) of patients receiving intravenous nivolumab had a dose interruption for an adverse reaction. The most frequent serious adverse reactions in at least 2% of patients were: acute kidney injury, pleural effusion, pneumonia, diarrhea, and hypercalcemia. The most common adverse reactions (≥20%) were fatigue, cough, nausea, rash, dyspnea, diarrhea, constipation, decreased appetite, back pain, and arthralgia. The most common laboratory abnormalities which have worsened compared to baseline in ≥30% of patients include increased creatinine, lymphopenia, anemia, increased AST, increased alkaline phosphatase, hyponatremia, increased triglycerides, and hyperkalemia. In addition, among patients with TSH < ULN at baseline, a greater proportion of patients experienced a treatment-emergent elevation of TSH > ULN in the intravenous nivolumab group compared to the everolimus group (26% and 14%, respectively). Tables 11 and 12 summarize adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-025. Table 11: Adverse Reactions in >15% of Patients Receiving Intravenous Nivolumab - CHECKMATE-025 Toxicity was graded per NCI CTCAE v4. a Includes asthenia, decreased activity, fatigue, and malaise. b Includes nasopharyngitis, pharyngitis, rhinitis, and viral upper respiratory infection (URI). c Includes colitis, enterocolitis, and gastroenteritis. d Includes dermatitis, acneiform dermatitis, erythematous rash, generalized rash, macular rash, maculopapular rash, papular rash, pruritic rash, erythema multiforme, and erythema. Adverse Reaction Intravenous Nivolumab (n=406) Everolimus (n=397) Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Adverse Reaction 98 56 96 62 General Fatigue a 56 6 57 7 Pyrexia 17 0.7 20 0.8 Respiratory, Thoracic and Mediastinal Cough/productive cough 34 0 38 0.5 Dyspnea/exertional dyspnea 27 3 31 2 Upper respiratory infection b 18 0 11 0 Gastrointestinal Nausea 28 0.5 29 1 Diarrhea c 25 2.2 32 1.8 Constipation 23 0.5 18 0.5 Vomiting 16 0.5 16 0.5 Skin and Subcutaneous Tissue Rash d 28 1.5 36 1 Pruritus/generalized pruritus 19 0 14 0 Metabolism and Nutrition Decreased appetite 23 1.2 30 1.5 Musculoskeletal and Connective Tissue Arthralgia 20 1 14 0.5 Back pain 21 3.4 16 2.8 Other clinically important adverse reactions in CHECKMATE-025 were: General Disorders and Administration Site Conditions: peripheral edema/edema Gastrointestinal Disorders: abdominal pain/discomfort Musculoskeletal and Connective Tissue Disorders: extremity pain, musculoskeletal pain Nervous System Disorders: headache/migraine, peripheral neuropathy Investigations: weight decreased Skin Disorders: palmar-plantar erythrodysesthesia Table 12: Laboratory Values Worsening from Baseline a Occurring in >15% of Patients on Intravenous Nivolumab - CHECKMATE-025 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab group (range: 259 to 401 patients) and everolimus group (range: 257 to 376 patients). Laboratory Abnormality Intravenous Nivolumab Everolimus Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Hematology Lymphopenia 42 6 53 11 Anemia 39 8 69 16 Chemistry Increased creatinine 42 2 45 1.6 Increased AST 33 2.8 39 1.6 Increased alkaline phosphatase 32 2.3 32 0.8 Hyponatremia 32 7 26 6 Hyperkalemia 30 4 20 2.1 Hypocalcemia 23 0.9 26 1.3 Increased ALT 22 3.2 31 0.8 Hypercalcemia 19 3.2 6 0.3 Lipids Increased triglycerides 32 1.5 67 11 Increased cholesterol 21 0.3 55 1.4 Unresectable or Metastatic Melanoma Previously Treated Metastatic Melanoma CHECKMATE-037 The safety of intravenous nivolumab was evaluated in CHECKMATE-037, a randomized, open-label trial in 370 patients with unresectable or metastatic melanoma [see Clinical Studies (14.2) ] . Patients had documented disease progression following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. The trial excluded patients with autoimmune disease, prior ipilimumab-related Grade 4 adverse reactions (except for endocrinopathies) or Grade 3 ipilimumab-related adverse reactions that had not resolved or were inadequately controlled within 12 weeks of the initiating event, patients with a condition requiring chronic systemic treatment with corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications, a positive test for hepatitis B or C, and a history of HIV. Patients received intravenous nivolumab 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks (n=268) or investigator’s choice of chemotherapy (n=102): dacarbazine 1000 mg/m 2 intravenously every 3 weeks or carboplatin AUC 6 mg/mL/min and paclitaxel 175 mg/m 2 intravenously every 3 weeks. The median duration of exposure was 5.3 months (range: 1 day to 13.8+ months) in intravenous nivolumab‑treated patients and was 2 months (range: 1 day to 9.6+ months) in chemotherapy-treated patients. In this ongoing trial, 24% of patients received intravenous nivolumab for >6 months and 3% of patients received intravenous nivolumab for >1 year. The population characteristics in the intravenous nivolumab group and the chemotherapy group were similar: 66% male, median age 59.5 years, 98% White, baseline Eastern Cooperative Oncology Group (ECOG) performance status 0 (59%) or 1 (41%), 74% with M1c stage disease, 73% with cutaneous melanoma, 11% with mucosal melanoma, 73% received two or more prior therapies for advanced or metastatic disease, and 18% had brain metastasis. There were more patients in the intravenous nivolumab group with elevated lactate dehydrogenase (LDH) at baseline (51% vs. 38%). Serious adverse reactions occurred in 41% of patients receiving intravenous nivolumab. Intravenous nivolumab was discontinued for adverse reactions in 9% of patients. Twenty-six percent of patients receiving intravenous nivolumab had a dose interruption for an adverse reaction. Grade 3 and 4 adverse reactions occurred in 42% of patients receiving intravenous nivolumab. The most frequent Grade 3 and 4 adverse reactions reported in 2% to <5% of patients receiving intravenous nivolumab were abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase. The most common adverse reaction (reported in ≥20% of patients) was rash. Tables 13 and 14 summarize the adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-037. Table 13: Adverse Reactions Occurring in ≥10% of Intravenous Nivolumab-Treated Patients and at a Higher Incidence than in the Chemotherapy Arm (Between Arm Difference of ≥5% All Grades or ≥2% Grades 3-4) - CHECKMATE-037 Toxicity was graded per NCI CTCAE v4. a Includes maculopapular rash, erythematous rash, pruritic rash, follicular rash, macular rash, papular rash, pustular rash, vesicular rash, and acneiform dermatitis. b Includes rhinitis, pharyngitis, and nasopharyngitis. Adverse Reaction Intravenous Nivolumab (n=268) Chemotherapy (n=102) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Skin and Subcutaneous Tissue Rash a 21 0.4 7 0 Pruritus 19 0 3.9 0 Respiratory, Thoracic and Mediastinal Cough 17 0 6 0 Infections Upper respiratory tract infection b 11 0 2 0 General Peripheral edema 10 0 5 0 Clinically important adverse reactions in <10% of patients who received intravenous nivolumab were: Cardiac Disorders: ventricular arrhythmia Eye Disorders: iridocyclitis General Disorders and Administration Site Conditions: infusion-related reactions Investigations: increased amylase, increased lipase Nervous System Disorders: dizziness, peripheral and sensory neuropathy Skin and Subcutaneous Tissue Disorders: exfoliative dermatitis, erythema multiforme, vitiligo, psoriasis Table 14: Laboratory Abnormalities Worsening from Baseline a Occurring in ≥10% of Intravenous Nivolumab-Treated Patients and at a Higher Incidence than in the Chemotherapy Arm (Between Arm Difference of ≥5% All Grades or ≥2% Grades 3-4) - CHECKMATE-037 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab group (range: 252 to 256 patients) and chemotherapy group (range: 94 to 96 patients). Laboratory Abnormality Intravenous Nivolumab Chemotherapy All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Increased AST 28 2.4 12 1 Hyponatremia 25 5 18 1.1 Increased alkaline phosphatase 22 2.4 13 1.1 Increased ALT 16 1.6 5 0 Hyperkalemia 15 2 6 0 Previously Untreated Metastatic Melanoma CHECKMATE-066 The safety of intravenous nivolumab was also evaluated in CHECKMATE-066, a randomized, double-blind, active‑controlled trial in 411 previously untreated patients with BRAF V600 wild-type unresectable or metastatic melanoma [see Clinical Studies (14.2) ] . The trial excluded patients with autoimmune disease and patients requiring chronic systemic treatment with corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications. Patients received intravenous nivolumab 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks (n=206) or dacarbazine 1000 mg/m 2 intravenously every 3 weeks (n=205). The median duration of exposure was 6.5 months (range: 1 day to 16.6 months) in intravenous nivolumab-treated patients. In this trial, 47% of patients received intravenous nivolumab for >6 months and 12% of patients received intravenous nivolumab for >1 year. The trial population characteristics in the intravenous nivolumab group and dacarbazine group: 59% male, median age 65 years, 99.5% White, 61% with M1c stage disease, 74% with cutaneous melanoma, 11% with mucosal melanoma, 4% with brain metastasis, and 37% with elevated LDH at baseline. There were more patients in the intravenous nivolumab group with ECOG performance status 0 (71% vs. 59%). Serious adverse reactions occurred in 36% of patients receiving intravenous nivolumab. Adverse reactions led to permanent discontinuation of intravenous nivolumab in 7% of patients and dose interruption in 26% of patients; no single type of adverse reaction accounted for the majority of intravenous nivolumab discontinuations. Grade 3 and 4 adverse reactions occurred in 41% of patients receiving intravenous nivolumab. The most frequent Grade 3 and 4 adverse reactions reported in ≥2% of patients receiving intravenous nivolumab were increased gamma-glutamyl transferase (3.9%) and diarrhea (3.4%). The most common adverse reactions (reported in ≥20% of patients and at a higher incidence than in the dacarbazine arm) were fatigue, musculoskeletal pain, rash, and pruritus. Tables 15 and 16 summarize selected adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-066. Table 15: Adverse Reactions Occurring in ≥10% of Intravenous Nivolumab-Treated Patients and at a Higher Incidence than in the Dacarbazine Arm (Between Arm Difference of ≥5% All Grades or ≥2% Grades 3-4) - CHECKMATE-066 Toxicity was graded per NCI CTCAE v4. a Includes periorbital edema, face edema, generalized edema, gravitational edema, localized edema, peripheral edema, pulmonary edema, and lymphedema. b Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity, pain in jaw, and spinal pain. c Includes maculopapular rash, erythematous rash, pruritic rash, follicular rash, macular rash, papular rash, pustular rash, vesicular rash, dermatitis, allergic dermatitis, exfoliative dermatitis, acneiform dermatitis, drug eruption, and skin reaction. d Includes rhinitis, viral rhinitis, pharyngitis, and nasopharyngitis. Adverse Reaction Intravenous Nivolumab (n=206) Dacarbazine (n=205) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) General Fatigue 49 1.9 39 3.4 Edema a 12 1.5 4.9 0 Musculoskeletal and Connective Tissue Musculoskeletal pain b 32 2.9 25 2.4 Skin and Subcutaneous Tissue Rash c 28 1.5 12 0 Pruritus 23 0.5 12 0 Vitiligo 11 0 0.5 0 Erythema 10 0 2.9 0 Infections Upper respiratory tract infection d 17 0 6 0 Clinically important adverse reactions in <10% of patients who received intravenous nivolumab were: Nervous System Disorders: peripheral neuropathy Table 16: Laboratory Abnormalities Worsening from Baseline a Occurring in ≥10% of Intravenous Nivolumab-Treated Patients and at a Higher Incidence than in the Dacarbazine Arm (Between Arm Difference of ≥5% All Grades or ≥2% Grades 3-4) - CHECKMATE-066 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab group (range: 194 to 197 patients) and dacarbazine group (range: 186 to 193 patients). Laboratory Abnormality Intravenous Nivolumab Dacarbazine All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Increased ALT 25 3 19 0.5 Increased AST 24 3.6 19 0.5 Increased alkaline phosphatase 21 2.6 14 1.6 Increased bilirubin 13 3.1 6 0 CHECKMATE-067 The safety of intravenous nivolumab, administered with ipilimumab or as a single agent, was evaluated in CHECKMATE-067, a randomized (1:1:1), double-blind trial in 937 patients with previously untreated, unresectable or metastatic melanoma [see Clinical Studies (14.2) ] . The trial excluded patients with autoimmune disease, a medical condition requiring systemic treatment with corticosteroids (more than 10 mg daily prednisone equivalent) or other immunosuppressive medication within 14 days of the start of study therapy, a positive test result for hepatitis B or C, or a history of HIV. Patients were randomized to receive: • Intravenous nivolumab 1 mg/kg over 60 minutes with ipilimumab 3 mg/kg by intravenous infusion every 3 weeks for 4 doses followed by intravenous nivolumab as a single agent at a dose of 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks (nivolumab and ipilimumab arm; n=313), or • Intravenous nivolumab 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks (nivolumab arm; n=313), or • Ipilimumab 3 mg/kg by intravenous infusion every 3 weeks for up to 4 doses (ipilimumab arm; n=311). The median duration of exposure to intravenous nivolumab was 2.8 months (range: 1 day to 36.4 months) for the intravenous nivolumab and ipilimumab arm and 6.6 months (range: 1 day to 36.0 months) for the intravenous nivolumab arm. In the intravenous nivolumab and ipilimumab arm, 39% were exposed to intravenous nivolumab for ≥6 months and 30% exposed for >1 year. In the intravenous nivolumab arm, 53% were exposed for ≥6 months and 40% for >1 year. The population characteristics were: 65% male, median age 61 years, 97% White, baseline ECOG performance status 0 (73%) or 1 (27%), 93% with American Joint Committee on Cancer (AJCC) Stage IV disease, 58% with M1c stage disease; 36% with elevated LDH at baseline, 4% with a history of brain metastasis, and 22% had received adjuvant therapy. Serious adverse reactions (74% and 44%), adverse reactions leading to permanent discontinuation (47% and 18%) or to dosing delays (58% and 36%), and Grade 3 or 4 adverse reactions (72% and 51%) all occurred more frequently in the intravenous nivolumab and ipilimumab arm relative to the intravenous nivolumab arm. The most frequent (≥10%) serious adverse reactions in the intravenous nivolumab and ipilimumab arm and the intravenous nivolumab arm, respectively, were diarrhea (13% and 2.2%), colitis (10% and 1.9%), and pyrexia (10% and 1%). The most frequent adverse reactions leading to discontinuation of both drugs in the intravenous nivolumab and ipilimumab arm and of intravenous nivolumab in the intravenous nivolumab arm, respectively, were colitis (10% and 0.6%), diarrhea (8% and 2.2%), increased ALT (4.8% and 1%), increased AST (4.5% and 0.6%), and pneumonitis (1.9% and 0.3%). The most common (≥20%) adverse reactions in the intravenous nivolumab and ipilimumab arm were fatigue, diarrhea, rash, nausea, pyrexia, pruritus, musculoskeletal pain, vomiting, decreased appetite, cough, headache, dyspnea, upper respiratory tract infection, arthralgia, and increased transaminases. The most common (≥20%) adverse reactions in the intravenous nivolumab arm were fatigue, rash, musculoskeletal pain, diarrhea, nausea, cough, pruritus, upper respiratory tract infection, decreased appetite, headache, constipation, arthralgia, and vomiting. Tables 17 and 18 summarize the incidence of adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-067. Table 17: Adverse Reactions Occurring in ≥10% of Patients on the Intravenous Nivolumab and Ipilimumab Arm or the Intravenous Nivolumab Arm and at a Higher Incidence than in the Ipilimumab Arm (Between Arm Difference of ≥5% All Grades or ≥2% Grades 3-4) - CHECKMATE-067 Toxicity was graded per NCI CTCAE v4. a Includes asthenia and fatigue. b Includes pustular rash, dermatitis, acneiform dermatitis, allergic dermatitis, atopic dermatitis, bullous dermatitis, exfoliative dermatitis, psoriasiform dermatitis, drug eruption, exfoliative rash, erythematous rash, generalized rash, macular rash, maculopapular rash, morbilliform rash, papular rash, papulosquamous rash, and pruritic rash. c Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity, and spinal pain. d Includes upper respiratory tract infection, nasopharyngitis, pharyngitis, and rhinitis. e Includes hypertension and blood pressure increased. Adverse Reaction Intravenous Nivolumab and Ipilimumab (n=313) Intravenous Nivolumab (n=313) Ipilimumab (n=311) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) General Fatigue a 62 7 59 1.6 51 4.2 Pyrexia 40 1.6 16 0 18 0.6 Gastrointestinal Diarrhea 54 11 36 5 47 7 Nausea 44 3.8 30 0.6 31 1.9 Vomiting 31 3.8 20 1 17 1.6 Skin and Subcutaneous Tissue Rash b 53 6 40 1.9 42 3.5 Vitiligo 9 0 10 0.3 5 0 Musculoskeletal and Connective Tissue Musculoskeletal pain c 32 2.6 42 3.8 36 1.9 Arthralgia 21 0.3 21 1 16 0.3 Metabolism and Nutrition Decreased appetite 29 1.9 22 0 24 1.3 Respiratory, Thoracic and Mediastinal Cough/productive cough 27 0.3 28 0.6 22 0 Dyspnea/exertional dyspnea 24 2.9 18 1.3 17 0.6 Infections Upper respiratory tract infection d 23 0 22 0.3 17 0 Endocrine Hypothyroidism 19 0.6 11 0 5 0 Hyperthyroidism 11 1.3 6 0 1 0 Investigations Decreased weight 12 0 7 0 7 0.3 Vascular Hypertension e 7 2.2 11 5 9 2.3 Clinically important adverse reactions in <10% of patients who received intravenous nivolumab with ipilimumab or intravenous nivolumab as a single agent were: Gastrointestinal Disorders: stomatitis, intestinal perforation Skin and Subcutaneous Tissue Disorders: vitiligo Musculoskeletal and Connective Tissue Disorders: myopathy, Sjogren’s syndrome, spondyloarthropathy, myositis (including polymyositis) Nervous System Disorders: neuritis, peroneal nerve palsy Table 18: Laboratory Abnormalities Worsening from Baseline a Occurring in ≥20% of Patients Treated with Intravenous Nivolumab with Ipilimumab or Single-Agent Intravenous Nivolumab and at a Higher Incidence than in the Ipilimumab Arm (Between Arm Difference of ≥5% All Grades or ≥2% Grades 3-4) - CHECKMATE-067 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab and ipilimumab (range: 75 to 297); intravenous nivolumab (range: 81 to 306); ipilimumab (range: 61 to 301). Laboratory Abnormality Intravenous Nivolumab and Ipilimumab Intravenous Nivolumab Ipilimumab All Grades (%) Grade 3-4 (%) All Grades (%) Grade 3-4 (%) All Grades (%) Grade 3-4 (%) Chemistry Increased ALT 55 16 25 3 29 2.7 Hyperglycemia 53 5.3 46 7 26 0 Increased AST 52 13 29 3.7 29 1.7 Hyponatremia 45 10 22 3.3 26 7 Increased lipase 43 22 32 12 24 7 Increased alkaline phosphatase 41 6 27 2 23 2 Hypocalcemia 31 1.1 15 0.7 20 0.7 Increased amylase 27 10 19 2.7 15 1.6 Increased creatinine 26 2.7 19 0.7 17 1.3 Hematology Anemia 52 2.7 41 2.6 41 6 Lymphopenia 39 5 41 4.9 29 4 Adjuvant Treatment of Melanoma CHECKMATE-76K The safety of intravenous nivolumab as a single agent was evaluated in CHECKMATE-76K, a randomized (2:1), double-blind trial in 788 patients with completely resected Stage IIB/C melanoma who received intravenous nivolumab 480 mg by intravenous infusion over 30 minutes every 4 weeks (n=524) or placebo by intravenous infusion over 30 minutes every 4 weeks (n=264) for up to 1 year [see Clinical Studies (14.3) ] . The median duration of exposure was 11 months in patients treated with intravenous nivolumab and 11 months in patients treated with placebo. Serious adverse reactions occurred in 18% of patients treated with intravenous nivolumab. A fatal adverse reaction occurred in 1 (0.2%) patient (heart failure and acute kidney injury). Permanent discontinuation of intravenous nivolumab due to an adverse reaction occurred in 17% of patients. Adverse reactions which resulted in permanent discontinuation of intravenous nivolumab in >1% of patients included diarrhea (1.1%), arthralgia (1.7%), and rash (1.7%). Dosage interruptions of intravenous nivolumab due to an adverse reaction occurred in 25% of patients. Adverse reactions which required dosage interruption in >1% of patients included COVID-19 infection, infusion related reaction, diarrhea, arthralgia, and increased ALT. The most common adverse reactions (reported in ≥20% of patients) were fatigue, musculoskeletal pain, rash, diarrhea, and pruritus. Tables 19 and 20 summarize the adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-76K. Table 19: Adverse Reactions Occurring in ≥10% of Patients Treated with Intravenous Nivolumab - CHECKMATE-76K Toxicity was graded per NCI CTCAE v5. a Includes asthenia. b Includes arthralgia, arthritis, back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal stiffness, myalgia, neck pain, non-cardiac chest pain, spinal pain, pain in extremity. c Includes dermatitis, dermatitis acneiform, dyshidrotic eczema, eczema, eczema asteatotic, eyelid rash, genital rash, pemphigoid, penile rash, rash erythematous, rash follicular, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, rash vesicular, skin exfoliation, toxic skin eruption. d Includes autoimmune colitis, colitis, diarrhea, enteritis, enterocolitis e Includes autoimmune hypothyroidism, blood thyroid stimulating hormone increased. f Includes cluster headache, migraine. Adverse Reaction Intravenous Nivolumab (n=524) Placebo (n=264) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) General Fatigue a 36 0.4 34 0.4 Musculoskeletal and connective tissue Musculoskeletal pain b 30 0.4 26 0.4 Skin and Subcutaneous Tissue Rash c 28 1.1 15 0.4 Pruritus 20 0.2 11 0 Gastrointestinal Diarrhea d 23 1.3 16 0 Nausea 14 0 11 0 Endocrine Hypothyroidism e 14 0 2.3 0 Nervous system Headache f 12 0.2 14 0.8 Table 20: Laboratory Abnormalities Worsening from Baseline a Occurring in ≥10% of Intravenous Nivolumab-Treated Patients - CHECKMATE-76K a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab group (range: 262 to 513 patients) and placebo group (range: 138 to 261 patients). Laboratory Abnormality Intravenous Nivolumab (n=524) Placebo (n=264) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Hematology Anemia 19 0 14 0 Lymphopenia 17 1.1 17 1.7 Neutropenia 10 0 10 0.4 Chemistry AST increased 25 2.2 16 0.4 Lipase increased 22 2.9 21 2.3 ALT increased 20 2.1 15 0.4 Amylase increased 17 0.4 9 0 Creatinine increased 15 0.4 13 0 Sodium decreased 13 0.6 11 0.4 Potassium increased 13 1 15 1.1 CHECKMATE-238 The safety of intravenous nivolumab as a single agent was evaluated in CHECKMATE-238, a randomized (1:1), double-blind trial in 905 patients with completely resected Stage IIIB/C or Stage IV melanoma received intravenous nivolumab 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks (n=452) or ipilimumab 10 mg/kg by intravenous infusion every 3 weeks for 4 doses then every 12 weeks beginning at Week 24 for up to 1 year (n=453) [see Clinical Studies (14.3) ] . The median duration of exposure was 11.5 months in intravenous nivolumab‑treated patients and was 2.7 months in ipilimumab-treated patients. In this ongoing trial, 74% of patients received intravenous nivolumab for >6 months. Serious adverse reactions occurred in 18% of intravenous nivolumab-treated patients. Study therapy was discontinued for adverse reactions in 9% of intravenous nivolumab-treated patients and 42% of ipilimumab-treated patients. Twenty-eight percent of intravenous nivolumab-treated patients had at least one omitted dose for an adverse reaction. Grade 3 or 4 adverse reactions occurred in 25% of intravenous nivolumab-treated patients. The most frequent Grade 3 and 4 adverse reactions reported in ≥2% of intravenous nivolumab-treated patients were diarrhea and increased lipase and amylase. The most common adverse reactions (at least 20%) were fatigue, diarrhea, rash, musculoskeletal pain, pruritus, headache, nausea, upper respiratory infection, and abdominal pain. The most common immune-mediated adverse reactions were rash (16%), diarrhea/colitis (6%), and hepatitis (3%). Tables 21 and 22 summarize the adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-238. Table 21: Adverse Reactions Occurring in ≥10% of Intravenous Nivolumab-Treated Patients - CHECKMATE-238 Toxicity was graded per NCI CTCAE v4. a Includes asthenia. b Includes abdominal discomfort, lower abdominal pain, upper abdominal pain, and abdominal tenderness. c Includes dermatitis described as acneiform, allergic, bullous, or exfoliative and rash described as generalized, erythematous, macular, papular, maculopapular, pruritic, pustular, vesicular, or butterfly, and drug eruption. d Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, neck pain, spinal pain, and pain in extremity. e Includes postural dizziness and vertigo. f Includes upper respiratory tract infection including viral respiratory tract infection, lower respiratory tract infection, rhinitis, pharyngitis, and nasopharyngitis. g Includes secondary hypothyroidism and autoimmune hypothyroidism. Adverse Reaction Intravenous Nivolumab (n=452) Ipilimumab 10 mg/kg (n=453) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) General Fatigue a 57 0.9 55 2.4 Gastrointestinal Diarrhea 37 2.4 55 11 Nausea 23 0.2 28 0 Abdominal pain b 21 0.2 23 0.9 Constipation 10 0 9 0 Skin and Subcutaneous Tissue Rash c 35 1.1 47 5.3 Pruritus 28 0 37 1.1 Musculoskeletal and Connective Tissue Musculoskeletal pain d 32 0.4 27 0.4 Arthralgia 19 0.4 13 0.4 Nervous System Headache 23 0.4 31 2.0 Dizziness e 11 0 8 0 Infections Upper respiratory tract infection f 22 0 15 0.2 Respiratory, Thoracic and Mediastinal Cough/productive cough 19 0 19 0 Dyspnea/exertional dyspnea 10 0.4 10 0.2 Endocrine Hypothyroidism g 12 0.2 7.5 0.4 Table 22: Laboratory Abnormalities Worsening from Baseline a Occurring in ≥10% of Intravenous Nivolumab-Treated Patients - CHECKMATE-238 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab group (range: 400 to 447 patients) and ipilimumab 10 mg/kg group (range: 392 to 443 patients). Laboratory Abnormality Intravenous Nivolumab Ipilimumab 10 mg/kg All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Hematology Lymphopenia 27 0.4 12 0.9 Anemia 26 0 34 0.5 Leukopenia 14 0 2.7 0.2 Neutropenia 13 0 6 0.5 Chemistry Increased Lipase 25 7 23 9 Increased ALT 25 1.8 40 12 Increased AST 24 1.3 33 9 Increased Amylase 17 3.3 13 3.1 Hyponatremia 16 1.1 22 3.2 Hyperkalemia 12 0.2 9 0.5 Increased Creatinine 12 0 13 0 Hypocalcemia 10 0.7 16 0.5 Non-Small Cell Lung Cancer Neoadjuvant Treatment of Resectable (Tumors ≥4 cm or Node Positive) Non-Small Cell Lung Cancer CHECKMATE-816 The safety of intravenous nivolumab in combination with platinum-doublet chemotherapy was evaluated in CHECKMATE-816, a randomized, open-label, multicenter trial in patients with resectable NSCLC [see Clinical Studies (14.4) ] . Patients received either intravenous nivolumab 360 mg administered in combination with platinum-doublet chemotherapy administered every 3 weeks for 3 cycles; or platinum-doublet chemotherapy administered every 3 weeks for 3 cycles. The median age of patients who received intravenous nivolumab in combination with platinum-doublet chemotherapy or platinum-doublet chemotherapy was 65 years (range: 34 – 84); 72% male; 47% White, 50% Asian, and 2% Black/African American. Serious adverse reactions occurred in 30% of patients who were treated with intravenous nivolumab in combination with platinum-doublet chemotherapy. Serious adverse reactions in >2% included pneumonia and vomiting. No fatal adverse reactions occurred in patients who received intravenous nivolumab in combination with platinum-doublet chemotherapy. Study therapy with intravenous nivolumab in combination with platinum-doublet chemotherapy was permanently discontinued for adverse reactions in 10% of patients and 30% had at least one treatment withheld for an adverse reaction. The most common adverse reactions (≥1%) resulting in permanent discontinuation of intravenous nivolumab in combination with platinum-doublet chemotherapy were anaphylactic reaction (1.7%), acute kidney injury (1.1%), rash (1.1%), and fatigue (1.1%). The most common (>20%) adverse reactions were nausea, constipation, fatigue, decreased appetite, and rash. The most common Grade 3 or 4 laboratory abnormalities (≥2%) were neutropenia, hyperglycemia, leukopenia, lymphopenia, increased amylase, anemia, thrombocytopenia, and hyponatremia. Tables 23 and 24 summarize selected adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-816. Table 23: Adverse Reactions in >10% of Patients with Early-Stage NSCLC Receiving Neoadjuvant Intravenous Nivolumab and Platinum-Doublet Chemotherapy in CHECKMATE-816 Toxicity was graded per NCI CTCAE v4. a Includes fatigue and asthenia b Includes rash, dermatitis, acneiform dermatitis, atopic dermatitis, bullous dermatitis, drug eruption, maculopapular rash, and pruritic rash. c Includes peripheral neuropathy, dysesthesia, hypoesthesia, peripheral motor neuropathy, peripheral sensory neuropathy. Adverse Reaction Intravenous Nivolumab and Platinum-Doublet Chemotherapy (n=176) Platinum-Doublet Chemotherapy (n=176) All Grades (%) Grades 3 or 4 (%) All Grades (%) Grades 3 or 4 (%) Gastrointestinal Nausea 38 0.6 45 1.1 Constipation 34 0 32 1.1 Vomiting 11 1.1 13 0.6 General Fatigue a 26 2.3 23 1.1 Malaise 15 0.6 14 0.6 Metabolism and Nutrition Decreased appetite 20 1.1 23 2.3 Skin and Subcutaneous Tissue Rash b 20 2.3 7 0 Alopecia 11 0 15 0 Nervous System Peripheral neuropathy c 13 0 6 0 Table 24: Select Laboratory Values Worsening from Baseline a Occurring in >20% of Patients with Early-Stage NSCLC Receiving Neoadjuvant Intravenous Nivolumab and Platinum-Doublet Chemotherapy in CHECKMATE-816 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab and platinum-doublet chemotherapy group (range: 73 to 171 patients) and platinum-doublet chemotherapy group (range: 68 to 171 patients). Laboratory Abnormality Intravenous Nivolumab and Platinum-Doublet Chemotherapy a Platinum-Doublet Chemotherapy a All Grades (%) Grades 3 or 4 (%) All Grades (%) Grades 3 or 4 (%) Hematology Anemia 63 3.5 70 6 Neutropenia 58 22 58 27 Leukopenia 53 5 51 11 Lymphopenia 38 4.7 31 1.8 Thrombocytopenia 24 2.9 22 3 Chemistry Hyperglycemia 37 6 35 2.9 Hypomagnesemia 25 1.2 29 1.2 Hyponatremia 25 2.4 28 1.8 Increased amylase 23 3.6 13 1.8 Increased ALT 23 0 20 1.2 Neoadjuvant and Adjuvant Treatment of Resectable (Tumors ≥4 cm or Node Positive) Non-Small Cell Lung Cancer CHECKMATE-77T The safety of intravenous nivolumab in combination with neoadjuvant platinum-doublet chemotherapy followed by surgery and continued adjuvant treatment with intravenous nivolumab as a single agent after surgery was evaluated in CHECKMATE-77T, a randomized, double-blind, multicenter trial in patients with previously untreated resectable Stage IIA (>4 cm) to IIIB (T3N2 or T4N2) NSCLC (per the AJCC Cancer Staging Manual 8th Edition) [see Clinical Studies (14.5) ] . Patients with active autoimmune disease or a medical condition that required immunosuppression were ineligible. The median duration of exposure to intravenous nivolumab was 10.3 months (range: 1 day to 22.3 months). The study population characteristics were: median age 66 years (range: 35 - 86); 71% male; 72% White, 25% Asian, 1.7% Black/African American, and 1.5% other race; and 6% Hispanic or Latino. Adverse reactions occurring in patients with resectable NSCLC receiving intravenous nivolumab in combination with platinum-doublet chemotherapy, given as neoadjuvant treatment and followed as a single agent adjuvant treatment after surgery, were generally similar to those occurring in patients in other clinical trials across tumor types receiving intravenous nivolumab in combination with chemotherapy. Neoadjuvant Phase of CHECKMATE-77T A total of 228 patients received at least 1 dose of intravenous nivolumab in combination with platinum-doublet chemotherapy as neoadjuvant treatment and 230 patients received at least 1 dose of placebo in combination with platinum-doublet chemotherapy as neoadjuvant treatment. Serious adverse reactions occurred in 21% of patients who received intravenous nivolumab in combination with platinum-doublet chemotherapy as neoadjuvant treatment; the most frequent (≥2%) serious adverse reactions was pneumonia. Fatal adverse reactions occurred in 2.2% of patients, due to cerebrovascular accident, COVID-19 infection, hemoptysis, pneumonia, and pneumonitis (0.4% each). Permanent discontinuation of any study drug due to an adverse reaction occurred in 13% of patients who received intravenous nivolumab in combination with platinum-doublet chemotherapy as neoadjuvant treatment; the most frequent (≥1%) adverse reaction that led to permanent discontinuation of any study drug was peripheral sensory neuropathy (2.2%). Of the 228 intravenous nivolumab-treated patients and 230 placebo-treated patients who received neoadjuvant treatment, 5.3% (n=12) and 3.5% (n=8), respectively, did not receive surgery due to adverse reactions. The adverse reactions that led to cancellation of surgery in intravenous nivolumab-treated patients were cerebrovascular accident, pneumonia, and colitis/diarrhea (2 patients each) and acute coronary syndrome, myocarditis, hemoptysis, pneumonitis, COVID-19, and myositis (1 patient each). Of the 178 intravenous nivolumab-treated patients who received surgery, 4.5% (n=8) experienced delay of surgery (surgery more than 6 weeks from last neoadjuvant treatment) due to adverse reactions. Of the 178 placebo-treated patients who received surgery, 3.9% (n=7) experienced delay of surgery due to adverse reactions. Of the 178 intravenous nivolumab-treated patients who received surgery, 7% (n=13) did not receive adjuvant treatment due to adverse reactions. Of the 178 placebo-treated patients who received surgery, 2.8% (n=5) did not receive adjuvant treatment due to adverse reactions. Adjuvant Phase of CHECKMATE-77T A total of 142 patients in the intravenous nivolumab arm and 152 patients in the placebo arm received at least 1 dose of adjuvant treatment. Of the patients who received single agent intravenous nivolumab as adjuvant treatment, 22% experienced serious adverse reactions; the most frequent serious adverse reaction was pneumonitis/ILD (2.8%). One fatal adverse reaction due to COVID-19 occurred. Permanent discontinuation of adjuvant intravenous nivolumab due to an adverse reaction occurred in 14% of patients; the most frequent (≥1%) adverse reactions that led to permanent discontinuation of adjuvant intravenous nivolumab were pneumonitis (4.2%) and diarrhea (1.4%). Second-line Treatment of Metastatic NSCLC CHECKMATE-017 and CHECKMATE-057 The safety of intravenous nivolumab was evaluated in CHECKMATE-017, a randomized open-label, multicenter trial in patients with metastatic squamous NSCLC and progression on or after one prior platinum doublet-based chemotherapy regimen and in CHECKMATE-057, a randomized, open-label, multicenter trial in patients with metastatic non-squamous NSCLC and progression on or after one prior platinum doublet-based chemotherapy regimen [see Clinical Studies (14.6) ] . These trials excluded patients with active autoimmune disease, medical conditions requiring systemic immunosuppression, or with symptomatic interstitial lung disease. Patients received intravenous nivolumab 3 mg/kg over 60 minutes by intravenous infusion every 2 weeks or docetaxel 75 mg/m 2 intravenously every 3 weeks. The median duration of therapy in intravenous nivolumab-treated patients in CHECKMATE-017 was 3.3 months (range: 1 day to 21.7+ months) and in CHECKMATE-057 was 2.6 months (range: 0 to 24.0+ months). In CHECKMATE-017, 36% of patients received intravenous nivolumab for at least 6 months and 18% of patients received intravenous nivolumab for at least 1 year and in CHECKMATE-057, 30% of patients received intravenous nivolumab for >6 months and 20% of patients received intravenous nivolumab for >1 year. Across both trials, the median age of intravenous nivolumab-treated patients was 61 years (range: 37 to 85); 38% were ≥65 years of age, 61% were male, and 91% were White. Ten percent of patients had brain metastases and ECOG performance status was 0 (26%) or 1 (74%). In CHECKMATE-057, in the intravenous nivolumab arm, seven deaths were due to infection including one case of Pneumocystis jirovecii pneumonia, four were due to pulmonary embolism, and one death was due to limbic encephalitis. Serious adverse reactions occurred in 46% of patients receiving intravenous nivolumab. Intravenous nivolumab was discontinued in 11% of patients and was delayed in 28% of patients for an adverse reaction. The most frequent serious adverse reactions reported in ≥2% of patients receiving intravenous nivolumab were pneumonia, pulmonary embolism, dyspnea, pyrexia, pleural effusion, pneumonitis, and respiratory failure. Across both trials, the most common adverse reactions (≥20%) were fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite. Tables 25 and 26 summarize selected adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-057. Table 25: Adverse Reactions Occurring in ≥10% of Intravenous Nivolumab-Treated Patients and at a Higher Incidence than Docetaxel (Between Arm Difference of ≥5% All Grades or ≥2% Grades 3-4) - CHECKMATE-017 and CHECKMATE-057 Toxicity was graded per NCI CTCAE v4. Adverse Reaction Intravenous Nivolumab (n=418) Docetaxel (n=397) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Respiratory, Thoracic and Mediastinal Cough 31 0.7 24 0 Metabolism and Nutrition Decreased appetite 28 1.4 23 1.5 Skin and Subcutaneous Tissue Pruritus 10 0.2 2 0 Other clinically important adverse reactions observed in intravenous nivolumab-treated patients and which occurred at a similar incidence in docetaxel-treated patients and not listed elsewhere in section 6 include: fatigue/asthenia (48% all Grades, 5% Grade 3-4), musculoskeletal pain (33% all Grades), pleural effusion (4.5% all Grades), pulmonary embolism (3.3% all Grades). Table 26: Laboratory Abnormalities Worsening from Baseline a Occurring in ≥10% of Intravenous Nivolumab-Treated Patients for all NCI CTCAE Grades and at a Higher Incidence than Docetaxel (Between Arm Difference of ≥5% All Grades or ≥2% Grades 3-4) - CHECKMATE-017 and CHECKMATE-057 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab group (range: 405 to 417 patients) and docetaxel group (range: 372 to 390 patients), except for TSH: intravenous nivolumab group n=314 and docetaxel group n=297. b Not graded per NCI CTCAE v4. Laboratory Abnormality Intravenous Nivolumab Docetaxel All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Chemistry Hyponatremia 35 7 34 4.9 Increased AST 27 1.9 13 0.8 Increased alkaline phosphatase 26 0.7 18 0.8 Increased ALT 22 1.7 17 0.5 Increased creatinine 18 0 12 0.5 Increased TSH b 14 N/A 6 N/A Squamous Cell Carcinoma of the Head and Neck CHECKMATE-141 The safety of intravenous nivolumab was evaluated in CHECKMATE-141, a randomized, active-controlled, open-label, multicenter trial in patients with recurrent or metastatic SCCHN with progression during or within 6 months of receiving prior platinum-based therapy [see Clinical Studies (14.7) ] . The trial excluded patients with active autoimmune disease, medical conditions requiring systemic immunosuppression, or recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary histology, salivary gland or non-squamous histologies (e.g., mucosal melanoma). Patients received intravenous nivolumab 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks (n=236) or investigator’s choice of either cetuximab (400 mg/m 2 initial dose intravenously followed by 250 mg/m 2 weekly), or methotrexate (40 to 60 mg/m 2 intravenously weekly), or docetaxel (30 to 40 mg/m 2 intravenously weekly). The median duration of exposure to nivolumab was 1.9 months (range: 1 day to 16.1+ months) in intravenous nivolumab-treated patients. In this trial, 18% of patients received intravenous nivolumab for >6 months and 2.5% of patients received intravenous nivolumab for >1 year. The median age of all randomized patients was 60 years (range: 28 to 83); 28% of patients in the intravenous nivolumab group were ≥65 years of age and 37% in the comparator group were ≥65 years of age, 83% were male and 83% were White, 12% were Asian, and 4% were Black. Baseline ECOG performance status was 0 (20%) or 1 (78%), 45% of patients received only one prior line of systemic therapy, the remaining 55% of patients had two or more prior lines of therapy, and 90% had prior radiation therapy. Serious adverse reactions occurred in 49% of patients receiving intravenous nivolumab. Intravenous nivolumab was discontinued in 14% of patients and was delayed in 24% of patients for an adverse reaction. Adverse reactions and laboratory abnormalities occurring in patients with SCCHN were generally similar to those occurring in patients with melanoma and NSCLC. The most frequent serious adverse reactions reported in ≥2% of patients receiving intravenous nivolumab were pneumonia, dyspnea, respiratory failure, respiratory tract infection, and sepsis. The most common adverse reactions occurring in ≥10% of intravenous nivolumab-treated patients and at a higher incidence than investigator’s choice were cough and dyspnea. The most common laboratory abnormalities occurring in ≥10% of intravenous nivolumab-treated patients and at a higher incidence than investigator’s choice were increased alkaline phosphatase, increased amylase, hypercalcemia, hyperkalemia, and increased TSH. Urothelial Carcinoma Adjuvant Treatment of Urothelial Carcinoma (UC) CHECKMATE-274 The safety of intravenous nivolumab was evaluated in CHECKMATE-274, a randomized, double‑blind, multicenter trial of adjuvant intravenous nivolumab versus placebo in adult patients who had undergone radical resection of UC originating in the bladder or upper urinary tract (renal pelvis or ureter) and were at high risk of recurrence [see Clinical Studies (14.8) ] . Patients received intravenous nivolumab 240 mg by intravenous infusion over 30 minutes every 2 weeks (n=351) or placebo (n=348) until recurrence or unacceptable toxicity for a maximum of 1 year. The median duration of intravenous nivolumab treatment was 8.8 months (range: 0 to 12.5). Serious adverse reactions occurred in 30% of intravenous nivolumab patients. The most frequent serious adverse reaction reported in ≥2% of patients was urinary tract infection. Fatal adverse reactions occurred in 1% of patients; these included events of pneumonitis (0.6%). Intravenous nivolumab was discontinued for adverse reactions in 18% of patients. Intravenous nivolumab was delayed for adverse reaction in 33% of patients. The most common adverse reactions (reported in ≥20% of patients) were rash, fatigue, diarrhea, pruritus, musculoskeletal pain, and urinary tract infection. Tables 27 and 28 summarize adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-274. Table 27: Adverse Reactions Occurring in ≥10% of Patients - CHECKMATE-274 Toxicity was graded per NCI CTCAE v4. a Includes acne, blister, dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis contact, eczema, eczema asteatotic, eczema nummular, erythema, erythema multiforme, lichen sclerosus, lichenoid keratosis, pemphigoid, photosensitivity reaction, pigmentation disorder, psoriasis, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, rosacea, skin exfoliation, skin lesion, skin reaction, toxic skin eruption, and urticaria. b Includes colitis, colitis microscopic, diarrhea, duodenitis, enteritis, immune-mediated enterocolitis c Includes abdominal pain, abdominal discomfort, abdominal tenderness, lower and upper abdominal pain. d Includes musculoskeletal pain, back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity and spinal pain. e Includes cystitis, escherichia urinary tract infection, pyelonephritis, pyelonephritis acute, pyelonephritis chronic, urethritis, urinary tract infection, urinary tract infection bacterial, urinary tract infection staphylococcal, and urosepsis. f Includes upper respiratory tract infection, nasopharyngitis, pharyngitis and rhinitis. g Includes acute kidney injury, autoimmune nephritis, blood creatinine increased, glomerular filtration rate decreased, immune-mediated nephritis, nephritis, renal failure, and renal impairment. h Includes cough, productive cough, and upper-airway cough syndrome. i Includes dyspnea and exertional dyspnea. j Includes dizziness, postural dizziness and vertigo. k Includes aspartate aminotransferase increased, alanine aminotransferase increased, blood bilirubin increased, cholangitis, drug-induced liver injury, hepatic failure, hepatic function abnormal, hepatitis, hepatocellular injury, hyperbilirubinemia, gamma-glutamyl transferase increased, liver injury, and transaminases increased. Adverse Reaction Intravenous Nivolumab (n=351) Placebo (n=348) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Skin and Subcutaneous Tissue Rash a 36 1.7 19 0.3 Pruritus 30 0 16 0 General Fatigue/Asthenia 36 1.1 32 0.3 Pyrexia 10 0.3 10 0.3 Gastrointestinal Diarrhea b 30 2.8 27 1.7 Nausea 16 0.6 13 0 Abdominal pain c 15 0.9 15 0.6 Constipation 13 0.3 15 0.3 Musculoskeletal and Connective Tissue Musculoskeletal pain d 28 0.6 24 0.9 Arthralgia 11 0.3 13 0 Infections Urinary tract infection e 22 6 23 9 Upper respiratory tract infection f 16 0.3 16 0.6 Endocrine Hyperthyroidism 11 0 1.1 0 Hypothyroidism 11 0 2.3 0 Renal and Urinary Disorders Renal dysfunction g 17 1.7 16 0.9 Respiratory, Thoracic and Mediastinal Cough h 14 0 11 0 Dyspnea i 11 0.3 6 0.3 Metabolism and Nutrition Decreased appetite 13 0.9 7 0.3 Nervous System Disorders Dizziness j 11 0.3 9 0 Hepatobiliary Hepatitis k 11 4 8 0.6 Table 28: Laboratory Abnormalities Worsening from Baseline a Occurring in ≥10% of Patients - CHECKMATE-274 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab group (range: 322 to 348 patients) and placebo group (range: 312 to 341 patients). Laboratory Abnormality Intravenous Nivolumab (n=351) Placebo (n=348) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Chemistry Increased creatinine 36 1.7 36 2.6 Increased amylase 34 8 23 3.2 Increased lipase 33 12 31 10 Hyperkalemia 32 5 30 6 Increased alkaline phosphatase 24 2.3 15 0.6 Increased AST 24 3.5 16 0.9 Increased ALT 23 2.9 15 0.6 Hyponatremia 22 4.1 17 1.8 Hypocalcemia 17 1.2 11 0.9 Hypomagnesemia 16 0 9 0 Hypercalcemia 12 0.3 8 0.3 Hematology Lymphopenia 33 2.9 27 1.5 Anemia 30 1.4 28 0.9 Neutropenia 11 0.6 10 0.3 First-line Treatment of Unresectable or Metastatic UC CHECKMATE-901 The safety of intravenous nivolumab was evaluated in CHECKMATE-901, a randomized, open-label trial in cisplatin-eligible patients with unresectable or metastatic UC [see Clinical Studies (14.8) ] . Patients received either intravenous nivolumab 360 mg with cisplatin and gemcitabine every 3 weeks for up to 6 cycles followed by single-agent intravenous nivolumab 480 mg every 4 weeks up to 2 years (n=304), or cisplatin and gemcitabine chemotherapy every 3 weeks for up to 6 cycles (n=288). Patients discontinuing cisplatin alone were permitted to switch to carboplatin. Among patients who received intravenous nivolumab with chemotherapy, the median duration of intravenous nivolumab exposure was 7.4 months (range: 0.03 to 47.9 months). Serious adverse reactions occurred in 48% of patients receiving intravenous nivolumab in combination with chemotherapy. The most frequent serious adverse reactions reported in ≥2% of patients who received intravenous nivolumab with chemotherapy were urinary tract infection (4.9%), acute kidney injury (4.3%), anemia (3%), pulmonary embolism (2.6%), sepsis (2.3%), and platelet count decreased (2.3%). The most common adverse reactions (reported in ≥20% of patients) were nausea, fatigue, musculoskeletal pain, constipation, decreased appetite, rash, vomiting, and peripheral neuropathy. Fatal adverse reactions occurred in 3.6% of patients who received intravenous nivolumab in combination with chemotherapy; these included sepsis (1%). Intravenous nivolumab and/or chemotherapy were discontinued in 30% of patients and were delayed in 67% of patients for an adverse reaction. Tables 29 and 30 summarize the adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-901. Table 29: Adverse Reactions Occurring in ≥10% of Treated Patients - CHECKMATE-901 Toxicity was graded per NCI CTCAE v4. a Includes colitis, immune-mediated enterocolitis. b Includes upper abdominal pain, lower abdominal pain, abdominal discomfort, epigastric discomfort, gastrointestinal pain, and hepatic pain. c Includes asthenia. d Includes peripheral edema, swelling, peripheral swelling, localized edema, swelling, face edema, testicular edema, gravitational edema, and edema genital. e Includes hyperthermia, body temperature increased and hyperpyrexia. f Includes back pain, arthralgia, bone pain, arthritis, musculoskeletal chest pain, non-cardiac chest pain, myalgia, neck pain, pain in extremity, and spinal pain. g Includes maculopapular rash, erythematous rash, macular rash, papular rash, pustular rash, acneiform dermatitis, dermatitis, allergic dermatitis, atopic dermatitis, exfoliative rash, eczema asteatotic, erythema multiforme, palmar-plantar erythrodysesthesia syndrome, eczema, dermatitis exfoliative generalized, and skin exfoliation. h Includes paresthesia, peripheral sensory neuropathy, hypoesthesia, dysesthesia, neuralgia, hyperesthesia, peripheral motor neuropathy, polyneuropathy. i Includes occipital neuralgia. j Includes urosepsis, cystitis, pyelonephritis, pyelonephritis acute, urinary tract infection enterococcal, escherichia urinary tract infection. k Includes blood stimulating hormone increased. l Includes acute kidney injury, renal failure, renal impairment, glomerular filtration rate decreased, anuria, azotemia. Adverse Reaction Intravenous Nivolumab and Platinum-Doublet Chemotherapy (n=304) Platinum-Doublet Chemotherapy (n=288) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Gastrointestinal disorders Nausea 52 0.3 53 1 Constipation 30 0 28 0.7 Vomiting 23 1.3 19 2.1 Diarrhea a 19 2 14 0 Abdominal pain b 14 0.3 9 0.3 General Fatigue c 48 3.9 43 4.2 Edema d 18 0 9 0.3 Pyrexia e 14 1 14 0 Musculoskeletal and Connective Tissue Musculoskeletal pain f 33 3 21 0.3 Metabolism and Nutrition Decreased appetite 30 1.6 19 1 Skin and Subcutaneous Tissue Rash g 25 2.3 7 0.3 Pruritus 17 0.7 3.5 0 Nervous System Disorders Peripheral neuropathy h 20 0.7 14 0 Headache i 11 0 5 0 Infections Urinary tract infection j 19 8 18 8 Endocrine disorders Hypothyroidism k 17 0 0.3 0 Renal and Urinary Disorders Renal dysfunction l 14 6 11 1.7 Hematuria 11 1 7 1.4 Investigations Weight decreased 11 0.3 6 0 Table 30: Selected Laboratory Abnormalities Worsening from Baseline a Occurring in ≥20% of Patients - CHECKMATE-901 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab group (range: 289-301 patients) and chemotherapy group (range: 265-281 patients). Laboratory Abnormality Intravenous Nivolumab and Platinum-Doublet Chemotherapy (n=304) Platinum-Doublet Chemotherapy (n=288) Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Hematology Anemia 88 21 80 21 Neutropenia 82 35 76 28 Lymphopenia 71 17 56 13 Thrombocytopenia 60 13 51 8 Chemistry Increased creatinine 53 2.4 42 1.1 Hypomagnesemia 48 3.8 39 1.5 Hyponatremia 43 13 39 8 Hyperglycemia 41 3.9 37 3.2 Hypocalcemia 36 2.1 24 1.1 Hyperkalemia 33 3.0 32 1.1 Increased amylase 32 4.2 23 3.6 Increased AST 31 2.4 17 0.7 Increased ALT 29 2.4 19 0.7 Previously Treated Advanced or Metastatic UC CHECKMATE-275 The safety of intravenous nivolumab was evaluated in CHECKMATE-275, a single arm trial in which 270 patients with locally advanced or metastatic UC had disease progression during or following platinum-containing chemotherapy or had disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy [see Clinical Studies (14.8) ] . Patients received intravenous nivolumab 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity. The median duration of treatment was 3.3 months (range: 0 to 13.4+). Forty-six percent (46%) of patients had a dose interruption for an adverse reaction. Fourteen patients (5.2%) died from causes other than disease progression. This includes 4 patients (1.5%) who died from pneumonitis or cardiovascular failure which was attributed to treatment with intravenous nivolumab. Serious adverse reactions occurred in 54% of patients. Intravenous nivolumab was discontinued for adverse reactions in 17% of patients. The most frequent serious adverse reactions reported in ≥2% of patients were urinary tract infection, sepsis, diarrhea, small intestine obstruction, and general physical health deterioration. The most common adverse reactions (reported in ≥20% of patients) were fatigue, musculoskeletal pain, nausea, and decreased appetite. Tables 31 and 32 summarize adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-275. Table 31: Adverse Reactions Occurring in ≥10% of Patients - CHECKMATE-275 Toxicity was graded per NCI CTCAE v4. a Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity and spinal pain. b Includes abdominal discomfort, lower and upper abdominal pain. c Includes dermatitis, dermatitis acneiform, dermatitis bullous, and rash described as generalized, macular, maculopapular, or pruritic. d Includes autoimmune thyroiditis, blood TSH decrease, blood TSH increase, hyperthyroidism, hypothyroidism, thyroiditis, thyroxine decreased, thyroxine free increased, thyroxine increased, tri-iodothyronine free increased, tri-iodothyronine increased. Adverse Reaction Intravenous Nivolumab (n=270) All Grades (%) Grades 3-4 (%) Adverse Reaction 99 51 General Asthenia/fatigue/malaise 46 7 Pyrexia/tumor associated fever 17 0.4 Edema/peripheral edema/peripheral swelling 13 0.4 Musculoskeletal and Connective Tissue Musculoskeletal pain a 30 2.6 Arthralgia 10 0.7 Metabolism and Nutrition Decreased appetite 22 2.2 Gastrointestinal Nausea 22 0.7 Diarrhea 17 2.6 Constipation 16 0.4 Abdominal pain b 13 1.5 Vomiting 12 1.9 Respiratory, Thoracic and Mediastinal Cough/productive cough 18 0 Dyspnea/exertional dyspnea 14 3.3 Infections Urinary tract infection/escherichia/fungal urinary tract infection 17 7 Skin and Subcutaneous Tissue Rash c 16 1.5 Pruritus 12 0 Endocrine Thyroid disorders d 15 0 Table 32: Laboratory Abnormalities Worsening from Baseline Occurring in ≥10% of Patients - CHECKMATE-275 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: range: 84 to 256 patients. Laboratory Abnormality Intravenous Nivolumab a All Grades (%) Grades 3-4 (%) Chemistry Hyperglycemia 42 2.4 Hyponatremia 41 11 Increased creatinine 39 2 Increased alkaline phosphatase 33 5.5 Hypocalcemia 26 0.8 Increased AST 24 3.5 Increased lipase 20 7 Hyperkalemia 19 1.2 Increased ALT 18 1.2 Increased amylase 18 4.4 Hypomagnesemia 16 0 Hematology Lymphopenia 42 9 Anemia 40 7 Thrombocytopenia 15 2.4 Leukopenia 11 0 MSI-H or dMMR Metastatic Colorectal Cancer CHECKMATE‑142 The safety of intravenous nivolumab administered as a single agent or in combination with ipilimumab was evaluated in CHECKMATE‑142, a multicenter, non-randomized, multiple parallel-cohort, open-label trial [see Clinical Studies (14.9) ] . In CHECKMATE-142, 74 patients with mCRC received intravenous nivolumab 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks until disease progression or until intolerable toxicity and 119 patients with mCRC received intravenous nivolumab 3 mg/kg and ipilimumab 1 mg/kg every 3 weeks for 4 doses, then intravenous nivolumab 3 mg/kg every 2 weeks until disease progression or until unacceptable toxicity. In the intravenous nivolumab with ipilimumab cohort, serious adverse reactions occurred in 47% of patients. Treatment was discontinued in 13% of patients and delayed in 45% of patients for an adverse reaction. The most frequent serious adverse reactions reported in ≥2% of patients were colitis/diarrhea, hepatic events, abdominal pain, acute kidney injury, pyrexia, and dehydration. The most common adverse reactions (reported in ≥20% of patients) were fatigue, diarrhea, pyrexia, musculoskeletal pain, abdominal pain, pruritus, nausea, rash, decreased appetite, and vomiting. Tables 33 and 34 summarize adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-142. Based on the design of CHECKMATE-142, the data below cannot be used to identify statistically significant differences between the two cohorts summarized below for any adverse reaction. Table 33: Adverse Reactions Occurring in ≥10% of Patients - CHECKMATE-142 Toxicity was graded per NCI CTCAE v4. a Includes asthenia. b Includes peripheral edema and peripheral swelling. c Includes upper abdominal pain, lower abdominal pain, and abdominal discomfort. d Includes back pain, pain in extremity, myalgia, neck pain, and bone pain. e Includes dermatitis, dermatitis acneiform, and rash described as maculo-papular, erythematous, and generalized. f Includes nasopharyngitis and rhinitis. Adverse Reaction Intravenous Nivolumab (n=74) Intravenous Nivolumab and Ipilimumab (n=119) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) General Fatigue a 54 5 49 6 Pyrexia 24 0 36 0 Edema b 12 0 7 0 Gastrointestinal Diarrhea 43 2.7 45 3.4 Abdominal pain c 34 2.7 30 5 Nausea 34 1.4 26 0.8 Vomiting 28 4.1 20 1.7 Constipation 20 0 15 0 Musculoskeletal and Connective Tissue Musculoskeletal pain d 28 1.4 36 3.4 Arthralgia 19 0 14 0.8 Respiratory, Thoracic and Mediastinal Cough 26 0 19 0.8 Dyspnea 8 1 13 1.7 Skin and Subcutaneous Tissue Rash e 23 1.4 25 4.2 Pruritus 19 0 28 1.7 Dry Skin 7 0 11 0 Infections Upper respiratory tract infection f 20 0 9 0 Endocrine Hyperglycemia 19 2.7 6 1 Hypothyroidism 5 0 14 0.8 Hyperthyroidism 4 0 12 0 Nervous System Headache 16 0 17 1.7 Dizziness 14 0 11 0 Metabolism and Nutrition Decreased appetite 14 1.4 20 1.7 Psychiatric Insomnia 9 0 13 0.8 Investigations Weight decreased 8 0 10 0 Clinically important adverse reactions reported in <10% of patients receiving intravenous nivolumab with ipilimumab were encephalitis (0.8%), necrotizing myositis (0.8%), and uveitis (0.8%). Table 34: Laboratory Abnormalities Worsening from Baseline a Occurring in ≥10% of Patients - CHECKMATE-142 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available. Number of evaluable patients ranges from 62 to 71 for the intravenous nivolumab cohort and from 87 to 114 for the intravenous nivolumab and ipilimumab cohort. Laboratory Abnormality Intravenous Nivolumab (n=74) Intravenous Nivolumab and Ipilimumab (n=119) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Hematology Anemia 50 7 42 9 Lymphopenia 36 7 25 6 Neutropenia 20 4.3 18 0 Thrombocytopenia 16 1.4 26 0.9 Chemistry Increased alkaline phosphatase 37 2.8 28 5 Increased lipase 33 19 39 12 Increased ALT 32 2.8 33 12 Increased AST 31 1.4 40 12 Hyponatremia 27 4.3 26 5 Hypocalcemia 19 0 16 0 Hypomagnesemia 17 0 18 0 Increased amylase 16 4.8 36 3.4 Increased bilirubin 14 4.2 21 5 Hypokalemia 14 0 15 1.8 Increased creatinine 12 0 25 3.6 Hyperkalemia 11 0 23 0.9 Hepatocellular Carcinoma CHECKMATE-040 The safety of intravenous nivolumab 1 mg/kg in combination with ipilimumab 3 mg/kg was evaluated in a subgroup comprising 49 patients with HCC and Child-Pugh Class A cirrhosis enrolled in Cohort 4 of CHECKMATE-040, a multicenter, multiple-cohort, open-label trial [see Clinical Studies (14.10) ] who progressed on or were intolerant to sorafenib. Intravenous nivolumab and ipilimumab were administered every 3 weeks for 4 doses, followed by single-agent intravenous nivolumab 240 mg every 2 weeks until disease progression or unacceptable toxicity. During the intravenous nivolumab and ipilimumab combination period, 33 of 49 (67%) patients received all 4 planned doses of intravenous nivolumab and ipilimumab. During the entire treatment period, the median duration of exposure to intravenous nivolumab was 5.1 months (range: 0 to 35+ months) and to ipilimumab was 2.1 months (range: 0 to 4.5 months). Forty-seven percent of patients were exposed to treatment for >6 months, and 35% of patients were exposed to treatment for >1 year. Serious adverse reactions occurred in 59% of patients. Treatment was discontinued in 29% of patients and delayed in 65% of patients for an adverse reaction. The most frequent serious adverse reactions (reported in ≥4% of patients) were pyrexia, diarrhea, anemia, increased AST, adrenal insufficiency, ascites, esophageal varices hemorrhage, hyponatremia, increased blood bilirubin, and pneumonitis. Tables 35 and 36 summarize the adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-040. Table 35: Adverse Reactions Occurring in ≥10% of Patients Receiving Intravenous Nivolumab in Combination with Ipilimumab in Cohort 4 of CHECKMATE-040 Adverse Reaction Intravenous Nivolumab and Ipilimumab (n=49) All Grades (%) Grades 3-4 (%) Skin and Subcutaneous Tissue Rash 53 8 Pruritus 53 4 Musculoskeletal and Connective Tissue Musculoskeletal pain 41 2 Arthralgia 10 0 Gastrointestinal Diarrhea 39 4 Abdominal pain 22 6 Nausea 20 0 Ascites 14 6 Constipation 14 0 Dry mouth 12 0 Dyspepsia 12 2 Vomiting 12 2 Stomatitis 10 0 Respiratory, Thoracic and Mediastinal Cough 37 0 Dyspnea 14 0 Pneumonitis 10 2 Metabolism and Nutrition Decreased appetite 35 2 General Fatigue 27 2 Pyrexia 27 0 Malaise 18 2 Edema 16 2 Influenza-like illness 14 0 Chills 10 0 Nervous System Headache 22 0 Dizziness 20 0 Endocrine Hypothyroidism 20 0 Adrenal insufficiency 18 4 Investigations Weight decreased 20 0 Psychiatric Insomnia 18 0 Blood and Lymphatic System Anemia 10 4 Infections Influenza 10 2 Vascular Hypotension 10 0 Clinically important adverse reactions reported in <10% of patients who received intravenous nivolumab with ipilimumab were hyperglycemia (8%), colitis (4%), and increased blood creatine phosphokinase (2%). Table 36: Laboratory Abnormalities Worsening from Baseline Occurring in ≥10% of Patients Receiving Intravenous Nivolumab in Combination with Ipilimumab in Cohort 4 of CHECKMATE-040 Laboratory Abnormality Intravenous Nivolumab and Ipilimumab (n=47) All Grades (%) Grades 3-4 (%) Hematology Lymphopenia 53 13 Anemia 43 4.3 Neutropenia 43 9 Leukopenia 40 2.1 Thrombocytopenia 34 4.3 Chemistry Increased AST 66 40 Increased ALT 66 21 Increased bilirubin 55 11 Increased lipase 51 26 Hyponatremia 49 32 Hypocalcemia 47 0 Increased alkaline phosphatase 40 4.3 Increased amylase 38 15 Hypokalemia 26 2.1 Hyperkalemia 23 4.3 Increased creatinine 21 0 Hypomagnesemia 11 0 In patients who received intravenous nivolumab with ipilimumab, virologic breakthrough occurred in 4 of 28 (14%) patients and 2 of 4 (50%) patients with active HBV or HCV at baseline, respectively. HBV virologic breakthrough was defined as at least a 1 log increase in HBV DNA for those patients with detectable HBV DNA at baseline. HCV virologic breakthrough was defined as a 1 log increase in HCV RNA from baseline. Esophageal Cancer Adjuvant Treatment of Resected Esophageal or Gastroesophageal Junction Cancer CHECKMATE-577 The safety of intravenous nivolumab was evaluated in CHECKMATE-577, a randomized, placebo-controlled, double-blinded, multicenter trial in 792 treated patients with completely resected (negative margins) esophageal or gastroesophageal junction cancer who had residual pathologic disease following chemoradiotherapy (CRT) [see Clinical Studies (14.11) ] . The trial excluded patients who did not receive concurrent CRT prior to surgery, had stage IV resectable disease, autoimmune disease, or any condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications. Patients received either intravenous nivolumab 240 mg or placebo by intravenous infusion over 30 minutes every 2 weeks for 16 weeks followed by 480 mg or placebo by intravenous infusion over 30 minutes every 4 weeks beginning at week 17. Patients were treated until disease recurrence, unacceptable toxicity, or for up to 1‑year total duration. The median duration of exposure was 10.1 months (range: <0.1 to 14 months) in intravenous nivolumab-treated patients and 9 months (range: <0.1 to 15 months) in placebo-treated patients. Among patients who received intravenous nivolumab, 61% were exposed for >6 months and 54% were exposed for >9 months. Serious adverse reactions occurred in 33% of patients receiving intravenous nivolumab. A serious adverse reaction reported in ≥2% of patients who received intravenous nivolumab was pneumonitis. A fatal adverse reaction of myocardial infarction occurred in one patient who received intravenous nivolumab. Intravenous nivolumab was discontinued in 12% of patients and was delayed in 28% of patients for an adverse reaction. Tables 37 and 38 summarize the adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-577. Table 37: Adverse Reactions Occurring in ≥10% of Patients Receiving Intravenous Nivolumab - CHECKMATE-577 a Includes upper abdominal pain, lower abdominal pain, and abdominal discomfort. b Includes gastroesophageal reflux. c Includes asthenia. d Includes productive cough. e Includes dyspnea exertional. f Includes rash pustular, dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis bullous, exfoliative rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic. g Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, myalgia intercostal, neck pain, pain in extremity, spinal pain. Adverse Reaction Intravenous Nivolumab (n=532) Placebo (n=260) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Adverse Reaction 96 34 93 32 Gastrointestinal Diarrhea 29 0.9 29 0.8 Nausea 23 0.8 21 0 Abdominal Pain a 17 0.8 20 1.5 Vomiting 15 0.6 16 1.2 Dysphagia 13 0.8 17 3.5 Dyspepsia b 12 0.2 16 0.4 Constipation 11 0 12 0 General Fatigue c 34 1.3 29 1.5 Respiratory, Thoracic and Mediastinal Cough d 20 0.2 21 0.4 Dyspnea e 12 0.8 12 0.4 Skin and Subcutaneous Tissue Rash f 21 0.9 10 0.4 Pruritus 13 0.4 6 0 Investigations Weight decreased 13 0.4 9 0 Musculoskeletal and Connective Tissue Musculoskeletal pain g 21 0.6 20 0.8 Arthralgia 10 0.2 8 0 Metabolism and Nutrition Decreased appetite 15 0.9 10 0.8 Endocrine Hypothyroidism 11 0 1.5 0 Table 38: Laboratory Abnormalities Worsening from Baseline a Occurring in ≥10% of Patients - CHECKMATE-577 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab group (range: 163 to 526 patients) and Placebo group (range: 86 to 256 patients). b Includes alanine aminotransferase increased, aspartate aminotransferase increased. Laboratory Abnormality Intravenous Nivolumab (n=532) Placebo (n=260) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Chemistry Increased AST 27 2.1 22 0.8 Increased alkaline phosphatase 25 0.8 18 0.8 Increased albumin 21 0.2 18 0 Increased ALT 20 1.9 16 1.2 Increased amylase 20 3.9 13 1.3 Hyponatremia 19 1.7 12 1.2 Hyperkalemia 17 0.8 15 1.6 Hypokalemia 12 1 11 1.2 Transaminases increased b 11 1.5 6 1.2 Hematology Lymphopenia 44 17 35 12 Anemia 27 0.8 21 0.4 Neutropenia 24 1.5 23 0.4 First-line Treatment of Unresectable Advanced or Metastatic ESCC CHECKMATE‑648 The safety of intravenous nivolumab in combination with chemotherapy or in combination with ipilimumab was evaluated in CHECKMATE‑648, a randomized, active-controlled, multicenter, open-label trial in patients with previously untreated unresectable advanced, recurrent or metastatic ESCC [see Clinical Studies (14.11) ] . Patients received one of the following treatments: • intravenous nivolumab 240 mg on days 1 and 15, 5-FU (fluorouracil) 800 mg/m 2 /day intravenously on days 1 through 5 (for 5 days), and cisplatin 80 mg/m 2 intravenously on day 1 (of a 4‑week cycle). • intravenous nivolumab 3 mg/kg every 2 weeks in combination with ipilimumab 1 mg/kg every 6 weeks. • 5-FU (fluorouracil) 800 mg/m 2 /day intravenously on days 1 through 5 (for 5 days), and cisplatin 80 mg/m 2 intravenously on day 1 (of a 4-week cycle). Among patients who received intravenous nivolumab with chemotherapy, the median duration of exposure was 5.7 months (range: 0.1 to 30.6 months). Among patients who received intravenous nivolumab and ipilimumab, the median duration of exposure was 2.8 months (range: 0 to 24 months). Serious adverse reactions occurred in 62% of patients receiving intravenous nivolumab in combination with chemotherapy and in 69% of patients receiving intravenous nivolumab in combination with ipilimumab. The most frequent serious adverse reactions reported in ≥2% of patients who received intravenous nivolumab with chemotherapy were pneumonia (11%), dysphagia (7%), esophageal stenosis (2.9%), acute kidney injury (2.9%), and pyrexia (2.3%). The most frequent serious adverse reactions reported in ≥2% of patients who received intravenous nivolumab with ipilimumab were pneumonia (10%), pyrexia (4.3%), pneumonitis (4%), aspiration pneumonia (3.7%), dysphagia (3.7%), hepatic function abnormal (2.8%), decreased appetite (2.8%), adrenal insufficiency (2.5%), and dehydration (2.5%). Fatal adverse reactions occurred in 5 (1.6%) patients who received intravenous nivolumab in combination with chemotherapy; these included pneumonitis, pneumatosis intestinalis, pneumonia, and acute kidney injury and in 5 (1.6%) patients who received intravenous nivolumab in combination with ipilimumab; these included pneumonitis, interstitial lung disease, pulmonary embolism, and acute respiratory distress syndrome. Intravenous nivolumab and/or chemotherapy were discontinued in 39% of patients and were delayed in 71% of patients for an adverse reaction. Intravenous nivolumab and/or ipilimumab were discontinued in 23% of patients and were delayed in 46% of patients for an adverse reaction. The most common adverse reactions reported in ≥20% of patients treated with intravenous nivolumab in combination with chemotherapy were nausea, decreased appetite, fatigue, constipation, stomatitis, diarrhea, and vomiting. The most common adverse reactions reported in ≥20% of patients treated with intravenous nivolumab in combination with ipilimumab were rash, fatigue, pyrexia, nausea, diarrhea, and constipation. Tables 39 and 40 summarize the adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-648. Table 39: Adverse Reactions in ≥10% of Patients - CHECKMATE-648 Toxicity was graded per NCI CTCAE v4. a Includes aphthous ulcer, mouth ulceration, and mucosal inflammation. b Includes abdominal discomfort, abdominal pain lower, and abdominal pain upper. c Includes asthenia and malaise. d Includes tumor associated fever. e Includes swelling, generalized edema, edema peripheral, and peripheral swelling. f Includes hyperesthesia, hypoesthesia, peripheral motor neuropathy, peripheral sensorimotor neuropathy, and peripheral sensory neuropathy. g Includes dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis bullous, drug eruption, exfoliative rash, rash erythematous, rash follicular, rash macular, rash maculo-papular, rash papular, and rash pruritic. h Includes productive cough. i Includes organizing pneumonia, pneumonia bacterial, and pneumonia pseudomonal. j Includes back pain, bone pain, musculoskeletal chest pain, myalgia, neck pain, pain in extremity, and spinal pain. Adverse Reaction Intravenous Nivolumab with Cisplatin and 5‑FU (n=310) Intravenous Nivolumab and Ipilimumab (n=322) Cisplatin and 5-FU (n=304) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3‑4 (%) Gastrointestinal Nausea 65 4.2 22 0.6 56 2.6 Constipation 44 1.0 20 0.3 43 1 Stomatitis a 44 9 11 0.6 35 3 Diarrhea 29 2.9 22 1.9 20 2 Vomiting 23 2.3 15 1.6 19 3 Dysphagia 14 7 12 5 12 4.9 Abdominal pain b 13 1.9 10 0.9 11 0.7 Metabolism and Nutrition Decreased appetite 51 7 17 4 50 6 General Fatigue c 47 3.5 28 2.5 41 4.9 Pyrexia d 19 0.3 23 0.9 12 0.3 Edema e 16 0 7 0 13 0 Nervous System Peripheral neuropathy f 18 1.3 2.8 0 13 1 Psychiatric Insomnia 16 0 8 0 10 0.3 Skin and Subcutaneous Tissue Rash g 16 0.6 31 3.1 7 0 Pruritus 11 0 17 0.9 3.6 0 Alopecia 10 0 11 0 Respiratory, Thoracic and Mediastinal Cough h 16 0.3 13 0.3 13 0.3 Infections and Infestations Pneumonia i 13 5 14 8 10 2.6 Endocrine Hypothyroidism 7 0 14 0 0.3 0 Investigations Weight decreased 12 0.6 12 1.9 11 1 Musculoskeletal and Connective Tissue Musculoskeletal pain j 11 0.3 14 0.6 8 0.3 Table 40: Laboratory Values Worsening from Baseline a Occurring in ≥10% of Patients - CHECKMATE-648 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab with cisplatin and 5-FU group (range: 60 to 305 patients), intravenous nivolumab and ipilimumab group (range: 59 to 307 patients) or cisplatin and 5-FU group (range: 56 to 283 patients). Laboratory Abnormality Intravenous Nivolumab with Cisplatin and 5‑FU (n=310) Intravenous Nivolumab and Ipilimumab (n=322) Cisplatin and 5-FU (n=304) Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Hematology Anemia 81 21 52 7 66 14 Lymphopenia 67 23 50 13 44 8 Neutropenia 61 18 13 1.3 48 13 Leukopenia 53 11 39 5 Thrombocytopenia 43 3.3 12 1 29 2.8 Chemistry Hyponatremia 52 15 45 11 40 8 Hypocalcemia 43 3 32 0 23 0.7 Increased creatinine 41 2.3 15 0.7 31 0.7 Hypomagnesemia 35 1.7 15 0 25 1.8 Hyperglycemia 34 0 43 4.3 36 0.8 Hyperkalemia 33 2.3 23 1.6 24 0.7 Hypokalemia 29 9 19 5 17 6 Increased alkaline phosphatase 26 1.3 31 3.3 15 0 Increased AST 23 3.3 39 6 11 1.4 Increased ALT 23 2.3 33 6 8 0.7 Hypoglycemia 18 0.4 15 1.2 7 0 Hypercalcemia 11 2.6 15 2 8 0 Previously-Treated Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) ATTRACTION-3 The safety of intravenous nivolumab was evaluated in ATTRACTION-3, a randomized, active-controlled, open‑label, multicenter trial in 209 patients with unresectable advanced, recurrent or metastatic ESCC refractory or intolerant to at least one fluoropyrimidine- and platinum‑based chemotherapy [see Clinical Studies (14.11) ] . The trial excluded patients who were refractory or intolerant to taxane therapy, had brain metastases that were symptomatic or required treatment, had autoimmune disease, used systemic corticosteroids or immunosuppressants, had apparent tumor invasion of organs adjacent to the esophageal tumor or had stents in the esophagus or respiratory tract. Patients received intravenous nivolumab 240 mg by intravenous infusion over 30 minutes every 2 weeks (n=209) or investigator’s choice: docetaxel 75 mg/m 2 intravenously every 3 weeks (n=65) or paclitaxel 100 mg/m 2 intravenously once a week for 6 weeks followed by 1 week off (n=143). Patients were treated until disease progression or unacceptable toxicity. The median duration of exposure was 2.6 months (range: 0 to 29.2 months) in intravenous nivolumab-treated patients and 2.6 months (range: 0 to 21.4 months) in docetaxel- or paclitaxel-treated patients. Among patients who received intravenous nivolumab, 26% were exposed for >6 months and 10% were exposed for >1 year. Serious adverse reactions occurred in 38% of patients receiving intravenous nivolumab. Serious adverse reactions reported in ≥2% of patients who received intravenous nivolumab were pneumonia, esophageal fistula, interstitial lung disease and pyrexia. The following fatal adverse reactions occurred in patients who received intravenous nivolumab: interstitial lung disease or pneumonitis (1.4%), pneumonia (1.0%), septic shock (0.5%), esophageal fistula (0.5%), gastrointestinal hemorrhage (0.5%), pulmonary embolism (0.5%), and sudden death (0.5%). Intravenous nivolumab was discontinued in 13% of patients and was delayed in 27% of patients for an adverse reaction. Tables 41 and 42 summarize the adverse reactions and laboratory abnormalities, respectively, in ATTRACTION-3. Table 41: Adverse Reactions Occurring in ≥10% of Patients Receiving Intravenous Nivolumab - ATTRACTION-3 Toxicity was graded per NCI CTCAE v4. a Includes urticaria, drug eruption, eczema, eczema asteatotic, eczema nummular, palmar-plantar erythrodysesthesia syndrome, erythema, erythema multiforme, blister, skin exfoliation, Stevens-Johnson syndrome, dermatitis, dermatitis described as acneiform, bullous, or contact, and rash described as maculo-papular, generalized, or pustular. b Includes hypophagia, and food aversion. c Includes colitis. d Includes spondylolisthesis, periarthritis, musculoskeletal chest pain, neck pain, arthralgia, back pain, myalgia, pain in extremity, arthritis, bone pain, and periarthritis calcarea. e Includes influenza, influenza like illness, pharyngitis, nasopharyngitis, tracheitis, and bronchitis and upper respiratory infection with bronchitis. f Includes pneumonia aspiration, pneumonia bacterial, and lung infection. Two patients (1.0%) died of pneumonia in the intravenous nivolumab treatment arm. Two patients (1.0%) died of pneumonia in the chemotherapy treatment arm; these deaths occurred with paclitaxel only. g Includes productive cough. h Includes tumor-associated fever. i Includes asthenia. j Includes hemoglobin decreased, and iron deficiency anemia. k Includes blood thyroid stimulating hormone increased. Adverse Reaction Intravenous Nivolumab (n=209) Docetaxel or Paclitaxel (n=208) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Skin and Subcutaneous Tissue Rash a 22 1.9 28 1 Pruritus 12 0 7 0 Metabolism and Nutrition Decreased appetite b 21 1.9 35 5 Gastrointestinal Diarrhea c 18 1.9 17 1.4 Constipation 17 0 19 0 Nausea 11 0 20 0.5 Musculoskeletal and Connective Tissue Musculoskeletal pain d 17 0 26 1.4 Infections Upper respiratory tract infection e 17 1 14 0 Pneumonia f 13 5 19 9 Respiratory, Thoracic and Mediastinal Cough g 16 0 14 0.5 General Pyrexia h 16 0.5 19 0.5 Fatigue i 12 1.4 27 4.8 Blood and Lymphatic System Anemia j 13 8 30 13 Endocrine Hypothyroidism k 11 0 1.4 0 Table 42: Laboratory Abnormalities Worsening from Baseline a Occurring in ≥10% of Patients - ATTRACTION-3 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab group (209 patients) and Docetaxel or Paclitaxel group (range: 207 to 208 patients). Laboratory Abnormality Intravenous Nivolumab (n=209) Docetaxel or Paclitaxel (n=208) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Chemistry Increased creatinine 78 0.5 68 0.5 Hyperglycemia 52 5 62 5 Hyponatremia 42 11 50 12 Increased AST 40 6 30 1 Increased alkaline phosphatase 33 4.8 24 1.0 Increased ALT 31 5 22 1.9 Hypercalcemia 22 6 14 2.9 Hyperkalemia 22 0.5 31 1 Hypoglycemia 14 1.4 14 0.5 Hypokalemia 11 2.9 13 3.4 Hematology Lymphopenia 46 19 72 43 Anemia 42 9 71 17 Leukopenia 11 0.5 79 45 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma CHECKMATE-649 The safety of intravenous nivolumab in combination with chemotherapy was evaluated in CHECKMATE-649, a randomized, multicenter, open-label trial in patients with previously untreated advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma [see Clinical Studies (14.12) ] . The trial excluded patients who were known human epidermal growth factor receptor 2 (HER2) positive or had untreated central nervous system (CNS) metastases. Patients were randomized to receive intravenous nivolumab in combination with chemotherapy or chemotherapy. Patients received one of the following treatments: • intravenous nivolumab 240 mg in combination with mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) every 2 weeks or mFOLFOX6 every 2 weeks. • intravenous nivolumab 360 mg in combination with CapeOX (capecitabine and oxaliplatin) every 3 weeks or CapeOX every 3 weeks. Patients were treated with intravenous nivolumab in combination with chemotherapy or chemotherapy until disease progression, unacceptable toxicity, or up to 2 years. The median duration of exposure was 6.8 months (range: 0 to 33.5 months) in intravenous nivolumab and chemotherapy-treated patients. Among patients who received intravenous nivolumab and chemotherapy, 54% were exposed for >6 months and 28% were exposed for >1 year. Fatal adverse reactions occurred in 16 (2.0%) patients who were treated with intravenous nivolumab in combination with chemotherapy; these included pneumonitis (4 patients), febrile neutropenia (2 patients), stroke (2 patients), gastrointestinal toxicity, intestinal mucositis, septic shock, pneumonia, infection, gastrointestinal bleeding, mesenteric vessel thrombosis, and disseminated intravascular coagulation. Serious adverse reactions occurred in 52% of patients treated with intravenous nivolumab in combination with chemotherapy. Intravenous nivolumab and/or chemotherapy were discontinued in 44% of patients and at least one dose was withheld in 76% of patients due to an adverse reaction. The most frequent serious adverse reactions reported in ≥2% of patients treated with intravenous nivolumab in combination with chemotherapy were vomiting (3.7%), pneumonia (3.6%), anemia (3.6%), pyrexia (2.8%), diarrhea (2.7%), febrile neutropenia (2.6%), and pneumonitis (2.4%). The most common adverse reactions reported in ≥20% of patients treated with intravenous nivolumab in combination with chemotherapy were peripheral neuropathy, nausea, fatigue, diarrhea, vomiting, decreased appetite, abdominal pain, constipation, and musculoskeletal pain. Tables 43 and 44 summarize the adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-649. Table 43: Adverse Reactions in ≥10% of Patients Receiving Intravenous Nivolumab and Chemotherapy - CHECKMATE-649 Toxicity was graded per NCI CTCAE v4. a Includes dysesthesia, hypoesthesia, peripheral motor neuropathy, peripheral sensorimotor neuropathy, and peripheral sensory neuropathy. b Includes abdominal discomfort, abdominal pain lower, and abdominal pain upper. c Includes aphthous ulcer, mouth ulceration, and mucosal inflammation. d Includes asthenia. e Includes tumor associated fever. f Includes swelling, generalized edema, edema peripheral, and peripheral swelling. g Includes blood albumin decreased. h Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity, and spinal pain. i Includes dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis bullous, drug eruption, exfoliative rash, nodular rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, and rash vesicular. j Includes productive cough. k Includes nasopharyngitis, pharyngitis, and rhinitis. Adverse Reaction Intravenous Nivolumab and mFOLFOX6 or CapeOX (n=782) mFOLFOX6 or CapeOX (n=767) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Adverse Reaction 99 69 98 59 Nervous System Peripheral neuropathy a 53 7 46 4.8 Headache 11 0.8 6 0.3 Gastrointestinal Nausea 48 3.2 44 3.7 Diarrhea 39 5 34 3.7 Vomiting 31 4.2 29 4.2 Abdominal pain b 27 2.8 24 2.6 Constipation 25 0.6 21 0.4 Stomatitis c 17 1.8 13 0.8 General Fatigue d 44 7 40 5 Pyrexia e 19 1 11 0.4 Edema f 12 0.5 8 0.1 Metabolism and Nutrition Decreased appetite 29 3.6 26 2.5 Hypoalbuminemia g 14 0.3 9 0.3 Investigations Weight decreased 17 1.3 15 0.7 Increased lipase 14 7 8 3.7 Increased amylase 12 3.1 5 0.4 Musculoskeletal and Connective Tissue Musculoskeletal pain h 20 1.3 14 2 Skin and Subcutaneous Tissue Rash i 18 1.7 4.4 0.1 Palmar-plantar erythrodysesthesia syndrome 13 1.5 12 0.8 Respiratory, Thoracic and Mediastinal Cough j 13 0.1 9 0 Infections and Infestations Upper respiratory tract infection k 10 0.1 7 0.1 Table 44: Laboratory Values Worsening from Baseline a Occurring in ≥10% of Patients - CHECKMATE-649 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous nivolumab and mFOLFOX6 or CapeOX group (407 to 767 patients) or mFOLFOX6 or CapeOX group (range: 405 to 735 patients). Laboratory Abnormality Intravenous Nivolumab and mFOLFOX6 or CapeOX (n=782) mFOLFOX6 or CapeOX (n=767) Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Hematology Neutropenia 73 29 62 23 Leukopenia 69 12 59 9 Thrombocytopenia 68 7 63 4.4 Anemia 59 14 60 10 Lymphopenia 59 12 49 9 Chemistry Increased AST 52 4.6 47 1.9 Hypocalcemia 42 1.6 37 1 Hyperglycemia 41 3.9 38 2.7 Increased ALT 37 3.4 30 1.9 Hyponatremia 34 6 24 5 Hypokalemia 27 7 24 4.8 Hyperbilirubinemia 24 2.8 21 2 Increased creatinine 15 1 9 0.5 Hyperkalemia 14 1.4 11 0.7 Hypoglycemia 12 0.7 9 0.2 Hypernatremia 11 0.5 7.1 0 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of intravenous nivolumab. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Eye: Vogt-Koyanagi-Harada (VKH) syndrome Complications of Intravenous Nivolumab Treatment After Allogeneic HSCT: Treatment refractory, severe acute and chronic GVHD Blood and lymphatic system disorders: Hemophagocytic lymphohistiocytosis (HLH) (including fatal cases), autoimmune hemolytic anemia (including fatal cases)

4 CONTRAINDICATIONS None. • None. (4)

11 DESCRIPTION OPDIVO QVANTIG is a fixed-combination drug product containing nivolumab and hyaluronidase (human recombinant). Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody. Nivolumab is an IgG4 kappa immunoglobulin that has a calculated molecular mass of 146 kDa. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line. Hyaluronidase (human recombinant) is an endoglycosidase used to increase the dispersion and absorption of co-administered drugs when administered subcutaneously. Hyaluronidase (human recombinant) is a glycosylated single-chain protein produced by CHO cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). Hyaluronidase (human recombinant) has a molecular weight of approximately 61 kDa. OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy) injection is a sterile, preservative-free, clear to opalescent, colorless to yellow solution that may contain a few translucent-to-white particles, supplied in a single-dose vial for subcutaneous use. Each 5 mL single-dose vial of OPDIVO QVANTIG contains 600 mg of nivolumab and 10,000 units of hyaluronidase (human recombinant), and the inactive ingredients: histidine (7.75 mg), histidine hydrochloride monohydrate (10.5 mg), methionine (3.73 mg), pentetic acid (0.0985 mg), polysorbate 80 (2.5 mg), sucrose (428 mg), and Water for Injection, USP. The pH is 5.5 to 6.5.

2 DOSAGE AND ADMINISTRATION • OPDIVO QVANTIG has different dosage and administration instructions than intravenous nivolumab products. • OPDIVO QVANTIG is for subcutaneous use only in the abdomen or thigh. • OPDIVO QVANTIG is to be administered by a healthcare professional only. (2.1) OPDIVO QVANTIG is for subcutaneous use only. • Administer by subcutaneous injection over 3-5 minutes. (2.1) • Renal cell carcinoma • 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks. (2.2) • 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks administered in combination with cabozantinib 40 mg once daily without food. (2.2) • Melanoma • 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks. (2.2) • Neoadjuvant and adjuvant treatment of resectable (tumors ≥4 cm or node positive) non-small cell lung cancer • 900 mg/15,000 units with platinum-doublet chemotherapy on the same day every 3 weeks for 3 cycles, then single-agent OPDIVO QVANTIG 1,200 mg/20,000 units every 4 weeks after surgery for up to 13 cycles. (2.2) • Metastatic non-small cell lung cancer • 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks. (2.2) • Squamous cell carcinoma of the head and neck • 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks. (2.2) • Urothelial carcinoma • 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks. (2.2) • First-line unresectable or metastatic urothelial carcinoma • 900 mg/15,000 units every 3 weeks with cisplatin and gemcitabine on the same day for up to 6 cycles, then 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks. (2.2) • Colorectal cancer • 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks. (2.2) • Hepatocellular carcinoma • 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks. (2.2) • Esophageal cancer • 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks. (2.2) • 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks administered in combination with fluoropyrimidine- and platinum-containing chemotherapy. (2.2) • Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • 600 mg/10,000 units every 2 weeks in combination with fluoropyrimidine- and platinum-containing chemotherapy every 2 weeks. (2.2) • 900 mg/15,000 units every 3 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 3 weeks. (2.2) • See full Prescribing Information for preparation and administration instructions and dosage modifications for adverse reactions. 2.1 Important Dosage and Administration Information OPDIVO QVANTIG has different dosage and administration instructions than intravenously administered nivolumab products [see Dosage and Administration (2.4) ]. OPDIVO QVANTIG is for subcutaneous use only in the abdomen or thigh. Do not administer intravenously. OPDIVO QVANTIG is to be administered by a healthcare professional only. Adult patients currently receiving intravenous nivolumab as a single agent, or in combination with chemotherapy or cabozantinib, may switch to subcutaneous OPDIVO QVANTIG at their next scheduled dose. 2.2 Recommended Dosage The recommended dosages of OPDIVO QVANTIG as monotherapy agent are presented in Table 1. Table 1: Recommended Dosages for OPDIVO QVANTIG as Monotherapy † Dosing recommendations for both monotherapy or following intravenous nivolumab and ipilimumab combination therapy. * Administer over 3-5 minutes. Indication Recommended OPDIVO QVANTIG Dosage Duration of Therapy Advanced renal cell carcinoma† 600 mg nivolumab and 10,000 units hyaluronidase* every 2 weeks or 1,200 mg nivolumab and 20,000 units hyaluronidase* every 4 weeks Until disease progression or unacceptable toxicity Unresectable or metastatic melanoma† Metastatic non-small cell lung cancer Squamous cell carcinoma of the head and neck Locally advanced or metastatic urothelial carcinoma Microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer† Hepatocellular carcinoma† Esophageal squamous cell carcinoma Adjuvant treatment of melanoma 600 mg nivolumab and 10,000 units hyaluronidase* every 2 weeks or 1,200 mg nivolumab and 20,000 units hyaluronidase* every 4 weeks Until disease recurrence or unacceptable toxicity for up to 1 year Adjuvant treatment of urothelial carcinoma Adjuvant treatment of resected esophageal or gastroesophageal junction cancer The recommended dosages of OPDIVO QVANTIG in combination with other therapeutic agents are presented in Table 2. Refer to the respective Prescribing Information for each therapeutic agent administered in combination with OPDIVO QVANTIG for the recommended dosage information, as appropriate. Table 2: Recommended Dosages for OPDIVO QVANTIG in Combination with Other Therapeutic Agents * Administer over 3-5 minutes. Indication Recommended OPDIVO QVANTIG Dosage Duration of Therapy Advanced renal cell carcinoma 600 mg nivolumab and 10,000 units hyaluronidase* every 2 weeks or 1,200 mg nivolumab and 20,000 units hyaluronidase* every 4 weeks Administer OPDIVO QVANTIG in combination with cabozantinib 40 mg orally once daily without food OPDIVO QVANTIG: Until disease progression, unacceptable toxicity, or up to 2 years Cabozantinib: Until disease progression or unacceptable toxicity Neoadjuvant treatment of resectable non-small cell lung cancer 900 mg nivolumab and 15,000 units hyaluronidase* with platinum-doublet chemotherapy on the same day every 3 weeks In combination with platinum-doublet chemotherapy for 3 cycles Neoadjuvant and adjuvant treatment of resectable non-small cell lung cancer Neoadjuvant: 900 mg nivolumab and 15,000 units hyaluronidase* with platinum-doublet chemotherapy on the same day every 3 weeks Neoadjuvant: in combination with platinum-doublet chemotherapy until disease progression or unacceptable toxicity, for up to 4 cycles Adjuvant: 1,200 mg nivolumab and 20,000 units hyaluronidase* every 4 weeks Adjuvant: following neoadjuvant therapy and surgery, administer as a single agent until disease progression, recurrence, or unacceptable toxicity, for up to 13 cycles (up to 1 year) First-line unresectable or metastatic urothelial carcinoma 900 mg nivolumab and 15,000 units hyaluronidase* every 3 weeks Administer OPDIVO QVANTIG in combination with cisplatin and gemcitabine on the same day every 3 weeks In combination with cisplatin and gemcitabine for up to 6 cycles 600 mg nivolumab and 10,000 units hyaluronidase* every 2 weeks or 1,200 mg nivolumab and 20,000 units hyaluronidase* every 4 weeks After completing up to 6 cycles of combination therapy, administer as single agent until disease progression, unacceptable toxicity, or up to 2 years from first dose Esophageal squamous cell carcinoma 600 mg nivolumab and 10,000 units hyaluronidase* every 2 weeks or 1,200 mg nivolumab and 20,000 units hyaluronidase* every 4 weeks Administer OPDIVO QVANTIG in combination with fluoropyrimidine- and platinum-containing chemotherapy Until disease progression, unacceptable toxicity, or up to 2 years Chemotherapy: Until disease progression or unacceptable toxicity Gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma 600 mg nivolumab and 10,000 units hyaluronidase* with fluoropyrimidine- and platinum-containing chemotherapy every 2 weeks or 900 mg nivolumab and 15,000 units hyaluronidase* with fluoropyrimidine- and platinum-containing chemotherapy every 3 weeks OPDIVO QVANTIG: Until disease progression, unacceptable toxicity, or up to 2 years Chemotherapy: Until disease progression or unacceptable toxicity 2.3 Dose Modifications No dose reduction for OPDIVO QVANTIG is recommended. In general, withhold OPDIVO QVANTIG for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue OPDIVO QVANTIG for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks of initiating steroids. Dosage modifications for OPDIVO QVANTIG or OPDIVO QVANTIG in combination with other anti-cancer agents for adverse reactions that require management different from these general guidelines are summarized in Table 3 and Table 4. Table 3: Recommended Dosage Modifications for Adverse Reactions a Resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of last dose or inability to reduce prednisone to 10 mg per day (or equivalent) or less within 12 weeks of initiating steroids. b If AST and ALT are less than or equal to ULN at baseline, withhold or permanently discontinue OPDIVO QVANTIG based on recommendations for hepatitis with no liver involvement. c Depending on clinical severity, consider withholding for Grade 2 endocrinopathy until symptom improvement with hormone replacement. Resume once acute symptoms have resolved. ALT = alanine aminotransferase, AST = aspartate aminotransferase, DRESS = Drug Rash with Eosinophilia and Systemic Symptoms, SJS = Stevens-Johnson Syndrome, TEN = toxic epidermal necrolysis, ULN = upper limit of normal Adverse Reaction Severity Dosage Modification Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1) ] Pneumonitis Grade 2 Withhold a Grade 3 or 4 Permanently discontinue Colitis For colitis in patients treated with combination therapy with ipilimumab, see Table 4. Grade 2 or 3 Withhold a Grade 4 Permanently discontinue Hepatitis with no tumor involvement of the liver For liver enzyme elevations in patients treated with combination therapy with cabozantinib, see Table 4. AST/ALT increases to >3 and ≤8 times ULN or Total bilirubin increases to >1.5 and ≤3 times ULN. Withhold a AST or ALT increases to >8 times ULN or Total bilirubin increases to >3 times ULN. Permanently discontinue Hepatitis with tumor involvement of the liver b Baseline AST/ALT is >1 and ≤3 times ULN and increases to >5 and ≤10 times ULN or Baseline AST/ALT is >3 and ≤5 times ULN and increases to >8 and ≤10 times ULN. Withhold a AST/ALT increases to >10 times ULN or Total bilirubin increases to >3 times ULN. Permanently discontinue Endocrinopathies c Grade 3 or 4 Withhold until clinically stable or permanently discontinue depending on severity Nephritis with Renal Dysfunction Grade 2 or 3 increased blood creatinine Withhold a Grade 4 increased blood creatinine Permanently discontinue Exfoliative Dermatologic Conditions Suspected SJS, TEN, or DRESS Withhold Confirmed SJS, TEN, or DRESS Permanently discontinue Myocarditis Grades 2, 3, or 4 Permanently discontinue Neurological Toxicities Grade 2 Withhold a Grade 3 or 4 Permanently discontinue Table 4: Recommended Dosage Modifications for Adverse Reactions in Patients Treated with Combination Therapy a Consider corticosteroid therapy for hepatic adverse reactions if OPDIVO QVANTIG is withheld or discontinued when administered in combination with cabozantinib. b After recovery, rechallenge with one or both of OPDIVO QVANTIG and cabozantinib may be considered. If rechallenging with cabozantinib with or without OPDIVO QVANTIG, refer to cabozantinib Prescribing Information. Treatment Adverse Reaction Severity Dosage Modification OPDIVO QVANTIG in combination with cabozantinib Liver enzyme elevations ALT or AST >3 times ULN but ≤10 times ULN with concurrent total bilirubin <2 times ULN Withhold a both OPDIVO QVANTIG and cabozantinib until adverse reactions recover b to Grades 0-1 ALT or AST >10 times ULN or >3 times ULN with concurrent total bilirubin ≥2 times ULN Permanently discontinue a both OPDIVO QVANTIG and cabozantinib 2.4 Preparation and Administration To prevent medication errors, check the vial labels to ensure that the drug being prepared and administered is OPDIVO QVANTIG for subcutaneous use and NOT intravenous nivolumab. Do NOT administer OPDIVO QVANTIG intravenously. OPDIVO QVANTIG should be administered by a healthcare professional. Each OPDIVO QVANTIG vial is for one-time use only. It is a ready-to-use solution for injection. It should not be diluted. Visually inspect for particulate matter and discoloration prior to administration. OPDIVO QVANTIG is a clear to opalescent, colorless to yellow solution. Discard if the solution is discolored or contains extraneous particulate matter other than a few translucent-to-white particles. Do not shake. Preparation No incompatibilities were observed between OPDIVO QVANTIG and polypropylene and polycarbonate syringes, or between OPDIVO QVANTIG and polyethylene, polyurethane, polyvinyl chloride, and fluorinated ethylene propylene subcutaneous administration sets. A syringe and a transfer needle are needed to withdraw OPDIVO QVANTIG solution from the vial. OPDIVO QVANTIG may be injected subcutaneously using a 23G-25G (3/8”-5/8”) hypodermic injection needle or subcutaneous administration set (eg., winged/butterfly). • 600 mg nivolumab and 10,000 units hyaluronidase ∘ Allow 1 OPDIVO QVANTIG vial to reach room temperature, then withdraw 5 mL of OPDIVO QVANTIG into the syringe. • 900 mg nivolumab and 15,000 units hyaluronidase ∘ Allow 2 OPDIVO QVANTIG vials to reach room temperature, then withdraw 5 mL from one vial and 2.5 mL from the other vial, for a total volume of 7.5 mL of OPDIVO QVANTIG into a single syringe. • 1,200 mg nivolumab and 20,000 units hyaluronidase ∘ Allow 2 OPDIVO QVANTIG vials to reach room temperature, then withdraw 10 mL of OPDIVO QVANTIG into a single syringe. Select the appropriate syringe label provided in the carton that matches the prescribed dose and apply to the prepared syringe. Discard partially used or empty vials of OPDIVO QVANTIG. If the dose is not to be used immediately, attach a tip cap to the syringe prior to storage. To avoid clogging of the hypodermic injection needle, attach a 23G-25G (3/8”-5/8”) hypodermic injection needle to the syringe immediately prior to administration. Storage in Syringe Once withdrawn into the syringe, OPDIVO QVANTIG should be used immediately. If not used immediately, store the syringe: • In the refrigerator at 2°C to 8°C (36°F to 46°F), protected from light for up to 48 hours; do not freeze, or • At room temperature 20°C to 25°C (68°F to 77°F) for up to 8 hours. Storage at room temperature for this duration does not require protection from light. • Discard if storage time exceeds these limits. • If stored in the refrigerator, allow the solution to come to room temperature before administration. Administration • Administer the full contents of the syringe into the subcutaneous tissue of 1 of the 4 quadrants of the abdomen, or thigh over a period of 3 to 5 minutes. • Alternate injection sites across the 4 quadrants of the abdomen or thighs for successive injections. Do not inject into areas where the skin is tender, red, or bruised, or areas where there are scars or moles. If the administration of OPDIVO QVANTIG is interrupted, continue administering at the same site, or at an alternate site. • During treatment with OPDIVO QVANTIG, do not administer other subcutaneous medications at the same site used for OPDIVO QVANTIG.

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth. Hyaluronan is a polysaccharide found in the extracellular matrix of the subcutaneous tissue. It is depolymerized by the naturally occurring enzyme hyaluronidase. Unlike the stable structural components of the interstitial matrix, hyaluronan has a half-life of approximately 0.5 days. Hyaluronidase increases permeability of the subcutaneous tissue by temporarily depolymerizing hyaluronan. In the doses administered, hyaluronidase in OPDIVO QVANTIG acts transiently and locally. The effects of hyaluronidase are reversible and permeability of the subcutaneous tissue is restored within 24 to 48 hours. 12.2 Pharmacodynamics Exposure-Response Relationship The exposure-response relationship and time course of pharmacodynamics of OPDIVO QVANTIG have not been fully characterized. 12.3 Pharmacokinetics When comparing nivolumab exposures following OPDIVO QVANTIG to those of intravenous nivolumab in CHECKMATE-67T [see Clinical Studies (14.1) ] , the geometric mean ratios (GMRs) (90% CI) for time-averaged concentration (C avg ) over 28 days and at steady state were 2.10 (2.00, 2.20) and 1.98 (1.87, 2.11), respectively, and for minimum concentration (C min ) at 28 days and at steady state were 1.60 (1.49, 1.72) and 1.77 (1.63, 1.93), respectively. Steady state was achieved by 16 weeks. The systemic accumulation ratio was 2.3. Absorption The geometric mean bioavailability (CV%) of nivolumab is 74% (14%). Peak concentrations occurred by around 6 days. Distribution The geometric mean (CV%) volume of distribution at steady state is 6.8 L (27%). Elimination Nivolumab clearance decreases over time, with a mean maximal reduction (CV%) from baseline values of 24.5% (47.6%), resulting in a geometric mean steady-state clearance (CV%) of 8.2 mL/h (53.9%) in patients with metastatic tumors; this decrease in clearance is not considered clinically relevant. Nivolumab clearance does not decrease over time in patients with completely resected melanoma, as the geometric mean population clearance is 24% lower in this patient population compared with patients with metastatic melanoma at steady state. The geometric mean (CV%) elimination half-life is 25 days (78%). Specific Populations Body weight (35 to 153 kg), sex, eGFR (24 to 124 mL/min/1.73 m 2 ), and performance status have no clinically significant effects on the clearance of nivolumab. 12.6 Immunogenicity The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of OPDIVO QVANTIG or of other nivolumab products or hyaluronidase products. During the 2-year treatment period in CHECKMATE-67T [see Clinical Studies (14.1) ] , 23% (46/202) of patients who received OPDIVO QVANTIG developed anti-nivolumab antibodies (ADA) and 4.3% (2/46) had neutralizing antibodies against nivolumab (NAb). The corresponding incidence of ADA was 7% (15/215) and NAb was 0% (0/15) for intravenous nivolumab in the same study. The incidence of anti-hyaluronidase antibodies in CHECKMATE-67T was 8.8% (19/215); 5 (26%) of these 19 patients developed NAb. Nivolumab clearance increased by approximately 26% in patients who received OPDIVO QVANTIG and tested positive for ADA compared to patients who tested negative for ADA; this change in clearance is not considered clinically significant. Local injection-site reactions were reported in 15% (7/46) of patients who developed ADA to nivolumab and 7% (10/155) of patients who did not develop ADA to nivolumab; however, all events were Grade 1 or 2 and resolved. Because of low occurrence of anti-nivolumab or anti-hyaluronidase antibodies, the effect of ADA on the effectiveness of OPDIVO QVANTIG is unknown.

12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth. Hyaluronan is a polysaccharide found in the extracellular matrix of the subcutaneous tissue. It is depolymerized by the naturally occurring enzyme hyaluronidase. Unlike the stable structural components of the interstitial matrix, hyaluronan has a half-life of approximately 0.5 days. Hyaluronidase increases permeability of the subcutaneous tissue by temporarily depolymerizing hyaluronan. In the doses administered, hyaluronidase in OPDIVO QVANTIG acts transiently and locally. The effects of hyaluronidase are reversible and permeability of the subcutaneous tissue is restored within 24 to 48 hours.

12.2 Pharmacodynamics Exposure-Response Relationship The exposure-response relationship and time course of pharmacodynamics of OPDIVO QVANTIG have not been fully characterized.

12.3 Pharmacokinetics When comparing nivolumab exposures following OPDIVO QVANTIG to those of intravenous nivolumab in CHECKMATE-67T [see Clinical Studies (14.1) ] , the geometric mean ratios (GMRs) (90% CI) for time-averaged concentration (C avg ) over 28 days and at steady state were 2.10 (2.00, 2.20) and 1.98 (1.87, 2.11), respectively, and for minimum concentration (C min ) at 28 days and at steady state were 1.60 (1.49, 1.72) and 1.77 (1.63, 1.93), respectively. Steady state was achieved by 16 weeks. The systemic accumulation ratio was 2.3. Absorption The geometric mean bioavailability (CV%) of nivolumab is 74% (14%). Peak concentrations occurred by around 6 days. Distribution The geometric mean (CV%) volume of distribution at steady state is 6.8 L (27%). Elimination Nivolumab clearance decreases over time, with a mean maximal reduction (CV%) from baseline values of 24.5% (47.6%), resulting in a geometric mean steady-state clearance (CV%) of 8.2 mL/h (53.9%) in patients with metastatic tumors; this decrease in clearance is not considered clinically relevant. Nivolumab clearance does not decrease over time in patients with completely resected melanoma, as the geometric mean population clearance is 24% lower in this patient population compared with patients with metastatic melanoma at steady state. The geometric mean (CV%) elimination half-life is 25 days (78%). Specific Populations Body weight (35 to 153 kg), sex, eGFR (24 to 124 mL/min/1.73 m 2 ), and performance status have no clinically significant effects on the clearance of nivolumab.

20241227

3

3 DOSAGE FORMS AND STRENGTHS Injection: 600 mg nivolumab and 10,000 units hyaluronidase per 5 mL (120 mg/2,000 units per mL), as a clear to opalescent, colorless to yellow solution in a single-dose vial. • Injection: 600 mg nivolumab and 10,000 units hyaluronidase per 5 mL (120 mg/2,000 units per mL) in a single-dose vial. (3)

OPDIVO QVANTIG nivolumab and hyaluronidase-nvhy NIVOLUMAB NIVOLUMAB HYALURONIDASE (HUMAN RECOMBINANT) HYALURONIDASE (HUMAN RECOMBINANT) HISTIDINE HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE SUCROSE METHIONINE PENTETIC ACID POLYSORBATE 80 SODIUM CHLORIDE WATER

13.2 Animal Toxicology and/or Pharmacology In animal models, inhibition of PD-1 signaling increased the severity of some infections and enhanced inflammatory responses. Mycobacterium tuberculosis –infected PD-1 knockout mice exhibit markedly decreased survival compared with wild-type controls, which correlated with increased bacterial proliferation and inflammatory responses in these animals. PD-1 blockade using a primate anti–PD-1 antibody was also shown to exacerbate M. tuberculosis infection in rhesus macaques. PD-1 knockout mice have also shown decreased survival following infection with lymphocytic choriomeningitis virus.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been performed to assess the potential of nivolumab for carcinogenicity or genotoxicity. Fertility studies have not been performed with nivolumab. In 1-month and 3-month repeat-dose toxicology studies in monkeys, there were no notable effects in the male and female reproductive organs; however, most animals in these studies were not sexually mature. Hyaluronidases are found in most tissues of the body. Long-term animal studies have not been performed to assess the carcinogenic or mutagenic potential of hyaluronidase. In addition, when subcutaneous hyaluronidase (recombinant human) was administered to cynomolgus monkeys for 39 weeks at dose levels up to 220,000 U/kg, which is at least 600 times higher than the human dose (U/kg basis), of 10,000 U once every 2 weeks, 15,000 U once every 3 weeks, or 20,000 U once every 4 weeks, no evidence of toxicity to the male or female reproductive system was found through periodic monitoring of in-life parameters, e.g., semen analyses, hormone levels, menstrual cycles, and also from gross pathology, histopathology and organ weight data.

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been performed to assess the potential of nivolumab for carcinogenicity or genotoxicity. Fertility studies have not been performed with nivolumab. In 1-month and 3-month repeat-dose toxicology studies in monkeys, there were no notable effects in the male and female reproductive organs; however, most animals in these studies were not sexually mature. Hyaluronidases are found in most tissues of the body. Long-term animal studies have not been performed to assess the carcinogenic or mutagenic potential of hyaluronidase. In addition, when subcutaneous hyaluronidase (recombinant human) was administered to cynomolgus monkeys for 39 weeks at dose levels up to 220,000 U/kg, which is at least 600 times higher than the human dose (U/kg basis), of 10,000 U once every 2 weeks, 15,000 U once every 3 weeks, or 20,000 U once every 4 weeks, no evidence of toxicity to the male or female reproductive system was found through periodic monitoring of in-life parameters, e.g., semen analyses, hormone levels, menstrual cycles, and also from gross pathology, histopathology and organ weight data. 13.2 Animal Toxicology and/or Pharmacology In animal models, inhibition of PD-1 signaling increased the severity of some infections and enhanced inflammatory responses. Mycobacterium tuberculosis –infected PD-1 knockout mice exhibit markedly decreased survival compared with wild-type controls, which correlated with increased bacterial proliferation and inflammatory responses in these animals. PD-1 blockade using a primate anti–PD-1 antibody was also shown to exacerbate M. tuberculosis infection in rhesus macaques. PD-1 knockout mice have also shown decreased survival following infection with lymphocytic choriomeningitis virus.

BLA761381

OPDIVO QVANTIG

nivolumab and hyaluronidase-nvhy

0003-6120

HUMAN PRESCRIPTION DRUG

SUBCUTANEOUS

OPDIVO QVANTIG TM 600 mg and 10,000 units/5 mL Representative Packaging Rx Only NDC 0003-6120-01 OPDIVO QVANTIG™ (nivolumab and hyaluronidase-nvhy) injection 600 mg and 10,000 units/5 mL (120mg and 2,000 units/mL) For Subcutaneous Use Only Administer Subcutaneous Injection Over 3 to 5 Minutes Single-dose vial; Discard unused portion. ATTENTION: Dispense the enclosed Medication Guide to each patient. Bristol Myers Squibb nivo-sc-carton

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Immune-Mediated Adverse Reactions Inform patients of the risk of immune-mediated adverse reactions that may require corticosteroid treatment and withholding or discontinuation of OPDIVO QVANTIG, including: • Pneumonitis: Advise patients to contact their healthcare provider immediately for any new or worsening cough, chest pain, or shortness of breath [see Warnings and Precautions (5.1) ] . • Colitis: Advise patients to contact their healthcare provider immediately for diarrhea or severe abdominal pain [see Warnings and Precautions (5.1) ] . • Hepatitis: Advise patients to contact their healthcare provider immediately for jaundice, severe nausea or vomiting, pain on the right side of abdomen, lethargy, or easy bruising or bleeding [see Warnings and Precautions (5.1) ] . • Endocrinopathies: Advise patients to contact their healthcare provider immediately for signs or symptoms of hypophysitis, adrenal insufficiency, hypothyroidism, hyperthyroidism, and diabetes mellitus [see Warnings and Precautions (5.1) ] . • Nephritis and Renal Dysfunction: Advise patients to contact their healthcare provider immediately for signs or symptoms of nephritis including decreased urine output, blood in urine, swelling in ankles, loss of appetite, and any other symptoms of renal dysfunction [see Warnings and Precautions (5.1) ] . • Skin Adverse Reactions: Advise patients to contact their healthcare provider immediately for rash [see Warnings and Precautions (5.1) ] . • Other immune-mediated adverse reactions: • Advise patients that immune-mediated adverse reactions can occur and may involve any organ system, and to contact their healthcare provider immediately for any new or worsening signs or symptoms [see Warnings and Precautions (5.1) ] . • Advise patients of the risk of solid organ transplant rejection and other transplant (including corneal graft) rejection. Advise patients to contact their healthcare provider immediately for signs or symptoms of organ transplant rejection and other transplant (including corneal graft) rejection [see Warnings and Precautions (5.1) ] . Complications of Allogeneic HSCT • Advise patients of potential risk of post-transplant complications [see Warnings and Precautions (5.2) ] . Embryo-Fetal Toxicity • Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1) ] . • Advise females of reproductive potential to use effective contraception during treatment with OPDIVO QVANTIG and for 5 months following the last dose [see Use in Specific Populations (8.3) ] . Lactation • Advise women not to breastfeed during treatment with OPDIVO QVANTIG and for 5 months after the last dose [see Use in Specific Populations (8.2) ] . Manufactured by: Bristol-Myers Squibb Company Princeton, NJ 08543 USA U.S. License No. 1713 Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego, CA 92130 U.S. License No. 2187

Medication Guide MEDICATION GUIDE OPDIVO QVANTIG™ (op-DEE-voh cue-VAN-tig) (nivolumab and hyaluronidase-nvhy) injection, for subcutaneous use Read this Medication Guide before you start receiving OPDIVO QVANTIG and before each injection. There may be new information. If your healthcare provider prescribes OPDIVO QVANTIG in combination with cabozantinib, also read the Patient Information that comes with cabozantinib. This Medication Guide does not take the place of talking with your healthcare provider about your medical condition or your treatment. What is the most important information I should know about OPDIVO QVANTIG? OPDIVO QVANTIG is a medicine that may treat certain cancers by working with your immune system. OPDIVO QVANTIG can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. You may have more than one of these problems at the same time. Some of these problems may happen more often when OPDIVO QVANTIG is used in combination with another therapy. Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including: Lung problems. • cough • shortness of breath • chest pain Intestinal problems. • diarrhea (loose stools) or more frequent bowel movements than usual • stools that are black, tarry, sticky, or have blood or mucus • severe stomach-area (abdominal) pain or tenderness Liver problems. • yellowing of your skin or the whites of your eyes • severe nausea or vomiting • pain on the right side of your stomach area (abdomen) • dark urine (tea colored) • bleeding or bruising more easily than normal Hormone gland problems. • headaches that will not go away or unusual headaches • eye sensitivity to light • eye problems • rapid heartbeat • increased sweating • extreme tiredness • weight gain or weight loss • feeling more hungry or thirsty than usual • urinating more often than usual • hair loss • feeling cold • constipation • your voice gets deeper • dizziness or fainting • changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness Kidney problems. • decrease in your amount of urine • blood in your urine • swelling of your ankles • loss of appetite Skin problems. • rash • itching • skin blistering or peeling • swollen lymph nodes • painful sores or ulcers in mouth or nose, throat, or genital area • fever or flu-like symptoms Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with OPDIVO QVANTIG. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: • chest pain, irregular heartbeat, shortness of breath or swelling of ankles • confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs • double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight • persistent or severe muscle pain or weakness, muscle cramps • low red blood cells, bruising Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ or tissue transplant that you have had. Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during treatment with OPDIVO QVANTIG. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with OPDIVO QVANTIG, if you have severe side effects. What is OPDIVO QVANTIG? OPDIVO QVANTIG is a prescription medicine used to treat adults with: • a type of kidney cancer that has spread called advanced renal cell carcinoma (RCC). ∘ OPDIVO QVANTIG may be used alone as a first treatment in certain people with advanced RCC, after completing combination treatment with nivolumab given into the vein (intravenous nivolumab) and ipilimumab. ∘ OPDIVO QVANTIG may be used in combination with cabozantinib as your first treatment for advanced RCC. ∘ OPDIVO QVANTIG may be used alone when your cancer has spread after treatment with other cancer medicines. • a type of skin cancer called melanoma. ∘ OPDIVO QVANTIG may be used alone to treat melanoma that has spread or cannot be removed by surgery (advanced melanoma). ∘ OPDIVO QVANTIG may be used alone to treat melanoma that has spread or cannot be removed by surgery (advanced melanoma), after completing combination treatment with intravenous nivolumab and ipilimumab. ∘ OPDIVO QVANTIG may be used alone to help prevent Stage IIB, Stage IIC, Stage III, or Stage IV melanoma from coming back after it has been completely removed by surgery. • a type of lung cancer called non-small cell lung cancer (NSCLC). ∘ OPDIVO QVANTIG may be used in combination with chemotherapy that contains platinum and another chemotherapy medicine before you have surgery for early-stage NSCLC. ∘ OPDIVO QVANTIG may be used in combination with chemotherapy that contains platinum and another chemotherapy medicine before you have surgery for early-stage NSCLC: ▪ that does not have an abnormal EGFR or ALK gene, and ▪ then OPDIVO QVANTIG may be continued alone after surgery to help prevent your lung cancer from coming back. ∘ OPDIVO QVANTIG may be used alone when your lung cancer: ▪ has spread, and ▪ you have tried chemotherapy that contains platinum, and it did not work or is no longer working. ▪ If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working. • head and neck cancer (squamous cell carcinoma). ∘ OPDIVO QVANTIG may be used alone when your head and neck cancer: ▪ has come back or spread, and ▪ you have tried chemotherapy that contains platinum and it did not work or is no longer working. • cancer of the lining of the urinary tract (urothelial carcinoma). ∘ OPDIVO QVANTIG may be used alone to help prevent cancer of the urinary tract from coming back after it was removed by surgery. ∘ OPDIVO QVANTIG may be used in combination with chemotherapy medicines cisplatin and gemcitabine as your first treatment when your urinary tract cancer has spread (metastatic) or cannot be removed by surgery. ∘ OPDIVO QVANTIG may be used alone when your urinary tract cancer has spread (locally advanced or metastatic), and: ▪ you have tried chemotherapy that contains platinum, and it did not work or is no longer working, or ▪ your cancer worsened within 12 months of treatment with chemotherapy that contains platinum, either before or after surgery to remove your cancer. • a type of colon or rectal cancer (colorectal cancer or CRC). ∘ OPDIVO QVANTIG may be used alone and after completing combination treatment with intravenous nivolumab and ipilimumab, when your colon or rectal cancer: ▪ has spread to other parts of the body (metastatic CRC), and ▪ is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and ▪ you have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working. • a type of liver cancer called hepatocellular carcinoma (HCC). ∘ OPDIVO QVANTIG may be used alone if you have previously received treatment with sorafenib and after completing combination treatment with intravenous nivolumab and ipilimumab. • cancer of the tube that connects your throat to your stomach (esophageal cancer). ∘ OPDIVO QVANTIG may be used alone to help prevent your esophageal or gastroesophageal junction cancer from coming back when: ▪ your esophageal or gastroesophageal junction cancer has been treated with chemoradiation followed by surgery to completely remove the cancer, but ▪ some cancer cells were still present in the removed tumor or lymph nodes. ∘ OPDIVO QVANTIG may be used in combination with chemotherapy that contains fluoropyrimidine and platinum as your first treatment when your esophageal cancer: ▪ is a type called squamous cell carcinoma, and ▪ cannot be removed with surgery (advanced), or ▪ has spread to other parts of the body (metastatic). ∘ OPDIVO QVANTIG may be used alone when your esophageal cancer: ▪ is a type called squamous cell carcinoma, and ▪ cannot be removed with surgery, has come back, or has spread to other parts of the body after you have received chemotherapy that contains fluoropyrimidine and platinum. • cancer of the stomach (gastric cancer), cancer where the esophagus joins the stomach (gastroesophageal junction cancer), and a type of cancer in the esophagus called esophageal adenocarcinoma. ∘ OPDIVO QVANTIG may be used in combination with chemotherapy that contains fluoropyrimidine and platinum when your gastric, gastroesophageal junction, or esophageal cancer: ▪ cannot be removed with surgery, or ▪ has spread to other parts of the body. It is not known if OPDIVO QVANTIG is safe and effective in children. Before receiving OPDIVO QVANTIG, tell your healthcare provider about all of your medical conditions, including if you: • have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus • have received an organ transplant, including corneal transplant • have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic) • have received radiation treatment to your chest area in the past • have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome • are pregnant or plan to become pregnant. OPDIVO QVANTIG can harm your unborn baby. Females who are able to become pregnant: ∘ Your healthcare provider should do a pregnancy test before you start receiving OPDIVO QVANTIG. ∘ You should use an effective method of birth control during treatment and for 5 months after your last dose of OPDIVO QVANTIG. Talk to your healthcare provider about birth control methods that you can use during this time. ∘ Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with OPDIVO QVANTIG. • are breastfeeding or plan to breastfeed. It is not known if OPDIVO QVANTIG passes into your breast milk. Do not breastfeed during treatment and for 5 months after your last dose of OPDIVO QVANTIG. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How will I receive OPDIVO QVANTIG? • Your healthcare provider will give you OPDIVO QVANTIG as an injection under the skin, in the stomach area (abdomen) or thigh, over about 3 to 5 minutes. • OPDIVO QVANTIG is usually given every 2, 3, or 4 weeks, depending on the dose you are receiving. • Your healthcare provider will decide how many treatments you will receive. • Your healthcare provider will do blood tests to check you for side effects. • For a type of kidney cancer called advanced renal cell carcinoma, your healthcare provider may also prescribe you cabozantinib. Take cabozantinib exactly as your healthcare provider tells you. • If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. What are the possible side effects of OPDIVO QVANTIG? OPDIVO QVANTIG can cause serious side effects, including: • See “What is the most important information I should know about OPDIVO QVANTIG?” • Complications, including graft-versus-host-disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with OPDIVO QVANTIG. Your healthcare provider will monitor you for signs of complications if you have an allogeneic stem cell transplant. The most common side effects of OPDIVO QVANTIG when used alone in people with renal cell carcinoma include: • pain in muscles, bones, and joints • feeling tired • itchy skin • rash • low thyroid hormone levels • diarrhea • cough • stomach-area (abdominal) pain The most common side effects observed with nivolumab given into the vein (intravenous nivolumab), which may be experienced with OPDIVO QVANTIG, are shown below. The most common side effects of intravenous nivolumab when used alone include: • feeling tired • rash • pain in muscles, bones, and joints • itchy skin • diarrhea • nausea • weakness • cough • shortness of breath • constipation • decreased appetite • back pain • upper respiratory tract infection • fever • headache • stomach-area (abdominal) pain • vomiting • urinary tract infection The most common side effects of intravenous nivolumab when used in combination with cabozantinib as the first treatment for advanced RCC include: • diarrhea • feeling tired • liver problems. See “What is the most important information I should know about OPDIVO QVANTIG?” • rash, redness, pain, swelling or blisters on the palms of your hands or soles of your feet • mouth sores • rash • high blood pressure • low thyroid hormone levels • pain in muscles, bones, and joints • decreased appetite • nausea • change in the sense of taste • stomach-area (abdominal) pain • cough • upper respiratory tract infection The most common side effects of intravenous nivolumab when used in combination with platinum-containing chemotherapy and another chemotherapy medicine before having surgery for NSCLC include: • nausea • constipation • feeling tired • decreased appetite • rash The most common side effects of intravenous nivolumab when used in combination with cisplatin and gemcitabine to treat urothelial cancer include: • nausea • feeling tired • pain in muscles, bones, and joints • constipation • decreased appetite • rash • vomiting • numbness, pain, tingling or burning in your hands and feet The most common side effects of intravenous nivolumab when used in combination with fluoropyrimidine and platinum-containing chemotherapy to treat esophageal cancer and gastric cancer include: • nausea • numbness, pain, tingling, or burning in your hands or feet • decreased appetite • feeling tired • constipation • mouth sores • diarrhea • vomiting • stomach-area (abdominal) pain • pain in muscles, bones, and joints These are not all the possible side effects of OPDIVO QVANTIG. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of OPDIVO QVANTIG. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about OPDIVO QVANTIG that is written for health professionals. What are the ingredients in OPDIVO QVANTIG? Active ingredients: nivolumab and hyaluronidase-nvhy Inactive ingredients: histidine, histidine hydrochloride monohydrate, methionine, pentetic acid, polysorbate 80, sucrose, and Water for Injection. Manufactured by: Bristol-Myers Squibb Company, Princeton, NJ 08543 USA U.S. License No. 1713 Halozyme Therapeutics, Inc., 12390 El Camino Real, San Diego, CA 92130, U.S. License No. 2187 OPDIVO QVANTIG ™ is a trademark of Bristol-Myers Squibb Company. Other brands listed are the trademarks of their respective owners. For more information, call 1-855-673-4861 or go to www.Qvantig.com. This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued: December 2024

14 CLINICAL STUDIES 14.1 Advanced Renal Cell Carcinoma Previously Treated Renal Cell Carcinoma - OPDIVO QVANTIG The efficacy of OPDIVO QVANTIG was evaluated in CHECKMATE-67T (NCT04810078), a multicenter, randomized, open-label study in patients with advanced or metastatic clear cell renal cell carcinoma. Patients 18 years of age or older with histologically confirmed advanced or metastatic renal cell carcinoma with a clear cell component, including those with sarcomatoid features, and who received no more than 2 prior systemic treatment regimens were randomized to receive OPDIVO QVANTIG (containing 1,200 mg of nivolumab and 20,000 units of hyaluronidase) every 4 weeks subcutaneously, or nivolumab 3 mg/kg every 2 weeks intravenously. Patients with untreated, symptomatic central nervous system (CNS) metastases; leptomeningeal metastases; concurrent malignancies requiring treatment or history of prior malignancy within the previous 2 years; active, known, or suspected autoimmune disease; or who received prior treatment with a checkpoint inhibitor were excluded from the study. Patients with asymptomatic, stable CNS metastases that did not require immediate treatment were eligible if there was no evidence of progression within 28 days prior to the first dose of study drug administration. Stratification factors for randomization were weight (<80 kg vs ≥80 kg) and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification (favorable vs intermediate, vs poor risk). The primary objective was to assess the nivolumab exposure of subcutaneous administration of OPDIVO QVANTIG as compared to the intravenous administration of nivolumab. The secondary objective of the study was to evaluate overall response rate (ORR) by blinded independent central review (BICR). A total of 495 patients were randomized to receive either OPDIVO QVANTIG (n=248) or intravenous nivolumab (n=247). The median age was 65 years (range: 20 to 93), with 51% ≥65 years of age and 14% ≥75 years of age; 68% male; 85% White, 12.5% not reported, 1% American Indian or Alaska Native, 0.8% Asian, and 0.4% Black; 36% Hispanic or Latino, 33% not Hispanic or Latino, and 31% not reported. Fifty-seven percent of patients weighed <80 kg and 43% weighed ≥80 kg. Baseline Karnofsky performance status was 70 (7%), 80 (20%), 90 (34%), or 100 (39%). Patient distribution by IMDC risk categories was 21% favorable, 62% intermediate, and 17% poor. When comparing subcutaneous administration of OPDIVO QVANTIG to the intravenous administration of nivolumab, CHECKMATE-67T met the predefined acceptance margin for pharmacokinetic endpoints, with the lower boundary of 90% confidence interval of geometric mean ratios of not less than 0.8 for both serum nivolumab C avg over 28 days and C min at steady state. [see Clinical Pharmacology 12.3 ]. Efficacy results are shown in Table 45. Table 45: Efficacy Results - CHECKMATE-67T a Confidence interval based on the Clopper and Pearson method. OPDIVO QVANTIG N=248 Intravenous Nivolumab N=247 ORR per BICR, n (%) 60 (24) 45 (18) 95% CI a (19, 30) (14, 24) RCC Trials - Intravenous Nivolumab The effectiveness of OPDIVO QVANTIG has been established for the following: • as monotherapy, for advanced renal cell carcinoma (RCC) following treatment with intravenous nivolumab and ipilimumab combination therapy (CHECKMATE-214 study). • in combination with cabozantinib, for the first-line treatment of adult patients with advanced RCC (CHECKMATE-9ER study). • as monotherapy, for the treatment of adult patients with advanced RCC who have received prior anti-angiogenic therapy (CHECKMATE-025 study). Use of OPDIVO QVANTIG for these RCC indications is supported by evidence from adequate and well-controlled studies conducted with intravenous nivolumab, and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab in the CHECKMATE-67T trial [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) , and Clinical Studies (14.1) ] . Below is a description of the efficacy results of these adequate and well-controlled studies of intravenous nivolumab in these RCC populations. First-line Renal Cell Carcinoma CHECKMATE-214 CHECKMATE-214 (NCT02231749) was a randomized (1:1), open-label trial in patients with previously untreated advanced RCC. Patients were included regardless of their PD-L1 status. CHECKMATE-214 excluded patients with any history of or concurrent brain metastases, active autoimmune disease, or medical conditions requiring systemic immunosuppression. Patients were stratified by International Metastatic RCC Database Consortium (IMDC) prognostic score and region. Efficacy was evaluated in intermediate/poor risk patients with at least 1 or more of 6 prognostic risk factors as per the IMDC criteria (less than one year from time of initial renal cell carcinoma diagnosis to randomization, Karnofsky performance status <80%, hemoglobin less than the lower limit of normal, corrected calcium of >10 mg/dL, platelet count greater than the upper limit of normal, and absolute neutrophil count greater than the upper limit of normal). Patients were randomized to nivolumab 3 mg/kg and ipilimumab 1 mg/kg intravenously every 3 weeks for 4 doses followed by nivolumab 3 mg/kg intravenously every two weeks (n=425), or sunitinib 50 mg orally daily for the first 4 weeks of a 6-week cycle (n=422). Treatment continued until disease progression or unacceptable toxicity. The trial population characteristics were: median age was 61 years (range: 21 to 85) with 38% ≥65 years of age and 8% ≥75 years of age. The majority of patients were male (73%) and White (87%) and 26% and 74% of patients had a baseline KPS of 70% to 80% and 90% to 100%, respectively. The major efficacy outcome measures were OS, PFS (independent radiographic review committee [IRRC]-assessed) and confirmed ORR (IRRC-assessed) in intermediate/poor risk patients. In this population, the trial demonstrated statistically significant improvement in OS and ORR for patients randomized to intravenous nivolumab and ipilimumab as compared with sunitinib (Table 46 and Figure 1). OS benefit was observed regardless of PD-L1 expression level. The trial did not demonstrate a statistically significant improvement in PFS. Efficacy results are shown in Table 46 and Figure 1. Table 46: Efficacy Results - CHECKMATE-214 a Not Reached b Based on a stratified proportional hazards model. c Based on a stratified log-rank test. d p-value is compared to alpha 0.002 in order to achieve statistical significance. e Based on the stratified DerSimonian-Laird test. f p-value is compared to alpha 0.001 in order to achieve statistical significance. g Not Significant at alpha level of 0.009. Intermediate/Poor-Risk Intravenous Nivolumab and Ipilimumab (n=425) Sunitinib (n=422) Overall Survival Deaths (%) 140 (32.9) 188 (44.5) Median survival (months) NR a 25.9 Hazard ratio (99.8% CI) b 0.63 (0.44, 0.89) p-value c,d <0.0001 Confirmed Overall Response Rate (95% CI) 41.6% (36.9, 46.5) 26.5% (22.4, 31.0) p-value e,f <0.0001 Complete response (CR) 40 (9.4) 5 (1.2) Partial response (PR) 137 (32.2) 107 (25.4) Median duration of response (months) (95% CI) NR a (21.8, NR a ) 18.2 (14.8, NR a ) Progression-free Survival Disease progression or death (%) 228 (53.6) 228 (54.0) Median (months) 11.6 8.4 Hazard ratio (99.1% CI) a 0.82 (0.64, 1.05) p-value c NS g Figure 1: Overall Survival (Intermediate/Poor Risk Population) - CHECKMATE-214 CHECKMATE-214 also randomized 249 favorable risk patients as per IMDC criteria to intravenous nivolumab and ipilimumab (n=125) or to sunitinib (n=124). These patients were not evaluated as part of the efficacy analysis population. OS in favorable risk patients receiving intravenous nivolumab and ipilimumab compared to sunitinib has a hazard ratio of 1.45 (95% CI: 0.75, 2.81). The efficacy of intravenous nivolumab and ipilimumab in previously untreated renal cell carcinoma with favorable-risk disease has not been established. CHECKMATE-9ER CHECKMATE-9ER (NCT03141177) was a randomized, open-label study of intravenous nivolumab combined with cabozantinib versus sunitinib in patients with previously untreated advanced RCC. CHECKMATE-9ER excluded patients with autoimmune disease or other medical conditions requiring systemic immunosuppression. Patients were stratified by IMDC prognostic score (favorable vs. intermediate vs. poor), PD-L1 tumor expression (≥1% vs. <1% or indeterminate), and region (US/Canada/Western Europe/Northern Europe vs. Rest of World). Patients were randomized to nivolumab 240 mg intravenously every 2 weeks and cabozantinib 40 mg orally daily (n=323), or sunitinib 50 mg orally daily for the first 4 weeks of a 6-week cycle (4 weeks on treatment followed by 2 weeks off) (n=328). Treatment continued until disease progression per RECIST v1.1 or unacceptable toxicity. Treatment beyond RECIST‑defined disease progression was permitted if the patient was clinically stable and considered to be deriving clinical benefit by the investigator. Tumor assessments were performed at baseline, after randomization at Week 12, then every 6 weeks until Week 60, and then every 12 weeks thereafter. The trial population characteristics were: median age 61 years (range: 28 to 90) with 38% ≥65 years of age and 10% ≥75 years of age. The majority of patients were male (74%) and White (82%) and 23% and 77% of patients had a baseline KPS of 70% to 80% and 90% to 100%, respectively. Patient distribution by IMDC risk categories was 22% favorable, 58% intermediate, and 20% poor. The major efficacy outcome measure was PFS (BICR assessed). Additional efficacy outcome measures were OS and ORR (BICR assessed). The trial demonstrated a statistically significant improvement in PFS, OS, and ORR for patients randomized to intravenous nivolumab and cabozantinib compared with sunitinib. Consistent results for PFS were observed across pre-specified subgroups of IMDC risk categories and PD-L1 tumor expression status. An updated OS analysis was conducted when 271 deaths were observed based on the pre-specified number of deaths for the pre-planned final analysis of OS. Efficacy results are shown in Table 47 and Figures 2 and 3. Table 47: Efficacy Results - CHECKMATE-9ER a Based on Kaplan-Meier estimates. b Stratified Cox proportional hazards model. c Based on stratified log-rank test d 2-sided p-values from stratified log-rank test. e Not Reached f p-value is compared with the allocated alpha of 0.0111 for this interim analysis g CI based on the Clopper-Pearson method. h 2-sided p-value from Cochran-Mantel-Haenszel test. Intravenous Nivolumab and Cabozantinib (n=323) Sunitinib (n=328) Progression-free Survival Disease progression or death (%) 144 (45) 191 (58) Median PFS (months) a (95% CI) 16.6 (12.5, 24.9) 8.3 (7.0, 9.7) Hazard ratio (95% CI) b 0.51 (0.41, 0.64) p-value c,d <0.0001 Overall Survival Deaths (%) 67 (21) 99 (30) Median OS (months) a (95% CI) NR e NR (22.6, NR e ) Hazard ratio (98.89% CI) b 0.60 (0.40, 0.89) p-value c,d,f 0.0010 Updated Overall Survival Deaths (%) 121 (37) 150 (46) Median OS (months) a (95% CI) 37.7 (35.5, NR) 34.3 (29.0, NR) Hazard ratio (95% CI) b 0.70 (0.55, 0.90) Confirmed Objective Response Rate (95% CI) g 55.7% (50.1, 61.2) 27.1% (22.4, 32.3) p-value h <0.0001 Complete Response 26 (8%) 15 (4.6%) Partial Response 154 (48%) 74 (23%) Median duration of response in months (95% CI) a 20.2 (17.3, NR e ) 11.5 (8.3, 18.4) Figure 2: Progression-free Survival - CHECKMATE-9ER Figure 3: Updated Overall Survival - CHECKMATE-9ER In an exploratory analysis, the updated analysis of OS in patients with IMDC favorable, intermediate, intermediate/poor, and poor risk demonstrated a HR (95% CI) of 1.03 (0.55, 1.92), 0.74 (0.54, 1.01), 0.65 (0.50, 0.85), and 0.49 (0.31, 0.79), respectively. oq-os-checkmate-214 oq-pfs-checkmate-9er oq-updated-os-checkmate-9er Previously Treated Renal Cell Carcinoma CHECKMATE-025 CHECKMATE-025 (NCT01668784) was a randomized (1:1), open-label trial in patients with advanced RCC who had experienced disease progression during or after one or two prior anti-angiogenic therapy regimens. Patients had to have a Karnofsky Performance Score (KPS) ≥70% and patients were included regardless of their PD-L1 status. The trial excluded patients with any history of or concurrent brain metastases, prior treatment with an mTOR inhibitor, active autoimmune disease, or medical conditions requiring systemic immunosuppression. Patients were stratified by region, Memorial Sloan Kettering Cancer Center (MSKCC) Risk Group and the number of prior anti-angiogenic therapies. Patients were randomized to nivolumab 3 mg/kg by intravenous infusion every 2 weeks (n=410) or everolimus 10 mg orally daily (n=411). The first tumor assessments were conducted 8 weeks after randomization and continued every 8 weeks thereafter for the first year and then every 12 weeks until progression or treatment discontinuation, whichever occurred later. The major efficacy outcome measure was overall survival (OS). The trial population characteristics were: median age was 62 years (range: 18 to 88) with 40% ≥65 years of age and 9% ≥75 years of age. The majority of patients were male (75%) and White (88%) and 34% and 66% of patients had a baseline KPS of 70% to 80% and 90% to 100%, respectively. The majority of patients (77%) were treated with one prior anti-angiogenic therapy. Patient distribution by MSKCC risk groups was 34% favorable, 47% intermediate, and 19% poor. The trial demonstrated a statistically significant improvement in OS for patients randomized to intravenous nivolumab as compared with everolimus at the prespecified interim analysis when 398 events were observed (70% of the planned number of events for final analysis). OS benefit was observed regardless of PD-L1 expression level. Efficacy results are shown in Table 48 and Figure 4. Table 48: Efficacy Results - CHECKMATE-025 a Not Reached b Based on a stratified proportional hazards model. c Based on a stratified log-rank test. d p-value is compared with 0.0148 of the allocated alpha for this interim analysis. Intravenous Nivolumab (n=410) Everolimus (n=411) Overall Survival Deaths (%) 183 (45) 215 (52) Median survival (months) (95% CI) 25.0 (21.7, NR a ) 19.6 (17.6, 23.1) Hazard ratio (95% CI) b 0.73 (0.60, 0.89) p-value c,d 0.0018 Confirmed Overall Response Rate (95% CI) 21.5% (17.6, 25.8) 3.9% (2.2, 6.2) Median duration of response (months) (95% CI) 23.0 (12.0, NR a ) 13.7 (8.3, 21.9) Median time to onset of confirmed response (months) (min, max) 3.0 (1.4, 13.0) 3.7 (1.5, 11.2) Figure 4: Overall Survival - CHECKMATE-025 oq-os-checkmate-025 14.2 Unresectable or Metastatic Melanoma Previously Treated Metastatic Melanoma The effectiveness of OPDIVO QVANTIG has been established for the treatment of previously treated unresectable or metastatic melanoma. Use of OPDIVO QVANTIG for this indication is supported by evidence from an adequate and well-controlled study conducted with intravenous nivolumab, and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of this adequate and well-controlled study of intravenous nivolumab in this melanoma population. OPDIVO QVANTIG is not indicated for the treatment of pediatric patients. CHECKMATE-037 CHECKMATE-037 (NCT01721746) was a multicenter, open-label trial that randomized (2:1) patients with unresectable or metastatic melanoma to receive nivolumab 3 mg/kg intravenously every 2 weeks or investigator’s choice of chemotherapy, either single-agent dacarbazine 1000 mg/m 2 every 3 weeks or the combination of carboplatin AUC 6 intravenously every 3 weeks and paclitaxel 175 mg/m 2 intravenously every 3 weeks. Patients were required to have progression of disease on or following ipilimumab treatment and, if BRAF V600 mutation positive, a BRAF inhibitor. The trial excluded patients with autoimmune disease, medical conditions requiring systemic immunosuppression, ocular melanoma, active brain metastasis, or a history of Grade 4 ipilimumab-related adverse reactions (except for endocrinopathies) or Grade 3 ipilimumab‑related adverse reactions that had not resolved or were inadequately controlled within 12 weeks of the initiating event. Tumor assessments were conducted 9 weeks after randomization then every 6 weeks for the first year, and every 12 weeks thereafter. Efficacy was evaluated in a single-arm, non-comparative, planned interim analysis of the first 120 patients who received intravenous nivolumab in CHECKMATE-037 and in whom the minimum duration of follow-up was 6 months. The major efficacy outcome measures in this population were confirmed overall response rate (ORR) as measured by blinded independent central review using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and duration of response. Among the 120 patients treated with intravenous nivolumab, the median age was 58 years (range: 25 to 88), 65% of patients were male, 98% were White, and the ECOG performance score was 0 (58%) or 1 (42%). Disease characteristics were M1c disease (76%), BRAF V600 mutation positive (22%), elevated LDH (56%), history of brain metastases (18%), and two or more prior systemic therapies for metastatic disease (68%). The ORR was 32% (95% confidence interval [CI]: 23, 41), consisting of 4 complete responses and 34 partial responses in intravenous nivolumab-treated patients. Of 38 patients with responses, 87% had ongoing responses with durations ranging from 2.6+ to 10+ months, which included 13 patients with ongoing responses of 6 months or longer. There were responses in patients with and without BRAF V600 mutation-positive melanoma. A total of 405 patients were randomized and the median duration of OS was 15.7 months (95% CI: 12.9, 19.9) in nivolumab-treated patients compared to 14.4 months (95% CI: 11.7, 18.2) (HR 0.95; 95.54% CI: 0.73, 1.24) in patients assigned to investigator’s choice of treatment. Figure 5 summarizes the OS results. Figure 5: Overall Survival - CHECKMATE-037* * The primary OS analysis was not adjusted to account for subsequent therapies, with 54 (40.6%) patients in the chemotherapy arm subsequently receiving an anti-PD1 treatment. OS may be confounded by dropout, imbalance of subsequent therapies, and differences in baseline factors. Previously Untreated Metastatic Melanoma The effectiveness of OPDIVO QVANTIG has been established for the treatment of previously untreated unresectable or metastatic melanoma. Use of OPDIVO QVANTIG for this indication is supported by evidence from adequate and well-controlled studies conducted with intravenous nivolumab, and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of these adequate and well-controlled studies of intravenous nivolumab in this melanoma population. OPDIVO QVANTIG is not indicated for the treatment of pediatric patients. CHECKMATE-066 CHECKMATE-066 (NCT01721772) was a multicenter, double-blind, randomized (1:1) trial in 418 patients with BRAF V600 wild-type unresectable or metastatic melanoma. Patients were randomized to receive either nivolumab 3 mg/kg by intravenous infusion every 2 weeks or dacarbazine 1000 mg/m 2 intravenously every 3 weeks until disease progression or unacceptable toxicity. Randomization was stratified by PD-L1 status (≥5% of tumor cell membrane staining by immunohistochemistry vs. <5% or indeterminate result) and M stage (M0/M1a/M1b versus M1c). Key eligibility criteria included histologically confirmed, unresectable or metastatic, cutaneous, mucosal, or acral melanoma; no prior therapy for metastatic disease; completion of prior adjuvant or neoadjuvant therapy at least 6 weeks prior to randomization; ECOG performance status 0 or 1; absence of autoimmune disease; and absence of active brain or leptomeningeal metastases. The trial excluded patients with ocular melanoma. Tumor assessments were conducted 9 weeks after randomization then every 6 weeks for the first year and then every 12 weeks thereafter. The major efficacy outcome measure was overall survival (OS). Additional outcome measures included investigator-assessed progression-free survival (PFS) and ORR per RECIST v1.1. The trial population characteristics were: median age was 65 years (range: 18 to 87), 59% were male, and 99.5% were White. Disease characteristics were M1c stage disease (61%), cutaneous melanoma (74%), mucosal melanoma (11%), elevated LDH level (37%), PD-L1 ≥5% tumor cell membrane expression (35%), and history of brain metastasis (4%). More patients in the intravenous nivolumab arm had an ECOG performance status of 0 (71% vs. 58%). CHECKMATE-066 demonstrated a statistically significant improvement in OS for the intravenous nivolumab arm compared with the dacarbazine arm in an interim analysis based on 47% of the total planned events for OS. At the time of analysis, 88% (63/72) of intravenous nivolumab-treated patients had ongoing responses, which included 43 patients with ongoing response of 6 months or longer. Efficacy results are shown in Table 49 and Figure 6. Table 49: Efficacy Results - CHECKMATE-066 a Not Reached b Based on a stratified proportional hazards model. c Based on stratified log-rank test. d p-value is compared with the allocated alpha of 0.0021 for this interim analysis. Intravenous Nivolumab (n=210) Dacarbazine (n=208) Overall Survival Deaths (%) 50 (24) 96 (46) Median (months) (95% CI) NR a 10.8 (9.3, 12.1) Hazard ratio (95% CI) b 0.42 (0.30, 0.60) p-value c,d <0.0001 Progression-free Survival Disease progression or death (%) 108 (51) 163 (78) Median (months) (95% CI) 5.1 (3.5, 10.8) 2.2 (2.1, 2.4) Hazard ratio (95% CI) b 0.43 (0.34, 0.56) p-value c,d <0.0001 Overall Response Rate 34% 9% (95% CI) (28, 41) (5, 13) Complete response rate 4% 1% Partial response rate 30% 8% Figure 6: Overall Survival - CHECKMATE-066 CHECKMATE-067 CHECKMATE-067 (NCT01844505) was a multicenter, randomized (1:1:1), double-blind trial in 945 patients with previously untreated, unresectable or metastatic melanoma to one of the following arms: intravenous nivolumab and ipilimumab, intravenous nivolumab, or ipilimumab. Patients were required to have completed adjuvant or neoadjuvant treatment at least 6 weeks prior to randomization and have no prior treatment with anti-CTLA-4 antibody and no evidence of active brain metastasis, ocular melanoma, autoimmune disease, or medical conditions requiring systemic immunosuppression. Patients were randomized to receive: • Nivolumab 1 mg/kg with ipilimumab 3 mg/kg intravenously every 3 weeks for 4 doses, followed by nivolumab as a single agent at a dose of 3 mg/kg by intravenous infusion every 2 weeks (nivolumab and ipilimumab arm), • Nivolumab 3 mg/kg by intravenous infusion every 2 weeks (nivolumab arm), or • Ipilimumab 3 mg/kg intravenously every 3 weeks for 4 doses, followed by placebo every 2 weeks (ipilimumab arm). Randomization was stratified by PD-L1 expression (≥5% vs. <5% tumor cell membrane expression) as determined by a clinical trial assay, BRAF V600 mutation status, and M stage per the AJCC staging system (M0, M1a, M1b vs. M1c). Tumor assessments were conducted 12 weeks after randomization then every 6 weeks for the first year, and every 12 weeks thereafter. The major efficacy outcome measures were investigator-assessed PFS per RECIST v1.1 and OS. Additional efficacy outcome measures were confirmed ORR and duration of response. The trial population characteristics were: median age 61 years (range: 18 to 90); 65% male; 97% White; ECOG performance score 0 (73%) or 1 (27%). Disease characteristics were: AJCC Stage IV disease (93%); M1c disease (58%); elevated LDH (36%); history of brain metastases (4%); BRAF V600 mutation-positive melanoma (32%); PD-L1 ≥5% tumor cell membrane expression as determined by the clinical trials assay (46%); and prior adjuvant therapy (22%). CHECKMATE-067 demonstrated statistically significant improvements in OS and PFS for patients randomized to either intravenous nivolumab-containing arm as compared with the ipilimumab arm. The trial was not designed to assess whether adding ipilimumab to intravenous nivolumab improves PFS or OS compared to intravenous nivolumab as a single agent. Efficacy results are shown in Table 50 and Figure 7. Table 50: Efficacy Results - CHECKMATE-067 a OS results are based on final OS analysis with 28 months of minimum follow-up; PFS (co-primary endpoint) and ORR (secondary endpoint) results were based on primary analysis with 9 months of minimum follow-up. b Based on a stratified proportional hazards model. c Based on stratified log-rank test. d If the maximum of the two OS p-values is less than 0.04 (a significance level assigned by the Hochberg procedure), then both p-values are considered significant. e p-value is compared with .005 of the allocated alpha for final PFS treatment comparisons. f Based on the stratified Cochran-Mantel-Haenszel test. + Censored observation Intravenous Nivolumab and Ipilimumab (n=314) Intravenous Nivolumab (n=316) Ipilimumab (n=315) Overall Survival a Deaths (%) 128 (41) 142 (45) 197 (63) Hazard ratio b (vs. ipilimumab) (95% CI) 0.55 (0.44, 0.69) 0.63 (0.50, 0.78) p-value c, d <0.0001 <0.0001 Progression-free Survival a Disease progression or death 151 (48%) 174 (55%) 234 (74%) Median (months) (95% CI) 11.5 (8.9, 16.7) 6.9 (4.3, 9.5) 2.9 (2.8, 3.4) Hazard ratio b (vs. ipilimumab) (95% CI) 0.42 (0.34, 0.51) 0.57 (0.47, 0.69) p-value c, e <0.0001 <0.0001 Confirmed Overall Response Rate a 50% 40% 14% (95% CI) (44, 55) (34, 46) (10, 18) p-value f <0.0001 <0.0001 Complete response 8.9% 8.5% 1.9% Partial response 41% 31% 12% Duration of Response Proportion ≥6 months in duration 76% 74% 63% Range (months) 1.2+ to 15.8+ 1.3+ to 14.6+ 1.0+ to 13.8+ Figure 7: Overall Survival - CHECKMATE-067 Based on a minimum follow-up of 48 months, the median OS was not reached (95% CI: 38.2, NR) in the intravenous nivolumab and ipilimumab arm. The median OS was 36.9 months (95% CI: 28.3, NR) in the intravenous nivolumab arm and 19.9 months (95% CI: 16.9, 24.6) in the ipilimumab arm. Based on a minimum follow-up of 28 months, the median PFS was 11.7 months (95% CI: 8.9, 21.9) in the intravenous nivolumab and ipilimumab arm, 6.9 months (95% CI: 4.3, 9.5) in the intravenous nivolumab arm, and 2.9 months (95% CI: 2.8, 3.2) in the ipilimumab arm. Based on a minimum follow-up of 28 months, the proportion of responses lasting ≥24 months was 55% in the intravenous nivolumab and ipilimumab arm, 56% in the intravenous nivolumab arm, and 39% in the ipilimumab arm. oq-os-checkmate-066 oq-os-checkmate-067 oq-os-checkmate-037 14.3 Adjuvant Treatment of Melanoma The effectiveness of OPDIVO QVANTIG has been established for the adjuvant treatment of Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. Use of OPDIVO QVANTIG for this indication is supported by evidence from adequate and well-controlled studies conducted with intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of these adequate and well-controlled studies of intravenous nivolumab in these melanoma populations. OPDIVO QVANTIG is not indicated for the treatment of pediatric patients. CHECKMATE-76K CHECKMATE-76K (NCT04099251) was a randomized, double-blind trial in 790 patients with completely resected Stage IIB/C melanoma. Patients were randomized (2:1) to receive nivolumab 480 mg or placebo by intravenous infusion every 4 weeks for up to 1 year or until disease recurrence or unacceptable toxicity. Enrollment required complete resection of the primary melanoma with negative margins and a negative sentinel lymph node within 12 weeks prior to randomization, and ECOG performance status of 0 or 1. The trial excluded patients with ocular/uveal or mucosal melanoma, autoimmune disease, any condition requiring systemic treatment with either corticosteroids (≥10 mg daily prednisone or equivalent) or other immunosuppressive medications, as well as patients with prior therapy for melanoma except surgery. Randomization was stratified by AJCC 8 th staging system edition (T3b vs. T4a vs. T4b). The major efficacy outcome measure was recurrence-free survival (RFS) defined as the time between the date of randomization and the date of first recurrence (local, regional, or distant metastasis), new primary melanoma, or death, from any cause, whichever occurred first and as assessed by the investigator. Tumor assessments were conducted every 26 weeks during years 1-3 and every 52 weeks thereafter until year 5. The trial population characteristics were: median age 62 years (range: 19 to 92), 61% were male, 98% were White, 0.4% Black or African American, 0.1% Asian, and 1.1% race unknown, 2.2% Hispanic or Latino, 58% Not Hispanic or Latino, 40% ethnicity unknown, and 94% had an ECOG performance status of 0. Sixty one percent had stage IIB and 39% had stage IIC melanoma. CHECKMATE-76K demonstrated a statistically significant improvement in RFS for patients randomized to the intravenous nivolumab arm compared with the placebo arm. Efficacy results are shown in Table 51 and Figure 8. Table 51: Efficacy Results - CHECKMATE-76K a Not reached. b Based on Kaplan-Meier estimates. c Hazard Ratio is intravenous nivolumab over placebo based on a stratified Cox proportional hazard model. d Based on a 2-sided stratified log-rank test. Boundary for statistical significance: p-value <0.033. Intravenous Nivolumab n=526 Placebo n=264 Recurrence-free Survival Number of events, n (%) 66 (13%) 69 (26%) Median (months) b (95% CI) NR a (28.5, NR) NR a (21.6, NR) Hazard ratio c (95% CI) p-value d 0.42 (0.30, 0.59) p<0.0001 Figure 8: Recurrence-free Survival - CHECKMATE-76K CHECKMATE-238 CHECKMATE-238 (NCT02388906) was a randomized, double-blind trial in 906 patients with completely resected Stage IIIB/C or Stage IV melanoma. Patients were randomized (1:1) to receive nivolumab 3 mg/kg by intravenous infusion every 2 weeks or ipilimumab 10 mg/kg intravenously every 3 weeks for 4 doses then every 12 weeks beginning at Week 24 for up to 1 year. Enrollment required complete resection of melanoma with margins negative for disease within 12 weeks prior to randomization. The trial excluded patients with a history of ocular/uveal melanoma, autoimmune disease, and any condition requiring systemic treatment with either corticosteroids (≥10 mg daily prednisone or equivalent) or other immunosuppressive medications, as well as patients with prior therapy for melanoma except surgery, adjuvant radiotherapy after neurosurgical resection for lesions of the central nervous system, and prior adjuvant interferon completed ≥6 months prior to randomization. Randomization was stratified by PD-L1 status (positive [based on 5% level] vs. negative/indeterminate) and AJCC stage (Stage IIIB/C vs. Stage IV M1a-M1b vs. Stage IV M1c). The major efficacy outcome measure was recurrence-free survival (RFS) defined as the time between the date of randomization and the date of first recurrence (local, regional, or distant metastasis), new primary melanoma, or death, from any cause, whichever occurs first and as assessed by the investigator. Patients underwent imaging for tumor recurrence every 12 weeks for the first 2 years then every 6 months thereafter. The trial population characteristics were: median age was 55 years (range: 18 to 86), 58% were male, 95% were White, and 90% had an ECOG performance status of 0. Disease characteristics were AJCC Stage IIIB (34%), Stage IIIC (47%), Stage IV (19%), M1a-b (14%), BRAF V600 mutation positive (42%), BRAF wild-type (45%), elevated LDH (8%), PD-L1 ≥5% tumor cell membrane expression determined by clinical trial assay (34%), macroscopic lymph nodes (48%), and tumor ulceration (32%). CHECKMATE-238 demonstrated a statistically significant improvement in RFS for patients randomized to the intravenous nivolumab arm compared with the ipilimumab 10 mg/kg arm. Efficacy results are shown in Table 52 and Figure 9. Table 52: Efficacy Results - CHECKMATE-238 a Not reached. b Based on a stratified proportional hazards model. c Based on a stratified log-rank test. d p-value is compared with 0.0244 of the allocated alpha for this analysis. e At the time of the final OS analysis, fewer overall survival events were observed than originally anticipated (approximately 302). Intravenous Nivolumab N=453 Ipilimumab 10 mg/kg N=453 Recurrence-free Survival Number of events, n (%) 154 (34%) 206 (45%) Median (months) (95% CI) NR a NR a (16.56, NR a ) Hazard ratio b (95% CI) p-value c,d 0.65 (0.53, 0.80) p<0.0001 Overall Survival Number of events, n (%) e 100 (22%) 111 (25%) Median (months) (95% CI) NR a NR a Hazard ratio b (95% CI) p-value 0.87 (0.67, 1.14) 0.3148 Figure 9: Recurrence-free Survival - CHECKMATE-238 oq-rfs-checkmate-76k oq-rfs-checkmate-238 14.4 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer The effectiveness of OPDIVO QVANTIG has been established for the neoadjuvant treatment of resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum doublet chemotherapy. Use of OPDIVO QVANTIG for this indication is supported by evidence from adequate and well-controlled studies conducted with intravenous nivolumab (CHECKMATE-816, NCT02998528), and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of the adequate and well-controlled study of intravenous nivolumab in this lung cancer population. CHECKMATE-816 CHECKMATE-816 (NCT02998528) was a randomized, open label trial in patients with resectable NSCLC. The trial included patients with resectable, histologically confirmed Stage IB (≥4 cm), II, or IIIA NSCLC (per the 7th edition American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging criteria), ECOG performance status 0 or 1, and measurable disease (per RECIST version 1.1). Patients with unresectable or metastatic NSCLC, known EGFR mutations or ALK translocations, Grade 2 or greater peripheral neuropathy, active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the study. Patients were randomized to receive either: • nivolumab 360 mg administered intravenously over 30 minutes and platinum-doublet chemotherapy administered intravenously every 3 weeks for up to 3 cycles, or • platinum-doublet chemotherapy administered every 3 weeks for up to 3 cycles. Platinum-doublet chemotherapy consisted of paclitaxel 175 mg/m 2 or 200 mg/m 2 and carboplatin AUC 5 or AUC 6 (any histology); pemetrexed 500 mg/m 2 and cisplatin 75 mg/m 2 (non-squamous histology); or gemcitabine 1000 mg/m 2 or 1250 mg/m 2 and cisplatin 75 mg/m 2 (squamous histology). In the platinum-doublet chemotherapy arm, two additional treatment regimen options included vinorelbine 25 mg/m 2 or 30 mg/m 2 and cisplatin 75 mg/m 2 ; or docetaxel 60 mg/m 2 or 75 mg/m 2 and cisplatin 75 mg/m 2 (any histology). Stratification factors for randomization were tumor PD-L1 expression level (≥1% versus <1% or non-quantifiable), disease stage (IB/II versus IIIA), and sex (male versus female). Tumor assessments were performed at baseline, within 14 days of surgery, every 12 weeks after surgery for 2 years, then every 6 months for 3 years, and every year for 5 years until disease recurrence or progression. The major efficacy outcome measures were event-free survival (EFS) based on blinded independent central review (BICR) assessment and pathologic complete response (pCR) as evaluated by blinded independent pathology review (BIPR). Additional efficacy outcome measures included OS. A total of 358 patients were randomized to receive either intravenous nivolumab in combination with platinum‑doublet chemotherapy (n=179) or platinum-doublet chemotherapy (n=179). The median age was 65 years (range: 34 to 84) with 51% of patients ≥65 years and 7% of patients ≥75 years, 50% were Asian, 47% were White, 2% were Black, and 71% were male. Baseline ECOG performance status was 0 (67%) or 1 (33%); 50% had tumors with PD-L1 expression ≥1%; 35% had stage IB/II and 64% had stage IIIA disease; 51% had tumors with squamous histology and 49% had tumors with non-squamous histology; and 89% were former/current smokers. Eighty-three percent of patients in the intravenous nivolumab in combination with platinum-doublet chemotherapy arm had definitive surgery compared to 75% of patients in the platinum-doublet chemotherapy arm. The study demonstrated statistically significant improvements in EFS and pCR. Efficacy results are presented in Table 53 and Figure 10. Table 53: Efficacy Results - CHECKMATE-816 Minimum follow-up for EFS was 21 months. a Kaplan-Meier estimate. b Based on a stratified Cox proportional hazard model. c Based on a stratified log-rank test. Boundary for statistical significance: p-value <0.0262. d Based on Clopper and Pearson method. e Strata-adjusted difference based on Cochran-Mantel-Haenszel method of weighting. f From stratified CMH test. Intravenous Nivolumab and Platinum-Doublet Chemotherapy (n=179) Platinum-Doublet Chemotherapy (n=179) Event-free Survival (EFS) per BICR Events (%) 64 (35.8) 87 (48.6) Median (months) a (95% CI) 31.6 (30.2, NR) 20.8 (14.0, 26.7) Hazard Ratio b (95% CI) 0.63 (0.45, 0.87) Stratified log-rank p-value c 0.0052 Pathologic Complete Response (pCR) per BIPR Number of patients with pCR 43 4 pCR Rate (%), (95% CI) d 24.0 (18.0, 31.0) 2.2 (0.6, 5.6) Estimated treatment difference (95% CI) e 21.6 (15.1, 28.2) p-value f <0.0001 Figure 10: Event-Free Survival - CHECKMATE-816 At the time of the EFS analysis, 26% of the patients had died. A prespecified interim analysis for OS resulted in a HR of 0.57 (95% CI: 0.38, 0.87), which did not cross the boundary for statistical significance. oq-efs-checkmate-816 14.5 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer The effectiveness of OPDIVO QVANTIG has been established for neoadjuvant treatment of resectable (tumors ≥4 cm or node positive) NSCLC and no EGFR mutations or ALK rearrangements in combination with platinum doublet chemotherapy followed by adjuvant treatment with intravenous nivolumab. Use of OPDIVO QVANTIG for this indication is supported by evidence from adequate and well-controlled studies conducted with intravenous nivolumab (CHECKMATE-77T, NCT04025879), and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of the adequate and well-controlled study of intravenous nivolumab in this lung cancer population. CHECKMATE-77T The efficacy of intravenous nivolumab, in combination with platinum-doublet chemotherapy, followed by surgery, and continued adjuvant treatment with intravenous nivolumab as a single agent, was investigated in CHECKMATE-77T (NCT04025879), a randomized, double-blind trial in 461 patients with resectable NSCLC. The trial included patients with resectable, suspected or histologically confirmed Stage IIA (>4 cm) to IIIB (T3-T4 N2) NSCLC (per the 8th edition American Joint Committee on Cancer (AJCC) Staging Manual), and ECOG performance status 0 or 1. Patients with unresectable or metastatic NSCLC, EGFR mutations or known ALK translocations, brain metastasis, Grade 2 or greater peripheral neuropathy, interstitial lung disease or active, non-infectious pneumonitis (symptomatic and/or requiring treatment), active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the study. Randomization was stratified by tumor PD-L1 expression level (≥1% versus <1% versus indeterminate/not evaluable), disease stage (Stage II versus Stage III), and tumor histology (squamous versus nonsquamous). Patients were randomized (1:1) to receive either: • Neoadjuvant nivolumab 360 mg administered intravenously over 30 minutes in combination with one of the following platinum-doublet chemotherapy regimens every 3 weeks for four cycles: ∘ Paclitaxel 175 mg/m 2 or 200 mg/m 2 and carboplatin AUC 5 or AUC 6 (any histology) ∘ Pemetrexed 500 mg/m 2 , and cisplatin 75 mg/m 2 or carboplatin AUC 5 or AUC 6 (nonsquamous histology) ∘ Cisplatin 75 mg/m 2 and docetaxel 75 mg/m 2 (squamous histology). Within 90 days after the surgery, nivolumab 480 mg was administered intravenously over 30 minutes every 4 weeks. or • Neoadjuvant placebo administered intravenously over 30 minutes in combination with platinum-doublet chemotherapy (see above) every 3 weeks for four cycles. Within 90 days after the surgery, placebo was administered intravenously over 30 minutes every 4 weeks. All study medications were administered via intravenous infusion. Treatment continued until disease progression, recurrence, or unacceptable toxicity for up to 13 cycles (1 year). Tumor assessments were performed every 12 weeks for 2 years, then every 24 weeks for up to 5 years or until disease recurrence or progression was confirmed by BICR. The trial was not designed to isolate the effect of intravenous nivolumab in each phase (neoadjuvant or adjuvant) of treatment. The major efficacy outcome measure was event-free survival (EFS) based on BICR assessment. Additional efficacy outcome measures included overall survival (OS), pathologic complete response (pCR), and major pathologic response (MPR). The median age was 66 years (range: 35 to 86); 71% were male; 72% were White, 25% were Asian, 1.7% were Black, and 1.5% were mixed race/ race unknown/ not reported; and 6% were Hispanic or Latino. Baseline ECOG performance status was 0 (62%) or 1 (38%); 56% had tumors with PD-L1 expression ≥1% and 40% had tumors with PD-L1 expression <1%; 35% had stage II and 64% had stage III disease; 23% had N1 disease and 39% had N2 disease; 51% had tumors with squamous histology and 49% had tumors with nonsquamous histology; and 90% were former/current smokers. Seventy-eight percent of patients in the neoadjuvant intravenous nivolumab in combination with platinum-doublet chemotherapy followed by adjuvant intravenous nivolumab arm had definitive surgery compared to 77% of patients in the neoadjuvant placebo and platinum-doublet chemotherapy followed by placebo arm. The study demonstrated a statistically significant improvement in EFS for patients treated with neoadjuvant intravenous nivolumab in combination with platinum-doublet chemotherapy followed by single agent intravenous nivolumab compared with patients randomized to placebo in combination with platinum-doublet chemotherapy followed by placebo. Efficacy results are presented in Table 54 and Figure 11. Table 54: Efficacy Results - CHECKMATE-77T a Kaplan-Meier estimate. b Based on a stratified Cox proportional hazard model. c Based on a stratified log-rank test. Boundary for statistical significance: p-value <0.0264. Neoadjuvant Intravenous Nivolumab and Platinum-Doublet Chemotherapy/Adjuvant Intravenous Nivolumab (n=229) Neoadjuvant Placebo and Platinum-Doublet Chemotherapy/Adjuvant Placebo (n=232) Event-free Survival (EFS) per BICR Events (%) 76 (33%) 113 (49%) Median (months) a (95% CI) NR (28.9, NR) 18.4 (13.6, 28.1) Hazard Ratio b (95% CI) 0.58 (0.43, 0.78) Stratified log-rank p-value c 0.00025 Figure 11: Event-Free Survival - CHECKMATE-77T In a pre-specified descriptive analysis, the pCR rate was 25% (95% CI: 20, 31) in the intravenous nivolumab arm and 4.7% (95% CI: 2.4, 8) in the placebo arm. At the time of the EFS analysis, OS data were immature. oq-efs-checkmate-77t 14.6 Metastatic Non-Small Cell Lung Cancer Second-line Treatment of Metastatic NSCLC The effectiveness of OPDIVO QVANTIG has been established for the treatment of NSCLC previously treated with platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. Use of OPDIVO QVANTIG for this indication is supported by evidence from adequate and well-controlled studies conducted with intravenous nivolumab, and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of this adequate and well-controlled study of intravenous nivolumab in this lung cancer population. CHECKMATE-017 CHECKMATE-017 (NCT01642004) was a randomized (1:1), open-label trial in 272 patients with metastatic squamous NSCLC who had experienced disease progression during or after one prior platinum doublet-based chemotherapy regimen. Patients received nivolumab 3 mg/kg by intravenous infusion every 2 weeks (n=135) or docetaxel 75 mg/m 2 intravenously every 3 weeks (n=137). Randomization was stratified by prior paclitaxel vs. other prior treatment and region (US/Canada vs. Europe vs. Rest of World). This trial included patients regardless of their PD-L1 status. The trial excluded patients with autoimmune disease, medical conditions requiring systemic immunosuppression, symptomatic interstitial lung disease, or untreated brain metastasis. Patients with treated brain metastases were eligible if neurologically returned to baseline at least 2 weeks prior to enrollment, and either off corticosteroids, or on a stable or decreasing dose of <10 mg daily prednisone equivalents. The first tumor assessments were conducted 9 weeks after randomization and continued every 6 weeks thereafter. The major efficacy outcome measure was OS. Additional efficacy outcome measures were investigator-assessed ORR and PFS. The trial population characteristics were: median age was 63 years (range: 39 to 85) with 44% ≥65 years of age and 11% ≥75 years of age. The majority of patients were White (93%) and male (76%); the majority of patients were enrolled in Europe (57%) with the remainder in US/Canada (32%) and the rest of the world (11%). Baseline ECOG performance status was 0 (24%) or 1 (76%) and 92% were former/current smokers. Baseline disease characteristics of the population as reported by investigators were Stage IIIb (19%), Stage IV (80%), and brain metastases (6%). All patients received prior therapy with a platinum-doublet regimen and 99% of patients had tumors of squamous-cell histology. The trial demonstrated a statistically significant improvement in OS for patients randomized to intravenous nivolumab as compared with docetaxel at the prespecified interim analysis when 199 events were observed (86% of the planned number of events for final analysis). Efficacy results are shown in Table 55 and Figure 12. Table 55: Efficacy Results - CHECKMATE-017 a Based on a stratified proportional hazards model. b Based on stratified log-rank test. c p-value is compared with .0315 of the allocated alpha for this interim analysis. d Based on the stratified Cochran-Mantel-Haenszel test. e Not Reached Intravenous Nivolumab (n=135) Docetaxel (n=137) Overall Survival Deaths (%) 86 (64%) 113 (82%) Median (months) (95% CI) 9.2 (7.3, 13.3) 6.0 (5.1, 7.3) Hazard ratio (95% CI) a 0.59 (0.44, 0.79) p-value b,c 0.0002 Overall Response Rate 27 (20%) 12 (9%) (95% CI) (14, 28) (5, 15) p-value d 0.0083 Complete response 1 (0.7%) 0 Median duration of response (months) (95% CI) NR e (9.8, NR e ) 8.4 (3.6, 10.8) Progression-free Survival Disease progression or death (%) 105 (78%) 122 (89%) Median (months) 3.5 2.8 Hazard ratio (95% CI) a 0.62 (0.47, 0.81) p-value b 0.0004 Figure 12: Overall Survival - CHECKMATE-017 Archival tumor specimens were retrospectively evaluated for PD-L1 expression. Across the trial population, 17% of 272 patients had non-quantifiable results. Among the 225 patients with quantifiable results, 47% had PD-L1 negative squamous NSCLC, defined as <1% of tumor cells expressing PD-L1 and 53% had PD-L1 positive squamous NSCLC defined as ≥1% of tumor cells expressing PD-L1. In pre-specified exploratory subgroup analyses, the hazard ratios for survival were 0.58 (95% CI: 0.37, 0.92) in the PD-L1 negative subgroup and 0.69 (95% CI: 0.45, 1.05) in the PD-L1 positive subgroup. CHECKMATE-057 CHECKMATE-057 (NCT01673867) was a randomized (1:1), open-label trial in 582 patients with metastatic non-squamous NSCLC who had experienced disease progression during or after one prior platinum doublet‑based chemotherapy regimen. Appropriate prior targeted therapy in patients with known sensitizing EGFR mutation or ALK translocation was allowed. Patients received nivolumab 3 mg/kg by intravenous infusion every 2 weeks (n=292) or docetaxel 75 mg/m 2 intravenously every 3 weeks (n=290). Randomization was stratified by prior maintenance therapy (yes vs. no) and number of prior therapies (1 vs. 2). The trial excluded patients with autoimmune disease, medical conditions requiring systemic immunosuppression, symptomatic interstitial lung disease, or untreated brain metastasis. Patients with treated brain metastases were eligible if neurologically stable. The first tumor assessments were conducted 9 weeks after randomization and continued every 6 weeks thereafter. The major efficacy outcome measure was OS. Additional efficacy outcome measures were investigator-assessed ORR and PFS. In addition, prespecified analyses were conducted in subgroups defined by PD-L1 expression. The trial population characteristics: median age was 62 years (range: 21 to 85) with 42% of patients ≥65 years and 7% of patients ≥75 years. The majority of patients were White (92%) and male (55%); the majority of patients were enrolled in Europe (46%) followed by the US/Canada (37%) and the rest of the world (17%). Baseline ECOG performance status was 0 (31%) or 1 (69%), 79% were former/current smokers, 3.6% had NSCLC with ALK rearrangement, 14% had NSCLC with EGFR mutation, and 12% had previously treated brain metastases. Prior therapy included platinum-doublet regimen (100%) and 40% received maintenance therapy as part of the first-line regimen. Histologic subtypes included adenocarcinoma (93%), large cell (2.4%), and bronchoalveolar (0.9%). CHECKMATE-057 demonstrated a statistically significant improvement in OS for patients randomized to intravenous nivolumab as compared with docetaxel at the prespecified interim analysis when 413 events were observed (93% of the planned number of events for final analysis). Efficacy results are shown in Table 56 and Figure 13. Table 56: Efficacy Results - CHECKMATE-057 a Based on a stratified proportional hazards model. b Based on stratified log-rank test. c p-value is compared with .0408 of the allocated alpha for this interim analysis. d Based on the stratified Cochran-Mantel-Haenszel test. e Not Reached. Intravenous Nivolumab (n=292) Docetaxel (n=290) Overall Survival Deaths (%) 190 (65%) 223 (77%) Median (months) (95% CI) 12.2 (9.7, 15.0) 9.4 (8.0, 10.7) Hazard ratio (95% CI) a 0.73 (0.60, 0.89) p-value b,c 0.0015 Overall Response Rate 56 (19%) 36 (12%) (95% CI) (15, 24) (9, 17) p-value d 0.02 Complete response 4 (1.4%) 1 (0.3%) Median duration of response (months) (95% CI) 17 (8.4, NR e ) 6 (4.4, 7.0) Progression-free Survival Disease progression or death (%) 234 (80%) 245 (84%) Median (months) 2.3 4.2 Hazard ratio (95% CI) a 0.92 (0.77, 1.11) p-value b 0.39 Figure 13: Overall Survival - CHECKMATE-057 Archival tumor specimens were evaluated for PD-L1 expression following completion of the trial. Across the trial population, 22% of 582 patients had non-quantifiable results. Of the remaining 455 patients, the proportion of patients in retrospectively determined subgroups based on PD-L1 testing using the PD-L1 IHC 28-8 pharmDx assay were: 46% PD-L1 negative, defined as <1% of tumor cells expressing PD-L1 and 54% had PD-L1 expression, defined as ≥1% of tumor cells expressing PD-L1. Among the 246 patients with tumors expressing PD-L1, 26% had ≥1% but <5% tumor cells with positive staining, 7% had ≥5% but <10% tumor cells with positive staining, and 67% had ≥10% tumor cells with positive staining. Figures 14 and 15 summarize the results of prespecified analyses of OS and PFS in subgroups determined by percentage of tumor cells expressing PD-L1. Figure 14: Forest Plot: OS Based on PD-L1 Expression - CHECKMATE-057 Figure 15: Forest Plot: PFS Based on PD-L1 Expression - CHECKMATE-057 oq-os-checkmate-017 oq-os-checkmate-057 oq-forest-plot-os-checkmate-057 oq-forest-plot-pfs-checkmate-057 14.7 Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck The effectiveness of OPDIVO QVANTIG has been established for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum-based therapy. Use of OPDIVO QVANTIG for this indication is supported by evidence from an adequate and well-controlled study conducted with intravenous nivolumab, and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of the adequate and well-controlled study of intravenous nivolumab in this head and neck carcinoma population. CHECKMATE-141 CHECKMATE-141 (NCT02105636) was a randomized (2:1), active-controlled, open-label trial enrolling patients with metastatic or recurrent SCCHN who had experienced disease progression during or within 6 months of receiving platinum-based therapy administered in either the adjuvant, neo-adjuvant, primary (unresectable locally advanced) or metastatic setting. The trial excluded patients with autoimmune disease, medical conditions requiring immunosuppression, recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary histology, salivary gland or non-squamous histologies (e.g., mucosal melanoma), or untreated brain metastasis. Patients with treated brain metastases were eligible if neurologically stable. Patients were randomized to receive nivolumab 3 mg/kg by intravenous infusion every 2 weeks or investigator’s choice of cetuximab (400 mg/m 2 initial dose intravenously followed by 250 mg/m 2 weekly), or methotrexate (40 to 60 mg/m 2 intravenously weekly), or docetaxel (30 to 40 mg/m 2 intravenously weekly). Randomization was stratified by prior cetuximab treatment (yes/no). The first tumor assessments were conducted 9 weeks after randomization and continued every 6 weeks thereafter. The major efficacy outcome measure was OS. Additional efficacy outcome measures were PFS and ORR. A total of 361 patients were randomized; 240 patients to the intravenous nivolumab arm and 121 patients to the investigator’s choice arm (docetaxel: 45%; methotrexate: 43%; and cetuximab: 12%). The trial population characteristics were: median age was 60 years (range: 28 to 83) with 31% ≥65 years of age, 83% were White, 12% Asian, and 4% were Black, and 83% male. Baseline ECOG performance status was 0 (20%) or 1 (78%), 76% were former/current smokers, 90% had Stage IV disease, 45% of patients received only one prior line of systemic therapy, the remaining 55% received two or more prior lines of systemic therapy, and 25% had HPVp16-positive tumors, 24% had HPV p16-negative tumors, and 51% had unknown status. The trial demonstrated a statistically significant improvement in OS for patients randomized to intravenous nivolumab as compared with investigator’s choice at a pre-specified interim analysis (78% of the planned number of events for final analysis). There were no statistically significant differences between the two arms for PFS (HR=0.89; 95% CI: 0.70, 1.13) or ORR (13.3% [95% CI: 9.3, 18.3] vs. 5.8% [95% CI: 2.4, 11.6] for nivolumab and investigator’s choice, respectively). Efficacy results are shown in Table 57 and Figure 16. Table 57: Overall Survival - CHECKMATE-141 a Based on stratified proportional hazards model. b Based on stratified log-rank test. c p-value is compared with 0.0227 of the allocated alpha for this interim analysis. Intravenous Nivolumab (n=240) Cetuximab, Methotrexate or Docetaxel (n=121) Overall Survival Deaths (%) 133 (55%) 85 (70%) Median (months) (95% CI) 7.5 (5.5, 9.1) 5.1 (4.0, 6.0) Hazard ratio (95% CI) a 0.70 (0.53, 0.92) p-value b,c 0.0101 Figure 16: Overall Survival - CHECKMATE-141 Archival tumor specimens were retrospectively evaluated for PD-L1 expression using the PD-L1 IHC 28-8 pharmDx assay. Across the trial population, 28% (101/361) of patients had non-quantifiable results. Among the 260 patients with quantifiable results, 43% (111/260) had PD-L1 negative SCCHN, defined as <1% of tumor cells expressing PD-L1, and 57% (149/260) had PD-L1 positive SCCHN, defined as ≥1% of tumor cells expressing PD-L1. In pre-specified exploratory subgroup analyses, the hazard ratio for survival was 0.89 (95% CI: 0.54, 1.45) with median survivals of 5.7 and 5.8 months for the nivolumab and chemotherapy arms, respectively, in the PD-L1 negative subgroup. The HR for survival was 0.55 (95% CI: 0.36, 0.83) with median survivals of 8.7 and 4.6 months for the nivolumab and chemotherapy arms, respectively, in the PD-L1 positive SCCHN subgroup. oq-os-checkmate-141 14.8 Urothelial Carcinoma Adjuvant Treatment of Urothelial Carcinoma (UC) at High Risk of Recurrence The effectiveness of OPDIVO QVANTIG has been established for the adjuvant treatment of UC at high risk of recurrence. Use of OPDIVO QVANTIG for this indication is supported by evidence from an adequate and well-controlled study conducted with intravenous nivolumab, and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of the adequate and well-controlled study of intravenous nivolumab in this UC population. CHECKMATE-274 CHECKMATE-274 (NCT02632409) was a randomized, double-blind, placebo‑controlled study of adjuvant intravenous nivolumab in patients who were within 120 days of radical resection (R0) of UC of the bladder or upper urinary tract (renal pelvis or ureter) at high risk of recurrence. High risk of recurrence was defined as either 1) ypT2-ypT4a or ypN + for patients who received neoadjuvant cisplatin or 2) pT3-pT4a or pN + for patients who did not receive neoadjuvant cisplatin and who also either were ineligible for or refused adjuvant cisplatin. Patients were randomized 1:1 to receive nivolumab 240 mg or placebo by intravenous infusion every 2 weeks until recurrence or until unacceptable toxicity for a maximum treatment duration of 1 year. Patients were stratified by pathologic nodal status (N+ vs. N0/x with <10 nodes removed vs. N0 with ≥10 nodes removed), tumor cells expressing PD-L1 (≥1% vs. <1%/indeterminate as determined by the central lab using the PD‑L1 IHC 28-8 pharmDx assay), and use of neoadjuvant cisplatin (yes vs. no). The trial population characteristics were: median age of 67 years (range: 30 to 92); 76% male; 76% White, 22% Asian, 0.7% Black, and 0.1% American Indian or Alaska Native. Of the 335 (47%) of patients with node-positive UC, 44 (6%) had non–muscle-invasive (1. Patients received nivolumab 3 mg/kg by intravenous infusion every 2 weeks until unacceptable toxicity or either radiographic or clinical progression. Tumor response assessments were conducted every 8 weeks for the first 48 weeks and every 12 weeks thereafter. Major efficacy outcome measures included confirmed ORR as assessed by IRRC using RECIST v1.1 and DOR. The median age was 66 years (range: 38 to 90), 78% were male, 86% were White. Twenty-seven percent had non-bladder urothelial carcinoma and 84% had visceral metastases. Thirty-four percent of patients had disease progression following prior platinum-containing neoadjuvant or adjuvant therapy. Twenty-nine percent of patients had received ≥2 prior systemic regimens in the metastatic setting. Thirty-six percent of patients received prior cisplatin only, 23% received prior carboplatin only, and 7% were treated with both cisplatin and carboplatin in the metastatic setting. Forty-six percent of patients had an ECOG performance status of 1. Eighteen percent of patients had a hemoglobin <10 g/dL, and twenty-eight percent of patients had liver metastases at baseline. Patients were included regardless of their PD-L1 status. Tumor specimens were evaluated prospectively using the PD-L1 IHC 28-8 pharmDx assay at a central laboratory and the results were used to define subgroups for pre-specified analyses. Of the 270 patients, 46% were defined as having PD-L1 expression of ≥1% (defined as ≥1% of tumor cells expressing PD-L1). The remaining 54% of patients were classified as having PD-L1 expression of <1% (defined as <1% of tumor cells expressing PD-L1). Confirmed ORR in all patients and the two PD-L1 subgroups are shown in Table 60. Median time to response was 1.9 months (range: 1.6-7.2). In 77 patients who received prior systemic therapy only in the neoadjuvant or adjuvant setting, the ORR was 23.4% (95% CI: 14.5%, 34.4%). Table 60: Efficacy Results - CHECKMATE-275 a Estimated from the Kaplan-Meier Curve b Not Reached All Patients N=270 PD-L1 <1% N=146 PD-L1 ≥1% N=124 Confirmed Overall Response Rate, n (%) (95% CI) 53 (19.6%) (15.1, 24.9) 22 (15.1%) (9.7, 21.9) 31 (25.0%) (17.7, 33.6) Complete response rate 7 (2.6%) 1 (0.7%) 6 (4.8%) Partial response rate 46 (17.0%) 21 (14.4%) 25 (20.2%) Median Duration of Response a (months) (range) 10.3 (1.9+, 12.0+) 7.6 (3.7, 12.0+) NR b (1.9+, 12.0+) 14.9 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer The effectiveness of OPDIVO QVANTIG has been established for the treatment of microsatellite instability-high or mismatch repair deficient colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Use of OPDIVO QVANTIG for this indication is supported by evidence from an adequate and well-controlled study conducted with intravenous nivolumab (CHECKMATE-142, NCT02060188), and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of the adequate and well-controlled study of intravenous nivolumab in this CRC population. OPDIVO QVANTIG is not indicated for the treatment of pediatric patients. CHECKMATE-142 CHECKMATE-142 (NCT02060188) was a multicenter, non-randomized, multiple parallel-cohort, open-label trial conducted in patients with locally determined dMMR or MSI-H metastatic CRC (mCRC) who had disease progression during or after prior treatment with fluoropyrimidine‑ , oxaliplatin‑ , or irinotecan-based chemotherapy. Key eligibility criteria were at least one prior line of treatment for metastatic disease, ECOG performance status 0 or 1, and absence of the following: active brain metastases, active autoimmune disease, or medical conditions requiring systemic immunosuppression. Patients enrolled in the single agent intravenous nivolumab MSI-H mCRC cohort received nivolumab 3 mg/kg by intravenous infusion (IV) every 2 weeks. Patients enrolled in the intravenous nivolumab and ipilimumab MSI-H mCRC cohort received nivolumab 3 mg/kg and ipilimumab 1 mg/kg intravenously every 3 weeks for 4 doses, followed by nivolumab as a single agent at a dose of 3 mg/kg as intravenous infusion every 2 weeks. Treatment in both cohorts continued until unacceptable toxicity or radiographic progression. Tumor assessments were conducted every 6 weeks for the first 24 weeks and every 12 weeks thereafter. Efficacy outcome measures included ORR and DOR as assessed by BICR using RECIST v1.1. A total of 74 patients were enrolled in the single-agent MSI-H mCRC intravenous nivolumab cohort. The median age was 53 years (range: 26 to 79) with 23% ≥65 years of age and 5% ≥75 years of age, 59% were male and 88% were White. Baseline ECOG performance status was 0 (43%), 1 (55%), or 3 (1.4%) and 36% were reported to have Lynch Syndrome. Across the 74 patients, 72% received prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan; 7%, 30%, 28%, 19%, and 16% received 0, 1, 2, 3, or ≥4 prior lines of therapy for metastatic disease, respectively, and 42% of patients had received an anti-EGFR antibody. A total of 119 patients were enrolled in the intravenous nivolumab and ipilimumab MSI-H mCRC cohort. The median age was 58 years (range: 21 to 88), with 32% ≥65 years of age and 9% ≥75 years of age; 59% were male and 92% were White. Baseline ECOG performance status was 0 (45%) and 1 (55%), and 29% were reported to have Lynch Syndrome. Across the 119 patients, 69% had received prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan; 10%, 40%, 24%, and 15% received 1, 2, 3, or ≥4 prior lines of therapy for metastatic disease, respectively, and 29% had received an anti-EGFR antibody. Efficacy results for each of these single-arm cohorts are shown in Table 61. Table 61: Efficacy Results - CHECKMATE-142 a Minimum follow-up 33.7 months for all patients treated with intravenous nivolumab (n=74). b Minimum follow-up 27.5 months for all patients treated with intravenous nivolumab and ipilimumab (n=119). c Estimated using the Clopper-Pearson method. Intravenous Nivolumab a MSI-H/dMMR Cohort Intravenous Nivolumab and Ipilimumab b MSI-H/dMMR Cohort All Patients (n=74) Prior Treatment (Fluoropyrimidine, Oxaliplatin, and Irinotecan) (n=53) All Patients (n=119) Prior Treatment (Fluoropyrimidine, Oxaliplatin, and Irinotecan) (n=82) Overall Response Rate per BICR; n (%) 28 (38%) 17 (32%) 71 (60%) 46 (56%) (95% CI) c (27, 50) (20, 46) (50, 69) (45, 67) Complete Response (%) 8 (11%) 5 (9%) 17 (14%) 11 (13%) Partial Response (%) 20 (27%) 12 (23%) 54 (45%) 35 (43%) Duration of Response Proportion of responders with ≥6 months response duration 86% 94% 89% 87% Proportion of responders with ≥12 months response duration 82% 88% 77% 74% 14.10 Hepatocellular Carcinoma The effectiveness of OPDIVO QVANTIG has been established for the treatment of hepatocellular carcinoma in patients who have been previously treated with sorafenib and following treatment with intravenous nivolumab and ipilimumab. Use of OPDIVO QVANTIG for this indication is supported by evidence from an adequate and well-controlled study conducted with intravenous nivolumab, and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of the adequate and well-controlled study of intravenous nivolumab in this hepatocellular carcinoma population. CHECKMATE-040 CHECKMATE-040 (NCT01658878) was a multicenter, multiple cohort, open-label trial that evaluated the efficacy of intravenous nivolumab as a single agent and in combination with ipilimumab in patients with hepatocellular carcinoma (HCC) who progressed on or were intolerant to sorafenib. Additional eligibility criteria included histologic confirmation of HCC and Child‑Pugh Class A cirrhosis. The trial excluded patients with active autoimmune disease, brain metastasis, a history of hepatic encephalopathy, clinically significant ascites, infection with HIV, or active co‑infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) or HBV and hepatitis D virus (HDV); however, patients with only active HBV or HCV were eligible. Tumor assessments were conducted every 6 weeks for 48 weeks and then every 12 weeks thereafter. The major efficacy outcome measure was confirmed overall response rate as assessed by BICR using RECIST v1.1 and modified RECIST (mRECIST) for HCC. Duration of response was also assessed. The efficacy of intravenous nivolumab in combination with ipilimumab was evaluated in 49 patients (Cohort 4) who received intravenous nivolumab 1 mg/kg and ipilimumab 3 mg/kg administered every 3 weeks for 4 doses, followed by single-agent intravenous nivolumab at 240 mg every 2 weeks until disease progression or unacceptable toxicity. The median age was 60 years (range: 18 to 80), 88% were male, 74% were Asian, and 25% were White. Baseline ECOG performance status was 0 (61%) or 1 (39%). Fifty-seven (57%) percent of patients had active HBV infection, 8% had active HCV infection, and 35% had no evidence of active HBV or HCV. The etiology for HCC was alcoholic liver disease in 16% and non‑alcoholic fatty liver disease in 6% of patients. Child-Pugh class and score was A5 for 82% and A6 for 18%; 80% of patients had extrahepatic spread; 35% had vascular invasion; and 51% had AFP levels ≥400 µg/L. Prior cancer treatment history included surgery (74%), radiotherapy (29%), or local treatment (59%). All patients had received prior sorafenib, of whom 10% were unable to tolerate sorafenib; 29% of patients had received 2 or more prior systemic therapies. Efficacy results are shown in Table 62. The results for intravenous nivolumab in combination with ipilimumab in Cohort 4 are based on a minimum follow-up of 28 months. Table 62: Efficacy Results - Cohort 4 of CHECKMATE-040 a Confirmed by BICR. b Confidence interval is based on the Clopper and Pearson method. Intravenous Nivolumab and Ipilimumab (Cohort 4) (n=49) Overall Response Rate per BICR, a n (%), RECIST v1.1 16 (33%) (95% CI) b (20, 48) Complete response 4 (8%) Partial response 12 (24%) Duration of Response per BICR, a RECIST v1.1 n=16 Range (months) 4.6, 30.5+ Percent with duration ≥6 months 88% Percent with duration ≥12 months 56% Percent with duration ≥24 months 31% Overall Response Rate per BICR, a n (%), mRECIST 17 (35%) (95% CI) b (22, 50) Complete response 6 (12%) Partial response 11 (22%) 14.11 Esophageal Cancer Adjuvant Treatment of Resected Esophageal or Gastroesophageal Junction Cancer The effectiveness of OPDIVO QVANTIG has been established for the adjuvant treatment of resected esophageal or gastroesophageal junction cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy (CRT). Use of OPDIVO QVANTIG for this indication is supported by evidence from an adequate and well-controlled study conducted with intravenous nivolumab, and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of the adequate and well-controlled study of intravenous nivolumab in this esophageal or gastroesophageal junction cancer population. CHECKMATE-577 CHECKMATE-577 (NCT02743494) was a randomized, multicenter, double-blind trial in 794 patients with completely resected (negative margins) esophageal or gastroesophageal junction cancer who had residual pathologic disease following concurrent chemoradiotherapy (CRT). Patients were randomized (2:1) to receive either nivolumab 240 mg or placebo by intravenous infusion over 30 minutes every 2 weeks for 16 weeks followed by 480 mg or placebo by intravenous infusion over 30 minutes every 4 weeks beginning at week 17. Treatment was until disease recurrence, unacceptable toxicity, or for up to 1 year in total duration. Enrollment required complete resection within 4 to 16 weeks prior to randomization. The trial excluded patients who did not receive CRT prior to surgery, had stage IV resectable disease, autoimmune disease, or any condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications. Randomization was stratified by tumor PD-L1 status (≥1% vs. <1% or indeterminate or non-evaluable), pathologic lymph node status (positive ≥ypN1 vs. negative ypN0), and histology (squamous vs. adenocarcinoma). The major efficacy outcome measure was disease-free survival (DFS) defined as the time between the date of randomization and the date of first recurrence (local, regional, or distant from the primary resected site) or death, from any cause, whichever occurred first as assessed by the investigator prior to subsequent anti-cancer therapy. Patients on treatment underwent imaging for tumor recurrence every 12 weeks for 2 years, and a minimum of one scan every 6 to 12 months for years 3 to 5. The trial population characteristics were: median age 62 years (range: 26 to 86), 36% were ≥65 years of age, 85% were male, 15% were Asian, 82% were White, and 1.1% were Black. Disease characteristics were AJCC Stage II (35%) or Stage III (65%) at initial diagnosis carcinoma, EC (60%) or GEJC (40%) at initial diagnosis, with pathologic positive lymph node status (58%) at study entry and histological confirmation of predominant adenocarcinoma (71%) or squamous cell carcinoma (29%). The baseline Tumor PD-L1 status ≥1% was positive for 16% of patients and negative for 72% of patients. Baseline ECOG performance status was 0 (58%) or 1 (42%). CHECKMATE-577 demonstrated a statistically significant improvement in DFS for patients randomized to the intravenous nivolumab arm as compared with the placebo arm. DFS benefit was observed regardless of tumor PD-L1 expression and histology. Efficacy results are shown in Table 63 and Figure 20. Table 63: Efficacy Results - CHECKMATE-577 a Based on a stratified proportional hazards model. b Based on a stratified log-rank test. Intravenous Nivolumab (n=532) Placebo (n=262) Disease-free Survival Number of events, n (%) 241 (45%) 155 (59%) Median (months) (95% CI) 22.4 (16.6, 34.0) 11.0 (8.3, 14.3) Hazard ratio a (95% CI) 0.69 (0.56, 0.85) p-value b 0.0003 Figure 20: Disease-free Survival - CHECKMATE-577 oq-dfs-checkmate-577 First-line Treatment of Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) The effectiveness of OPDIVO QVANTIG in combination with fluoropyrimidine- and platinum-containing chemotherapy has been established for the first-line treatment of unresectable advanced or metastatic ESCC. Use of OPDIVO QVANTIG for this indication is supported by evidence from an adequate and well-controlled study conducted with intravenous nivolumab, and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of the adequate and well-controlled study of intravenous nivolumab in this esophageal squamous cell carcinoma population. CHECKMATE-648 CHECKMATE-648 (NCT03143153) was a randomized, active-controlled, open-label trial in patients with previously untreated unresectable advanced, recurrent or metastatic ESCC (squamous or adenosquamous histology). The trial enrolled patients whose tumor was evaluable for tumor cell (TC) PD-L1 expression [also called PD-L1 tumor proportion score (TPS)], which was evaluated using the PD-L1 IHC 28-8 pharmDx assay at a central laboratory. A retrospective scoring of a patient’s tumor PD-L1 status using Combined Positive Score (CPS), was also conducted using the PD-L1-stained tumor specimens used for randomization. Patients were not amenable to chemoradiation or surgery with curative intent. Prior treatment with curative intent was allowed if completed more than six months prior to trial enrollment. The trial excluded patients with brain metastasis that were symptomatic, had active autoimmune disease, used systemic corticosteroids or immunosuppressants, or patients at high risk of bleeding or fistula due to apparent invasion of tumor to organs adjacent to the esophageal tumor. Patients were randomized to receive one of the following treatments: • Intravenous nivolumab 240 mg on days 1 and 15, fluorouracil 800 mg/m 2 /day intravenously on days 1 through 5 (for 5 days), and cisplatin 80 mg/m 2 intravenously on day 1 (of a 4-week cycle). • Intravenous nivolumab 3 mg/kg every 2 weeks in combination with ipilimumab 1 mg/kg every 6 weeks. • Fluorouracil 800 mg/m 2 /day intravenously on days 1 through 5 (for 5 days), and cisplatin 80 mg/m 2 intravenously on day 1 (of a 4-week cycle). Patients received intravenous nivolumab until disease progression, unacceptable toxicity, or up to 2 years. In patients who received intravenous nivolumab in combination with chemotherapy and in whom either fluorouracil and/or cisplatin were discontinued, other components of the treatment regimen were allowed to be continued. Patients who discontinued combination therapy because of an adverse reaction attributed to ipilimumab were permitted to continue intravenous nivolumab as a single agent. Randomization was stratified by TC PD-L1 expression (≥1% vs. <1% or indeterminate), region (East Asia vs. Rest of Asia vs. Rest of World), ECOG performance status (0 vs. 1), and number of organs with metastases (≤1 vs. ≥2). The major efficacy outcome measures were OS and BICR-assessed PFS in patients with TC PD-L1 expression ≥1%. Additional efficacy measures included OS in all randomized patients, BICR-assessed PFS in all randomized patients, and ORR assessed by BICR in TC PD-L1 expression ≥1% and in all randomized patients. The tumor assessments per RECIST v1.1 were conducted every 6 weeks up to and including week 48, then every 12 weeks thereafter. A total of 970 patients were randomized in CHECKMATE-648 study among whom 965 and 906 patients had quantifiable TC PD-L1 expression and CPS at baseline, respectively. The trial population characteristics for all randomized patients were median age 64 years (range: 26 to 90), 47% were ≥65 years of age, 82% were male, 71% were Asian, 26% were White, and 1.1% were Black or African American. Patients had histological confirmation of squamous cell carcinoma (98%) or adenosquamous cell carcinoma (1.9%) in the esophagus. Baseline ECOG performance status was 0 (47.0%) or 1 (53%). Efficacy results are shown in Table 64 and Figures 21 and 22. Table 64: Efficacy Results - CHECKMATE-648 a Assessed by BICR. b Based on stratified Cox proportional hazard model. Hazard ratios are reported for each intravenous nivolumab containing arm compared to chemotherapy within each analysis population. c Based on a stratified 2-sided log-rank test. S1, S2, S3, S4, S5 Significant p-value compared to stopping boundary of 0.009, 0.018, 0.005, 0.014, and 0.015 respectively. NS: Not Statistically significant, NT: Not evaluated for statistical significance as per pre-specified hierarchical testing procedure Intravenous Nivolumab with Cisplatin and Fluorouracil (n=321) Intravenous Nivolumab and Ipilimumab (n=325) Cisplatin and Fluorouracil (n=324) Intravenous Nivolumab with Cisplatin and Fluorouracil (n=158) Intravenous Nivolumab and Ipilimumab (n=158) Cisplatin and Fluorouracil (n=157) All Patients TC PD-L1 expression ≥1% Overall Survival Deaths (%) 209 (65) 216 (66) 232 (72) 98 (62) 106 (67) 121 (77) Median (months) (95% CI) 13.2 (11.1, 15.7) 12.8 (11.3, 15.5) 10.7 (9.4, 11.9) 15.4 (11.9, 19.5) 13.7 (11.2, 17.0) 9.1 (7.7, 10) Hazard ratio (95% CI) b 0.74 (0.61, 0.90) 0.78 (0.65, 0.95) - 0.54 (0.41, 0.71) 0.64 (0.49, 0.84) - p-value c 0.0021 S1 0.0110 S2 - <0.0001 S3 0.0010 S4 - Progression-free Survival a Disease progression or death (%) 235 (73) 258 (79) 210 (65) 117 (74) 123 (78) 100 (64) Median (months) (95% CI) 5.8 (5.6, 7.0) 2.9 (2.7, 4.2) 5.6 (4.3, 5.9) 6.9 (5.7, 8.3) 4.0 (2.4, 4.9) 4.4 (2.9, 5.8) Hazard ratio (95% CI) b 0.81 (0.67, 0.99) 1.26 (1.04, 1.52) - 0.65 (0.49, 0.86) 1.02 (0.78, 1.34) - p-value c NS NT - 0.0023 S5 NS - Overall Response Rate, n (%) a, NT 152 (47.4) 90 (27.7) 87 (26.9) 84 (53.2) 56 (35.4) 31 (19.7) (95% CI) (41.8, 53.0) (22.9, 32.9) (22.1, 32.0) (45.1, 61.1) (28.0, 43.4) (13.8, 26.8) Complete response (%) 43 (13.4) 36 (11.1) 20 (6.2) 26 (16.5) 28 (17.7) 8 (5.1) Partial response (%) 109 (34.0) 54 (16.6) 67 (20.7) 58 (36.7) 28 (17.7) 23 (14.6) Duration of Response (months) a Median (95% CI) 8.2 (6.9, 9.7) 11.1 (8.3, 14.0) 7.1 (5.7, 8.2) 8.4 (6.9, 12.4) 11.8 (7.1, 27.4) 5.7 (4.4, 8.7) Range 1.4+, 35.9+ 1.4+, 34.5+ 1.4+, 31.8+ 1.4+, 34.6+ 1.4+, 34.5+ 1.4+, 31.8+ Figure 21: Overall Survival – CHECKMATE-648 (A) OS in All Randomized Patients (B) OS in TC PD-L1 ≥1% Figure 22: Progression-free Survival – CHECKMATE-648 (A) PFS in All Randomized Patients (B) PFS in TC PD-L1 ≥1% Exploratory subgroup analyses of patients with TC PD-L1 expression <1% (n=492) were conducted. OS results for each intravenous nivolumab containing arm compared to chemotherapy were: • Intravenous Nivolumab with Chemotherapy (n=163) vs. Chemotherapy (n=165): unstratified OS HR was 0.99 (95% CI: 0.76, 1.29) with median OS of 12 months (95% CI: 9.9, 15.5) on the Intravenous Nivolumab with Chemotherapy arm and 12.2 months (95% CI: 10.7, 14) on the Chemotherapy arm • Intravenous Nivolumab with Ipilimumab (n=164) vs. Chemotherapy (n=165): unstratified OS HR was 0.97 (95% CI: 0.74, 1.26) with median OS of 12 months (95% CI: 10.1, 16.0) on the Intravenous Nivolumab with Ipilimumab arm and 12.2 months (95% CI: 10.7, 14) on the Chemotherapy arm Exploratory subgroup analyses were also conducted by PD-L1 status per CPS (≥1 and <1) for each intravenous nivolumab containing arm compared to chemotherapy. Among the 906 patients with quantifiable PD-L1 CPS at baseline, 278 in the intravenous nivolumab with chemotherapy arm, 266 in the intravenous nivolumab with ipilimumab arm, and 280 in the chemotherapy arm had PD-L1 CPS ≥1. A total of 27 patients in the intravenous nivolumab with chemotherapy arm, 31 patients in the intravenous nivolumab with ipilimumab arm, and 24 patients in the chemotherapy arm had PD-L1 CPS <1. OS results for each comparison by PD-L1 CPS status were: • Intravenous Nivolumab with Chemotherapy vs. Chemotherapy: unstratified OS HR was 0.69 (95% CI: 0.56, 0.84) for PD-L1 CPS ≥1 subgroup and 0.98 (95% CI: 0.50, 1.95) for PD-L1 CPS <1 subgroup. • Intravenous Nivolumab with Ipilimumab vs. Chemotherapy: unstratified OS HR was 0.76 (95% CI: 0.62, 0.93) for PD-L1 CPS ≥1 subgroup and 1.0 (95% CI: 0.52, 1.94) for PD-L1 CPS <1 subgroup. oq-os-checkmate-648a oq-os-checkmate-648b oq-pfs-checkmate-648a oq-pfs-checkmate-648b Previously Treated Unresectable Advanced, Recurrent or Metastatic ESCC The effectiveness of OPDIVO QVANTIG has been established for the treatment of unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. Use of OPDIVO QVANTIG for this indication is supported by evidence from an adequate and well-controlled study conducted with intravenous nivolumab, and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of the adequate and well-controlled study of intravenous nivolumab in this ESCC population. ATTRACTION-3 ATTRACTION-3 (NCT02569242) was a multicenter, randomized (1:1), active-controlled, open‑label trial in patients with unresectable advanced, recurrent, or metastatic ESCC, who were refractory or intolerant to at least one fluoropyrimidine- and platinum‑based regimen. The trial enrolled patients regardless of PD-L1 status, but tumor specimens were evaluated prospectively using the PD-L1 IHC 28-8 pharmDx assay at a central laboratory. The trial excluded patients who were refractory or intolerant to taxane therapy, had brain metastases that were symptomatic or required treatment, had autoimmune disease, used systemic corticosteroids or immunosuppressants, or had apparent tumor invasion of organs adjacent to the esophageal tumor or had stents in the esophagus or respiratory tract. Patients were randomized to receive nivolumab 240 mg by intravenous infusion over 30 minutes every 2 weeks or investigator’s choice of taxane chemotherapy consisting of docetaxel (75 mg/m 2 intravenously every 3 weeks) or paclitaxel (100 mg/m 2 intravenously once a week for 6 weeks followed by 1 week off). Randomization was stratified by region (Japan vs. Rest of World), number of organs with metastases (≤1 vs. ≥2), and PD-L1 status (≥1% vs. <1% or indeterminate). Patients were treated until disease progression, assessed by the investigator per RECIST v1.1, or unacceptable toxicity. The tumor assessments were conducted every 6 weeks for 1 year, and every 12 weeks thereafter. The major efficacy outcome measure was OS. Additional efficacy outcome measures were ORR and PFS as assessed by the investigator using RECIST v1.1 and DOR. A total of 419 patients were randomized; 210 to the intravenous nivolumab arm and 209 to the investigator’s choice arm (docetaxel: 31%, paclitaxel: 69%). The trial population characteristics were: median age 65 years (range: 33 to 87), 53% were ≥65 years of age, 87% were male, 96% were Asian and 4% were White. Sixty-seven percent of patients had received one prior systemic therapy regimen and 26% had received two prior systemic therapy regimens prior to enrolling in ATTRACTION‑3. Baseline ECOG performance status was 0 (50%) or 1 (50%). ATTRACTION-3 demonstrated a statistically significant improvement in OS for patients randomized to intravenous nivolumab as compared with investigator’s choice of taxane chemotherapy. OS benefit was observed regardless of PD-L1 expression level. The minimum follow-up was 17.6 months. Efficacy results are shown in Table 65 and Figure 23. Table 65: Efficacy Results - ATTRACTION-3 a Based on ITT analysis b Based on a stratified proportional hazards model. c Based on a stratified log-rank test. d Based on Response Evaluable Set (RES) analysis, n=171 in intravenous nivolumab group and n=158 in investigator’s choice group. e Based on stratified Cochran-Mantel-Haenszel test; p-value not significant. f PFS not tested due to pre-specified hierarchical testing strategy. Intravenous Nivolumab (n=210) Docetaxel or Paclitaxel (n=209) Overall Survival a Deaths (%) 160 (76%) 173 (83%) Median (months) (95% CI) 10.9 (9.2, 13.3) 8.4 (7.2, 9.9) Hazard ratio (95% CI) b 0.77 (0.62, 0.96) p-value c 0.0189 Overall Response Rate d 33 (19.3) 34 (21.5) (95% CI) (13.7, 26.0) (15.4, 28.8) Complete response (%) 1 (0.6) 2 (1.3) Partial response (%) 32 (18.7) 32 (20.3) Median duration of response (months) (95% CI) 6.9 (5.4, 11.1) 3.9 (2.8, 4.2) p-value e 0.6323 Progression-free Survival a, f Disease progression or death (%) 187 (89) 176 (84) Median (months) (95% CI) 1.7 (1.5, 2.7) 3.4 (3.0, 4.2) Hazard ratio (95% CI) b 1.1 (0.9, 1.3) Figure 23: Overall Survival - ATTRACTION-3 Of the 419 patients, 48% had PD-L1 positive ESCC, defined as ≥1% of tumor cells expressing PD-L1. The remaining 52% had PD-L1 negative ESCC defined as <1% of tumor cells expressing PD-L1. In a pre-specified exploratory analysis by PD-L1 status, the hazard ratio (HR) for OS was 0.69 (95% CI: 0.51, 0.94) with median survivals of 10.9 and 8.1 months for the intravenous nivolumab and investigator’s choice arms, respectively, in the PD-L1 positive subgroup. In the PD-L1 negative subgroup, the HR for OS was 0.84 (95% CI: 0.62, 1.14) with median survivals of 10.9 and 9.3 months for the intravenous nivolumab and investigator’s choice arms, respectively. oq-os-attraction-3 14.12 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma The effectiveness of OPDIVO QVANTIG in combination with fluoropyrimidine- and platinum-containing chemotherapy has been established for the treatment of gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Use of OPDIVO QVANTIG for this indication is supported by evidence from an adequate and well-controlled study conducted with intravenous nivolumab, and additional pharmacokinetic and safety data that demonstrated comparable pharmacokinetics and safety profiles between OPDIVO QVANTIG and intravenous nivolumab [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3) ] . Below is a description of the efficacy results of the adequate and well-controlled study of intravenous nivolumab in this population. CHECKMATE-649 CHECKMATE-649 (NCT02872116) was a randomized, multicenter, open-label trial in patients (n=1581) with previously untreated advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. The trial enrolled patients regardless of PD-L1 status, and tumor specimens were evaluated prospectively using the PD-L1 IHC 28-8 pharmDx assay at a central laboratory. The trial excluded patients who were known human epidermal growth factor receptor 2 (HER2) positive, or had untreated CNS metastases. Patients were randomized to receive intravenous nivolumab in combination with chemotherapy (n=789) or chemotherapy (n=792). Patients received one of the following treatments: • Intravenous nivolumab 240 mg in combination with mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) every 2 weeks or mFOLFOX6 every 2 weeks. • Intravenous nivolumab 360 mg in combination with CapeOX (capecitabine and oxaliplatin) every 3 weeks or CapeOX every 3 weeks. Patients were treated until disease progression, unacceptable toxicity, or up to 2 years. In patients who received intravenous nivolumab in combination with chemotherapy and in whom chemotherapy was discontinued, intravenous nivolumab monotherapy was allowed to be given at 240 mg every 2 weeks, 360 mg every 3 weeks, or 480 mg every 4 weeks up to 2 years after treatment initiation. Randomization was stratified by tumor cell PD-L1 status (≥1% vs. <1% or indeterminate), region (Asia vs. US vs. Rest of World), ECOG performance status (0 vs. 1), and chemotherapy regimen (mFOLFOX6 vs. CapeOX). The major efficacy outcome measures, assessed in patients with PD-L1 CPS ≥5, were PFS assessed by BICR and OS. Additional efficacy outcome measures included OS and PFS in patients with PD-L1 CPS ≥1 and in all randomized patients, and ORR and DOR as assessed by BICR in patients with PD-L1 CPS ≥1 and ≥5, and in all randomized patients. Tumor assessments were conducted per RECIST v1.1 every 6 weeks up to and including week 48, then every 12 weeks thereafter. The trial population characteristics were: median age 61 years (range: 18 to 90), 39% were ≥65 years of age, 70% were male, 24% were Asian, and 69% were White, and 1% were Black. Baseline ECOG performance status was 0 (42%) or 1 (58%). Seventy percent of patients had adenocarcinoma tumors in the stomach, 16% in the gastroesophageal junction, and 13% in the esophagus. CHECKMATE-649 demonstrated a statistically significant improvement in OS and PFS for patients with PD-L1 CPS ≥5. Statistically significant improvement in OS was also demonstrated for all randomized patients. The minimum follow-up was 12.1 months. Efficacy results are shown in Table 66 and Figures 24, 25, and 26. Table 66: Efficacy Results - CHECKMATE-649 a Based on stratified Cox proportional hazard model. b Based on stratified log-rank test. c Assessed by BICR. d Based on confirmed response. e Not evaluated for statistical significance. Intravenous Nivolumab and mFOLFOX6 or CapeOX (n=789) mFOLFOX6 or CapeOX (n=792) Intravenous Nivolumab and mFOLFOX6 or CapeOX (n=641) mFOLFOX6 or CapeOX (n=655) Intravenous Nivolumab and mFOLFOX6 or CapeOX (n=473) mFOLFOX6 or CapeOX (n=482) All Patients PD-L1 CPS ≥1 PD-L1 CPS ≥5 Overall Survival Deaths (%) 544 (69) 591 (75) 434 (68) 492 (75) 309 (65) 362 (75) Median (months) (95% CI) 13.8 (12.6, 14.6) 11.6 (10.9, 12.5) 14.0 (12.6, 15.0) 11.3 (10.6, 12.3) 14.4 (13.1, 16.2) 11.1 (10.0, 12.1) Hazard ratio (95% CI) a 0.80 (0.71, 0.90) 0.77 (0.68, 0.88) 0.71 (0.61, 0.83) p-value b 0.0002 <0.0001 <0.0001 Progression-free Survival c Disease progression or death (%) 559 (70.8) 557 (70.3) 454 (70.8) 472 (72.1) 328 (69.3) 350 (72.6) Median (months) (95% CI) 7.7 (7.1, 8.5) 6.9 (6.6, 7.1) 7.5 (7.0, 8.4) 6.9 (6.1, 7.0) 7.7 (7.0, 9.2) 6.0 (5.6, 6.9) Hazard ratio (95% CI) a 0.77 (0.68, 0.87) 0.74 (0.65, 0.85) 0.68 (0.58, 0.79) p-value b - e - e <0.0001 Overall Response Rate, n (%) c,d 370 (47) 293 (37) 314 (49) 249 (38) 237 (50) 184 (38) (95% CI) (43, 50) (34, 40) (45, 53) (34, 42) (46, 55) (34, 43) Complete response (%) 78 (10) 52 (7) 65 (10) 42 (6) 55 (12) 34 (7) Partial response (%) 292 (37) 241 (30) 249 (39) 207 (32) 182 (38) 150 (31) Duration of Response (months) c,d Median (95% CI) Range 8.5 (7.2, 9.9) 1.0+, 29.6+ 6.9 (5.8, 7.2) 1.2+, 30.8+ 8.5 (7.7, 10.3) 1.1+, 29.6+ 6.9 (5.8, 7.6) 1.2+, 30.8+ 9.5 (8.1, 11.9) 1.1+, 29.6+ 6.9 (5.6, 7.9) 1.2+, 30.8+ In an exploratory analysis in patients with PD-L1 CPS <1 (n=265), the median OS was 13.1 months (95% CI: 9.8, 16.7) for the intravenous nivolumab and chemotherapy arm and 12.5 months (95% CI: 10.1, 13.8) for the chemotherapy arm, with a stratified HR of 0.85 (95% CI: 0.63, 1.15). In an exploratory analysis in patients with PD-L1 CPS <5 (n=606), the median OS was 12.4 months (95% CI: 10.6, 14.3) for the intravenous nivolumab and chemotherapy arm and 12.3 months (95% CI: 11.0, 13.2) for the chemotherapy arm, with a stratified HR of 0.94 (95% CI: 0.78, 1.14). Figure 24: Overall Survival (All Patients) - CHECKMATE-649 Figure 25: Overall Survival (PD-L1 CPS ≥1) - CHECKMATE-649 Figure 26: Overall Survival (PD-L1 CPS ≥5) - CHECKMATE-649 oq-os-checkmate-649 oq-os-pd-l1-cps-greater-than-1-checkmate-649 oq-os-pd-l1-cps-greater-than-5-checkmate-649

8.5 Geriatric Use Monotherapy Of the 248 patients who were randomized to monotherapy OPDIVO QVANTIG in clinical studies, 48% were 65 years and over and 14% were 75 years and over. No overall differences in safety or effectiveness were observed between elderly patients and younger patients . Single Agent Intravenous Nivolumab Of 3569 patients with melanoma, NSCLC, renal cell carcinoma, urothelial carcinoma, ESCC, and esophageal or gastroesophageal junction cancer who were randomized to single agent intravenous nivolumab in clinical studies, 41% were 65 years and over and 10% were 75 years and over. No overall differences in safety or effectiveness were observed between elderly patients and younger patients [see Clinical Studies (14.1 , 14.2 , 14.3 , 14.6 , 14.8 , 14.11 , 14.12) ] . Clinical studies in patients with recurrent head and neck SCC, or dMMR or MSI-H metastatic CRC (mCRC) who were treated with single agent intravenous nivolumab did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients [see Clinical Studies (14.7 , 14.9) ] . Intravenous Nivolumab in Combination with Platinum-Containing Chemotherapy Of the 179 patients with NSCLC who were randomized to intravenous nivolumab in combination with platinum-doublet chemotherapy, 48% were 65 years old or older and 6% were 75 years old or older. No overall differences in safety or effectiveness were reported between patients older and younger than 65 years [see Clinical Studies (14.4) ] . Of the 229 patients with NSCLC who were randomized to intravenous nivolumab 360 mg in combination with platinum-doublet chemotherapy every 3 weeks for up to 4 cycles, followed by intravenous nivolumab 480 mg every 4 weeks, 56% were 65 years old or older and 7% were 75 years old or older. No overall differences in safety or effectiveness were reported between patients older and younger than 65 years. Of the 1,110 patients with ESCC, GC, GEJC, or EAC who were randomized to intravenous nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy, 42% were 65 years or older and 10% were 75 years or older. No overall difference in safety was reported between elderly patients and younger patients [see Clinical Studies (14.11 , 14.12) ] . Of the 304 patients with UC who were treated with intravenous nivolumab in combination with gemcitabine and platinum-doublet chemotherapy, 40% were 65 years or older and 11% were 75 years or older. No overall differences in safety or effectiveness were observed between patients 65 years of age and over and younger patients. Clinical studies of intravenous nivolumab with platinum-doublet chemotherapy did not include sufficient numbers of patients aged 75 years and over to determine whether safety and effectiveness differs compared to younger patients. [see Clinical Studies (14.8) ] . In Combination with Cabozantinib Of the 320 patients with renal cell carcinoma who were treated with intravenous nivolumab in combination with cabozantinib, 41% were 65 years or older and 9% were 75 years or older. No overall difference in safety was reported between elderly patients and younger patients [see Clinical Studies (14.1) ] .

8.4 Pediatric Use The safety and effectiveness of OPDIVO QVANTIG have not been established in pediatric patients.

8.1 Pregnancy Risk Summary Based on data from animal studies and its mechanism of action [see Clinical Pharmacology (12.1) ] , OPDIVO QVANTIG can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of nivolumab to cynomolgus monkeys from the onset of organogenesis through delivery resulted in increased abortion and premature infant death (see Data) . Human IgG4 is known to cross the placental barrier and nivolumab is an immunoglobulin G4 (IgG4); therefore, nivolumab has the potential to be transmitted from the mother to the developing fetus. The effects of OPDIVO QVANTIG are likely to be greater during the second and third trimesters of pregnancy. There are no available data on OPDIVO QVANTIG use in pregnant women to evaluate a drug-associated risk. Advise pregnant women of the potential risk to a fetus. The background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. Data Animal Data OPDIVO QVANTIG for subcutaneous injection contains nivolumab and hyaluronidase [see Description (11) ] . Nivolumab A central function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. Blockade of PD-L1 signaling has been shown in murine models of pregnancy to disrupt tolerance to the fetus and to increase fetal loss. The effects of nivolumab on prenatal and postnatal development were evaluated in monkeys that received nivolumab intravenously twice weekly from the onset of organogenesis through delivery, at exposure levels of between 4 and 15 times higher than those observed at the clinical dose of 600 mg once every 2 weeks, 900 mg once every 3 weeks, or 1,200 mg once every 4 weeks (based on AUC). Nivolumab administration resulted in a non-dose-related increase in spontaneous abortion and increased neonatal death. Based on its mechanism of action, fetal exposure to nivolumab may increase the risk of developing immune-mediated disorders or altering the normal immune response, and immune-mediated disorders have been reported in PD-1 knockout mice. In surviving infants (18 of 32 compared to 11 of 16 vehicle-exposed infants) of cynomolgus monkeys treated with nivolumab, there were no apparent malformations and no effects on neurobehavioral, immunological, or clinical pathology parameters throughout the 6-month postnatal period. Hyaluronidase In an embryo-fetal development study, mice were dosed daily by subcutaneous injection during the period of organogenesis with hyaluronidase (recombinant human) at dose levels up to 2,200,000 U/kg, which is at least 6,600 times higher than the human dose of 10,000 U once every 2 weeks, 15,000 U once every 3 weeks, or 20,000 U once every 4 weeks (U/kg basis), when administered with nivolumab. The study found no evidence of teratogenicity. Reduced fetal weight and increased numbers of fetal resorptions were observed, with no effects found at a daily dose of 360,000 U/kg, which is at least 1,080 times higher than the human dose of 10,000 U once every 2 weeks, 15,000 U once every 3 weeks, or 20,000 U once every 4 weeks (U/kg basis), when administered with nivolumab.

8 USE IN SPECIFIC POPULATIONS • Lactation: Advise not to breastfeed. (8.2) 8.1 Pregnancy Risk Summary Based on data from animal studies and its mechanism of action [see Clinical Pharmacology (12.1) ] , OPDIVO QVANTIG can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of nivolumab to cynomolgus monkeys from the onset of organogenesis through delivery resulted in increased abortion and premature infant death (see Data) . Human IgG4 is known to cross the placental barrier and nivolumab is an immunoglobulin G4 (IgG4); therefore, nivolumab has the potential to be transmitted from the mother to the developing fetus. The effects of OPDIVO QVANTIG are likely to be greater during the second and third trimesters of pregnancy. There are no available data on OPDIVO QVANTIG use in pregnant women to evaluate a drug-associated risk. Advise pregnant women of the potential risk to a fetus. The background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. Data Animal Data OPDIVO QVANTIG for subcutaneous injection contains nivolumab and hyaluronidase [see Description (11) ] . Nivolumab A central function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. Blockade of PD-L1 signaling has been shown in murine models of pregnancy to disrupt tolerance to the fetus and to increase fetal loss. The effects of nivolumab on prenatal and postnatal development were evaluated in monkeys that received nivolumab intravenously twice weekly from the onset of organogenesis through delivery, at exposure levels of between 4 and 15 times higher than those observed at the clinical dose of 600 mg once every 2 weeks, 900 mg once every 3 weeks, or 1,200 mg once every 4 weeks (based on AUC). Nivolumab administration resulted in a non-dose-related increase in spontaneous abortion and increased neonatal death. Based on its mechanism of action, fetal exposure to nivolumab may increase the risk of developing immune-mediated disorders or altering the normal immune response, and immune-mediated disorders have been reported in PD-1 knockout mice. In surviving infants (18 of 32 compared to 11 of 16 vehicle-exposed infants) of cynomolgus monkeys treated with nivolumab, there were no apparent malformations and no effects on neurobehavioral, immunological, or clinical pathology parameters throughout the 6-month postnatal period. Hyaluronidase In an embryo-fetal development study, mice were dosed daily by subcutaneous injection during the period of organogenesis with hyaluronidase (recombinant human) at dose levels up to 2,200,000 U/kg, which is at least 6,600 times higher than the human dose of 10,000 U once every 2 weeks, 15,000 U once every 3 weeks, or 20,000 U once every 4 weeks (U/kg basis), when administered with nivolumab. The study found no evidence of teratogenicity. Reduced fetal weight and increased numbers of fetal resorptions were observed, with no effects found at a daily dose of 360,000 U/kg, which is at least 1,080 times higher than the human dose of 10,000 U once every 2 weeks, 15,000 U once every 3 weeks, or 20,000 U once every 4 weeks (U/kg basis), when administered with nivolumab. 8.2 Lactation Risk Summary There are no data on the presence of nivolumab or hyaluronidase in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment and for 5 months after the last dose of OPDIVO QVANTIG. 8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiating OPDIVO QVANTIG [see Use in Specific Populations (8.1) ] . Contraception OPDIVO QVANTIG can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] . Advise females of reproductive potential to use effective contraception during treatment with OPDIVO QVANTIG and for 5 months following the last dose. 8.4 Pediatric Use The safety and effectiveness of OPDIVO QVANTIG have not been established in pediatric patients. 8.5 Geriatric Use Monotherapy Of the 248 patients who were randomized to monotherapy OPDIVO QVANTIG in clinical studies, 48% were 65 years and over and 14% were 75 years and over. No overall differences in safety or effectiveness were observed between elderly patients and younger patients . Single Agent Intravenous Nivolumab Of 3569 patients with melanoma, NSCLC, renal cell carcinoma, urothelial carcinoma, ESCC, and esophageal or gastroesophageal junction cancer who were randomized to single agent intravenous nivolumab in clinical studies, 41% were 65 years and over and 10% were 75 years and over. No overall differences in safety or effectiveness were observed between elderly patients and younger patients [see Clinical Studies (14.1 , 14.2 , 14.3 , 14.6 , 14.8 , 14.11 , 14.12) ] . Clinical studies in patients with recurrent head and neck SCC, or dMMR or MSI-H metastatic CRC (mCRC) who were treated with single agent intravenous nivolumab did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients [see Clinical Studies (14.7 , 14.9) ] . Intravenous Nivolumab in Combination with Platinum-Containing Chemotherapy Of the 179 patients with NSCLC who were randomized to intravenous nivolumab in combination with platinum-doublet chemotherapy, 48% were 65 years old or older and 6% were 75 years old or older. No overall differences in safety or effectiveness were reported between patients older and younger than 65 years [see Clinical Studies (14.4) ] . Of the 229 patients with NSCLC who were randomized to intravenous nivolumab 360 mg in combination with platinum-doublet chemotherapy every 3 weeks for up to 4 cycles, followed by intravenous nivolumab 480 mg every 4 weeks, 56% were 65 years old or older and 7% were 75 years old or older. No overall differences in safety or effectiveness were reported between patients older and younger than 65 years. Of the 1,110 patients with ESCC, GC, GEJC, or EAC who were randomized to intravenous nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy, 42% were 65 years or older and 10% were 75 years or older. No overall difference in safety was reported between elderly patients and younger patients [see Clinical Studies (14.11 , 14.12) ] . Of the 304 patients with UC who were treated with intravenous nivolumab in combination with gemcitabine and platinum-doublet chemotherapy, 40% were 65 years or older and 11% were 75 years or older. No overall differences in safety or effectiveness were observed between patients 65 years of age and over and younger patients. Clinical studies of intravenous nivolumab with platinum-doublet chemotherapy did not include sufficient numbers of patients aged 75 years and over to determine whether safety and effectiveness differs compared to younger patients. [see Clinical Studies (14.8) ] . In Combination with Cabozantinib Of the 320 patients with renal cell carcinoma who were treated with intravenous nivolumab in combination with cabozantinib, 41% were 65 years or older and 9% were 75 years or older. No overall difference in safety was reported between elderly patients and younger patients [see Clinical Studies (14.1) ] .

16 HOW SUPPLIED/STORAGE AND HANDLING OPDIVO QVANTIG™ (nivolumab and hyaluronidase-nvhy) injection is a sterile, preservative-free, clear to opalescent and colorless to yellow solution for subcutaneous use. It is supplied as an individually packaged single-dose vial providing 600 mg nivolumab and 10,000 units hyaluronidase per 5 mL (120 mg/ 2,000 units per mL) (NDC-00003-6120-01). Store OPDIVO QVANTIG vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or shake.